<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Vaccines (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Vaccines (Basel)</journal-id><journal-id journal-id-type="publisher-id">vaccines</journal-id><journal-title-group><journal-title>Vaccines</journal-title></journal-title-group><issn pub-type="epub">2076-393X</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11680330</article-id><article-id pub-id-type="doi">10.3390/vaccines12121389</article-id><article-id pub-id-type="publisher-id">vaccines-12-01389</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Senolytic Vaccines from the Central and Peripheral Tolerance Perspective</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-7735-0602</contrib-id><name><surname>Vasilieva</surname><given-names>Mariia I.</given-names></name><xref rid="af1-vaccines-12-01389" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-3822-0784</contrib-id><name><surname>Shatalova</surname><given-names>Rimma O.</given-names></name><xref rid="af1-vaccines-12-01389" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-8728-5816</contrib-id><name><surname>Matveeva</surname><given-names>Kseniia S.</given-names></name><xref rid="af1-vaccines-12-01389" ref-type="aff">1</xref><xref rid="af2-vaccines-12-01389" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0006-3165-6872</contrib-id><name><surname>Shindyapin</surname><given-names>Vadim V.</given-names></name><xref rid="af2-vaccines-12-01389" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-1137-373X</contrib-id><name><surname>Minskaia</surname><given-names>Ekaterina</given-names></name><xref rid="af1-vaccines-12-01389" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-9573-4183</contrib-id><name><surname>Ivanov</surname><given-names>Roman A.</given-names></name><xref rid="af1-vaccines-12-01389" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-7084-081X</contrib-id><name><surname>Shevyrev</surname><given-names>Daniil V.</given-names></name><xref rid="af1-vaccines-12-01389" ref-type="aff">1</xref><xref rid="c1-vaccines-12-01389" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Im</surname><given-names>Sin-Hyeog</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-vaccines-12-01389"><label>1</label>Research Center for Translational Medicine, Sirius University of Science and Technology, Federal Territory Sirius, Krasnodarsky Krai, Sirius 354349, Russia</aff><aff id="af2-vaccines-12-01389"><label>2</label>Research Center for Genetics and Life Sciences, Sirius University of Science and Technology, Federal Territory Sirius, Krasnodarsky Krai, Sirius 354349, Russia; <email>shindyapinvadim1996@yandex.ru</email></aff><author-notes><corresp id="c1-vaccines-12-01389"><label>*</label>Correspondence: <email>dr.daniil25@mail.ru</email></corresp></author-notes><pub-date pub-type="epub"><day>10</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2024</year></pub-date><volume>12</volume><issue>12</issue><elocation-id>1389</elocation-id><history><date date-type="received"><day>01</day><month>11</month><year>2024</year></date><date date-type="rev-recd"><day>02</day><month>12</month><year>2024</year></date><date date-type="accepted"><day>09</day><month>12</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; 2024 by the authors.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Preventive medicine has proven its long-term effectiveness and economic feasibility. Over the last century, vaccination has saved more lives than any other medical technology. At present, preventative measures against most infectious diseases are successfully used worldwide; in addition, vaccination platforms against oncological and even autoimmune diseases are being actively developed. At the same time, the development of medicine led to an increase in both life expectancy and the proportion of age-associated diseases, which pose a heavy socio-economic burden. In this context, the development of vaccine-based approaches for the prevention or treatment of age-related diseases opens up broad prospects for extending the period of active longevity and has high economic potential. It is well known that the development of age-related diseases is associated with the accumulation of senescent cells in various organs and tissues. It has been demonstrated that the elimination of such cells leads to the restoration of functions, rejuvenation, and extension of the lives of experimental animals. However, the development of vaccines against senescent cells is complicated by their antigenic heterogeneity and the lack of a unique marker. In addition, senescent cells are the body&#x02019;s own cells, which may be the reason for their low immunogenicity. This mini-review discusses the mechanisms of central and peripheral tolerance that may influence the formation of an anti-senescent immune response and be responsible for the accumulation of senescent cells with age.</p></abstract><kwd-group><kwd>ageing</kwd><kwd>senescence</kwd><kwd>senolytic vaccines</kwd><kwd>senescent-associated antigens</kwd><kwd>senescent-specific antigens</kwd><kwd>central tolerance</kwd><kwd>peripheral tolerance</kwd></kwd-group><funding-group><award-group><funding-source>Russian Scientific Foundation</funding-source><award-id>24-15-20003</award-id></award-group><funding-statement>This work was supported by Russian Scientific Foundation, project &#x02116; 24-15-20003 <uri xlink:href="https://rscf.ru/project/24-15-20003/">https://rscf.ru/project/24-15-20003/</uri> (accessed on 1 November 2024).</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-vaccines-12-01389"><title>1. Introduction</title><p>The development of medicine led to a significant increase in life expectancy in most countries [<xref rid="B1-vaccines-12-01389" ref-type="bibr">1</xref>]. According to the World Health Organization (WHO), the number of people over 60 will double by 2050 and reach 2.1 billion people [<xref rid="B2-vaccines-12-01389" ref-type="bibr">2</xref>]. The global trend toward an aging population leads to an increase in age-associated diseases and places a burden on the world economies [<xref rid="B3-vaccines-12-01389" ref-type="bibr">3</xref>,<xref rid="B4-vaccines-12-01389" ref-type="bibr">4</xref>,<xref rid="B5-vaccines-12-01389" ref-type="bibr">5</xref>]. However, as a result of scientific and technological progress, the arsenal of methods for treating age-related diseases is constantly expanding. In recent years, the possibility of using vaccines to prevent and treat the most common age-related diseases has been actively studied [<xref rid="B6-vaccines-12-01389" ref-type="bibr">6</xref>]. Thus, the first positive results were obtained from vaccines used to treat Alzheimer&#x02019;s disease, type II diabetes mellitus, osteoarthritis, arterial hypertension, and some other cardiovascular diseases. Such vaccines can be based on different platforms and include peptide, protein, viral, cellular, and mRNA vaccines, as well as vaccines based on lipid particles (<xref rid="vaccines-12-01389-t001" ref-type="table">Table 1</xref>) [<xref rid="B7-vaccines-12-01389" ref-type="bibr">7</xref>].</p><p>A conceptually new approach is associated with the development of senolytic drugs. A number of studies have shown that aging of the body is accompanied by the accumulation of senescent cells in various tissues and organs [<xref rid="B50-vaccines-12-01389" ref-type="bibr">50</xref>,<xref rid="B51-vaccines-12-01389" ref-type="bibr">51</xref>]. This leads to tissue homeostasis and functional disorders typical of old age [<xref rid="B52-vaccines-12-01389" ref-type="bibr">52</xref>]. Senescent cells are cells with accumulated mutations, impaired autophagy, and defects in mitochondrial function, incapable of proliferating [<xref rid="B53-vaccines-12-01389" ref-type="bibr">53</xref>]. These cells are characterized by shortened telomeres, low heterochromatin orderliness, and defects in the nuclear membrane [<xref rid="B54-vaccines-12-01389" ref-type="bibr">54</xref>,<xref rid="B55-vaccines-12-01389" ref-type="bibr">55</xref>]. Morphologically, they are distinguished by an increased size and hypertrophy of the lysosomal apparatus [<xref rid="B56-vaccines-12-01389" ref-type="bibr">56</xref>,<xref rid="B57-vaccines-12-01389" ref-type="bibr">57</xref>,<xref rid="B58-vaccines-12-01389" ref-type="bibr">58</xref>]. Senescent cells also typically express some age-related markers (such as p16<sup>INK4A</sup>, p21<sup>CIP1</sup>, etc.), have increased senescence-associated &#x003b2;-galactosidase (SA-&#x003b2;-Gal) activity, produce a number of cytokines and pro-inflammatory substances (Senescence-Associated Secretory Phenotype&#x02014;SASP), and have various defects in the protein quality control machinery [<xref rid="B59-vaccines-12-01389" ref-type="bibr">59</xref>,<xref rid="B60-vaccines-12-01389" ref-type="bibr">60</xref>,<xref rid="B61-vaccines-12-01389" ref-type="bibr">61</xref>,<xref rid="B62-vaccines-12-01389" ref-type="bibr">62</xref>,<xref rid="B63-vaccines-12-01389" ref-type="bibr">63</xref>]. The physiological features of senescent cells affect their antigen profiles [<xref rid="B64-vaccines-12-01389" ref-type="bibr">64</xref>]. Unique sets of mutations and abnormalities in post-translational modifications (PTMs) typical of senescent cells can alter the structure of various proteins [<xref rid="B65-vaccines-12-01389" ref-type="bibr">65</xref>,<xref rid="B66-vaccines-12-01389" ref-type="bibr">66</xref>]. In addition, the accumulating body of evidence points at the increased genomic instability, activation of retroelements, and awakening of some latent viruses in senescent cells, which also causes the emergence of new antigen determinants [<xref rid="B67-vaccines-12-01389" ref-type="bibr">67</xref>,<xref rid="B68-vaccines-12-01389" ref-type="bibr">68</xref>]. Thus, senescent cell antigens (SAs) can be divided into Senescent-Associated Antigens (SAAs) and Senescent-Specific Antigens (SSAs). The first case refers to unchanged self-antigens that have increased levels of expression on some types of senescent cells (e.g., uPAR) [<xref rid="B69-vaccines-12-01389" ref-type="bibr">69</xref>]. The second case refers to &#x0201c;neoantigens&#x0201d; that appeared de novo and are unique to senescent cells.</p><p>It is worth noting that senescent cells play an important role in some physiological processes. Thus, SASP factors are involved in tissue remodeling in early ontogenesis, as well as in repair and regeneration processes at later stages of development [<xref rid="B70-vaccines-12-01389" ref-type="bibr">70</xref>]. In addition, cell cycle arrest, which is the most important feature of senescence, prevents possible malignancy [<xref rid="B71-vaccines-12-01389" ref-type="bibr">71</xref>]. Senescent cells are normally present in tissues in limited numbers. However, the accumulation of these cells during the aging process is associated with the dysfunction of various tissues and organs, and the cumulative effect of SASP production contributes to chronic age-related inflammation, which increases the risk of developing age-related diseases [<xref rid="B72-vaccines-12-01389" ref-type="bibr">72</xref>]. At the same time, selective elimination of these cells during aging leads to the restoration of functions gradually lost with age and, in some cases, was demonstrated to extend the life of experimental animals [<xref rid="B73-vaccines-12-01389" ref-type="bibr">73</xref>,<xref rid="B74-vaccines-12-01389" ref-type="bibr">74</xref>].</p><p>Despite the promising results of using some drugs aimed at killing senescent cells (senolytics) or reducing the negative effects of SASP (senomorphics), the existing pharmacological approaches still do not possess the high specificity toward senescent cells, do not take into account their diversity, and are associated with the risk of side effects [<xref rid="B75-vaccines-12-01389" ref-type="bibr">75</xref>,<xref rid="B76-vaccines-12-01389" ref-type="bibr">76</xref>,<xref rid="B77-vaccines-12-01389" ref-type="bibr">77</xref>,<xref rid="B78-vaccines-12-01389" ref-type="bibr">78</xref>]. This significantly limits their translational potential. In this context, a promising alternative is the development of methods for targeted elimination of senescent cells with the help of adaptive immunity mechanisms. Various attempts to create senolytic vaccines that remove senescent cells from specific tissues have already been made. For example, vaccines against GPNMB (glycoprotein nonmetastatic melanoma protein B) and CD153 antigens showed positive results with minimal side effects [<xref rid="B79-vaccines-12-01389" ref-type="bibr">79</xref>,<xref rid="B80-vaccines-12-01389" ref-type="bibr">80</xref>]. In mice, targeting GPNMB with a peptide vaccine reduced senescence load, improved metabolic indices, and reduced atherosclerotic plaques [<xref rid="B81-vaccines-12-01389" ref-type="bibr">81</xref>]. Furthermore, the anti-CD153 peptide vaccine reduced the number of senescent T cells in adipose tissue, increased glucose tolerance, and improved the response to endogenous insulin [<xref rid="B80-vaccines-12-01389" ref-type="bibr">80</xref>]. In addition, CAR-T therapy against uPAR, a marker of senescent cells that can potentially be used in senolytic vaccines, showed a beneficial effect, increasing stamina and improving glucose tolerance in aged mice [<xref rid="B69-vaccines-12-01389" ref-type="bibr">69</xref>]. Targeting the senescent cell marker NKG2D with CAR-T selectively eliminates senescent cells in vitro with minimal impact on healthy cells, suggesting its therapeutic potential for senolytic vaccines [<xref rid="B82-vaccines-12-01389" ref-type="bibr">82</xref>]. However, the development of such vaccines is associated with certain problems. Unique SSAs absent in normal cells are still unknown, which hinders the development of safe senolytic vaccines due to the risk of damage to the healthy tissues [<xref rid="B53-vaccines-12-01389" ref-type="bibr">53</xref>,<xref rid="B83-vaccines-12-01389" ref-type="bibr">83</xref>]. The high antigenic diversity of senescent cells, both at individual and population levels, significantly complicates the search for target antigens for the creation of universal senolytic vaccines [<xref rid="B53-vaccines-12-01389" ref-type="bibr">53</xref>,<xref rid="B64-vaccines-12-01389" ref-type="bibr">64</xref>]. Obviously, tolerance to senescence-associated antigens is a serious problem [<xref rid="B84-vaccines-12-01389" ref-type="bibr">84</xref>,<xref rid="B85-vaccines-12-01389" ref-type="bibr">85</xref>]. Since senescent cells are the body&#x02019;s own cells, the mechanisms of central and peripheral tolerance can act toward the antigens they express. They are carried out due to the elimination of autoreactive lymphocytes in the thymus and bone marrow, as well as through clonal inactivation and anergy of autoreactive clones in the periphery [<xref rid="B86-vaccines-12-01389" ref-type="bibr">86</xref>,<xref rid="B87-vaccines-12-01389" ref-type="bibr">87</xref>,<xref rid="B88-vaccines-12-01389" ref-type="bibr">88</xref>]. Thus, overcoming tolerance to senescence-associated antigens is one of the key challenges in the development of senolytic vaccines.</p></sec><sec id="sec2-vaccines-12-01389"><title>2. Central Tolerance for Senescent Antigens</title><p>Mechanisms of central tolerance are crucial for preventing autoimmune diseases. The removal of potentially autoreactive immature T and B lymphocytes occurs during negative selection in the thymus and bone marrow, respectively [<xref rid="B89-vaccines-12-01389" ref-type="bibr">89</xref>,<xref rid="B90-vaccines-12-01389" ref-type="bibr">90</xref>]. The key role in this process is played by the diversity of self-antigens that immature lymphocytes encounter during maturation [<xref rid="B91-vaccines-12-01389" ref-type="bibr">91</xref>]. Unlike the thymus, the bone marrow does not have a specialized system for presenting self-antigens. Therefore, lymphocyte selection is less strict and limited to the default set of self-antigens present in the bone marrow. At the same time, the aging of bone marrow cells can lead to the emergence of senescence-associated antigens and the formation of tolerance of B cells to these antigens [<xref rid="B92-vaccines-12-01389" ref-type="bibr">92</xref>,<xref rid="B93-vaccines-12-01389" ref-type="bibr">93</xref>].</p><p>The situation is different in the thymus, where a complex system of presentation of self-antigens exists [<xref rid="B91-vaccines-12-01389" ref-type="bibr">91</xref>]. The multitude of antigens presented in the thymus forms the clonal diversity of effector (Teff) and regulatory (Treg) T lymphocytes and ensures equilibrium in the immune system and its ability to respond to antigen challenges, maintaining protection against oncological, autoimmune, and infectious diseases [<xref rid="B94-vaccines-12-01389" ref-type="bibr">94</xref>,<xref rid="B95-vaccines-12-01389" ref-type="bibr">95</xref>]. Apparently, the thymus is simultaneously involved in the formation of an anti-senescent immune response and the elimination of senescent cells, as well as in maintaining tolerance to a multitude of SA [<xref rid="B96-vaccines-12-01389" ref-type="bibr">96</xref>,<xref rid="B97-vaccines-12-01389" ref-type="bibr">97</xref>,<xref rid="B98-vaccines-12-01389" ref-type="bibr">98</xref>]. The balance between these processes is determined by the repertoires of Teff and Treg cells that recognize SA [<xref rid="B95-vaccines-12-01389" ref-type="bibr">95</xref>]. In other words, the nature of the immune response to these antigens depends on their presentation in the thymus.</p><p>The action of the transcription factors AIRE, FezF2, and DEAF1 in cooperation with the helicase CHD4 in the thymus provides promiscuous gene expression (PGE) of the overwhelming majority of tissue-specific antigens [<xref rid="B91-vaccines-12-01389" ref-type="bibr">91</xref>]. Along with alternative splicing, the diversity of self-antigens in the thymus increases due to the expression of endogenous retroelements [<xref rid="B99-vaccines-12-01389" ref-type="bibr">99</xref>]. In addition, some dendritic cells migrate to the thymus and carry peripheral antigens with them (see <xref rid="vaccines-12-01389-f001" ref-type="fig">Figure 1</xref>). The intensity of this process increases with age, which may be the reason for the formation of central tolerance to some SA [<xref rid="B100-vaccines-12-01389" ref-type="bibr">100</xref>,<xref rid="B101-vaccines-12-01389" ref-type="bibr">101</xref>,<xref rid="B102-vaccines-12-01389" ref-type="bibr">102</xref>,<xref rid="B103-vaccines-12-01389" ref-type="bibr">103</xref>]. Thus, a unique library of central tolerance antigens is formed in the thymus, which ensures the selection of thymocytes and participates in the formation of T-cell repertoires [<xref rid="B91-vaccines-12-01389" ref-type="bibr">91</xref>]. However, this library undergoes qualitative and quantitative changes during life. The age-related thymus involution is accompanied by a decrease in the number of medullary thymic epithelial cells (mTECs), a decrease in PGE, an increase in the number of dendritic cells with peripheral antigens, and an accumulation of cells with signs of senescence in Hassall&#x02019;s corpuscles [<xref rid="B104-vaccines-12-01389" ref-type="bibr">104</xref>,<xref rid="B105-vaccines-12-01389" ref-type="bibr">105</xref>,<xref rid="B106-vaccines-12-01389" ref-type="bibr">106</xref>]. This leads to a decrease in thymopoiesis (thymic output) and a decrease in the diversity of T-lymphocyte repertoires [<xref rid="B107-vaccines-12-01389" ref-type="bibr">107</xref>,<xref rid="B108-vaccines-12-01389" ref-type="bibr">108</xref>]. Apparently, age-related central tolerance to some SA is formed due to an increase in their share in the repertoire of antigens presented in the thymus. This is associated with the aging of the thymus itself and the appearance of senescent cells among mTEC and in Hassall&#x02019;s corpuscles, as well as an increase in the influx of SA from the periphery due to the migration of dendritic cells [<xref rid="B104-vaccines-12-01389" ref-type="bibr">104</xref>,<xref rid="B105-vaccines-12-01389" ref-type="bibr">105</xref>,<xref rid="B106-vaccines-12-01389" ref-type="bibr">106</xref>]. Accurate identification and determination of the number of these antigens is a complex task. Nevertheless, the described mechanism is a probable cause of the low efficiency of promising senolytic vaccines aimed at SA.</p><p>The solution to the problem can be found in a more detailed examination of the aging processes in the thymus and periphery. As noted earlier, PTM processes are disrupted in aging and senescent cells [<xref rid="B65-vaccines-12-01389" ref-type="bibr">65</xref>,<xref rid="B66-vaccines-12-01389" ref-type="bibr">66</xref>,<xref rid="B109-vaccines-12-01389" ref-type="bibr">109</xref>]. This leads to changes in the immunopeptidome in these cells. On one hand, the appearance of a PTM peptide in the molecule of the major histocompatibility complex (MHC) can shield it from the T-cell receptor (TCR) [<xref rid="B110-vaccines-12-01389" ref-type="bibr">110</xref>]. On the other hand, such a peptide, on the contrary, is capable of causing a strong immune response [<xref rid="B110-vaccines-12-01389" ref-type="bibr">110</xref>]. The latter, for instance, can be observed in some autoimmune diseases, when a protein with the correct primary structure activates T cells due to the features of PTMs [<xref rid="B111-vaccines-12-01389" ref-type="bibr">111</xref>,<xref rid="B112-vaccines-12-01389" ref-type="bibr">112</xref>]. In the thymus, the intensity of PTMs is much lower than in the periphery, and PTM proteins are almost not involved in negative selection, which determines the absence of central tolerance towards many modified proteins [<xref rid="B113-vaccines-12-01389" ref-type="bibr">113</xref>]. Some authors consider this to be one of the main factors in the development of autoimmune diseases [<xref rid="B111-vaccines-12-01389" ref-type="bibr">111</xref>,<xref rid="B112-vaccines-12-01389" ref-type="bibr">112</xref>]. It is worth noting that due to the imbalance of pro- and anti-oxidant processes in senescent cells, non-enzymatic PTMs (such as cysteine redox PTMs, acyl transfers, glycation, formylation, etc.) are apparently most common, as are some enzymatic PTMs (such as mono- and poly-ADP-ribosylation) [<xref rid="B65-vaccines-12-01389" ref-type="bibr">65</xref>,<xref rid="B109-vaccines-12-01389" ref-type="bibr">109</xref>]. Thus, the appearance of specific modifications may be more likely in the senescent state and may not occur in normal cells. Therefore, further search for common patterns of PTMs characteristic of senescent cells, as well as identification of specific PTMs, may open prospects for the development of a relatively universal senolytic vaccine.</p><p>Another approach is related to the detection of the activity of transposable elements (TEs), DNA segments that are capable of moving within the genome and are genetic parasites [<xref rid="B114-vaccines-12-01389" ref-type="bibr">114</xref>]. This heterogeneous group includes more than 800 subfamilies and can be divided into the following three categories: LTR (Long Terminal Repeats), LINE, and SINE (Long and Short Interspersed Nuclear Elements, respectively). In total, TEs occupy approximately 45% of the human and mouse genomes [<xref rid="B115-vaccines-12-01389" ref-type="bibr">115</xref>]. Due to their mutagenic potential, TE activity is constantly suppressed in healthy cells. However, with age, their activity increases significantly and accompanies the transition of cells to a senescent state [<xref rid="B116-vaccines-12-01389" ref-type="bibr">116</xref>,<xref rid="B117-vaccines-12-01389" ref-type="bibr">117</xref>]. Interestingly, TEs play a physiological role in the thymus; their activity is increased in mTECs and in plasmacytoid dendritic cells, where TEs enrich MHC-I immunopeptide, thus participating in the negative selection of thymocytes [<xref rid="B115-vaccines-12-01389" ref-type="bibr">115</xref>]. Despite this, many TE protein products are highly immunogenic, which is associated with an increase in the risk of autoimmune diseases with age due to the activation of TEs in various tissues [<xref rid="B117-vaccines-12-01389" ref-type="bibr">117</xref>,<xref rid="B118-vaccines-12-01389" ref-type="bibr">118</xref>,<xref rid="B119-vaccines-12-01389" ref-type="bibr">119</xref>,<xref rid="B120-vaccines-12-01389" ref-type="bibr">120</xref>]. This suggests the formation of incomplete tolerance to the entire diversity of TE antigens. Currently, there is very limited data on the activity of specific TE subfamilies in the thymus, depending on age. In general, the highest activity of LINE and SINE is observed at a young age and decreases with thymus involution [<xref rid="B115-vaccines-12-01389" ref-type="bibr">115</xref>]. No such general pattern of decreased activity is observed for LTR subfamilies. Some of them are inactivated in early ontogenesis, while others demonstrate high activity in mTECs both before and after thymus involution [<xref rid="B113-vaccines-12-01389" ref-type="bibr">113</xref>]. Aging is generally associated with the activation of all TE categories. However, a common pattern characteristic of senescent cells is an increase in the activity of some LINE1 subfamilies and even the formation of retrovirus-like particles [<xref rid="B121-vaccines-12-01389" ref-type="bibr">121</xref>]. Thus, the search for the most characteristic senescent cell subfamilies of TEs with low activity in the thymus, as well as the identification of their protein products, opens up opportunities for the creation of effective senolytic vaccines directed against various types of senescent cells.</p><p>In addition, a recent study demonstrated that during skin aging, latent cytomegalovirus is awakened in senescent fibroblasts. This leads to the presentation of glycoprotein B epitopes in MHC-II molecules and the destruction of senescent cells by CD4<sup>+</sup> lymphocytes with cytotoxic action [<xref rid="B122-vaccines-12-01389" ref-type="bibr">122</xref>,<xref rid="B123-vaccines-12-01389" ref-type="bibr">123</xref>]. It is plausible to speculate that cell aging is associated with the activation of other dormant pathogenic or commensal viruses, and the intensification of the immune response against them can serve to eliminate senescent cells [<xref rid="B124-vaccines-12-01389" ref-type="bibr">124</xref>,<xref rid="B125-vaccines-12-01389" ref-type="bibr">125</xref>]. Therefore, a detailed study of the genetic and antigen profiles of senescent cells, taking into account the features of the formation of central tolerance, opens up broad prospects for the development of universal, safe, and effective senolytic vaccines.</p></sec><sec id="sec3-vaccines-12-01389"><title>3. Peripheral Tolerance for Senescent Antigens</title><p>Negative selection in the thymus is not absolutely efficient, and a significant portion of potentially autoreactive T cells end up in the periphery. This requires the presence of peripheral mechanisms that suppress autoreactive cells and ensure irresponsiveness to self-antigens. The mechanisms of peripheral tolerance are very diverse and are well described by now [<xref rid="B126-vaccines-12-01389" ref-type="bibr">126</xref>,<xref rid="B127-vaccines-12-01389" ref-type="bibr">127</xref>]. In general, they are aimed at preventing or limiting the activation of autoreactive T and B cells. The tolerance of autoreactive lymphocytes to cognate antigens is achieved through various mechanisms: quiescence, ignorance, anergy, exhaustion, deletion of clones via the induction of apoptosis, and finally senescence [<xref rid="B128-vaccines-12-01389" ref-type="bibr">128</xref>]. It is worth noting that under conditions favorable for the induction of tolerance, lymphocytes of any specificity can be inactivated through these mechanisms. This can lead to the formation of tolerance to antigens that the immune system previously perceived as foreign [<xref rid="B128-vaccines-12-01389" ref-type="bibr">128</xref>]. Activation of a naive B cell is impossible without a T lymphocyte of the appropriate specificity, in particular due to the follicular exclusion mechanism [<xref rid="B86-vaccines-12-01389" ref-type="bibr">86</xref>,<xref rid="B129-vaccines-12-01389" ref-type="bibr">129</xref>]; therefore, further description of peripheral tolerance will be given from the T lymphocyte perspective. Naive T cells emerging from the thymus recognize various self-antigens in the peripheral area with low specificity. This provides them with a tonic TCR signal necessary for survival and homeostasis. At the same time, the intensity of this signal is below the activation threshold, which keeps lymphocytes in a quiescent state [<xref rid="B130-vaccines-12-01389" ref-type="bibr">130</xref>]. The mechanisms of ignorance are poorly understood; apparently, they are associated not only with low TCR specificity but also with low density and availability of self-antigens for recognition by naive T cells [<xref rid="B86-vaccines-12-01389" ref-type="bibr">86</xref>]. Deficiency of co-stimulation underlies T cell anergy and prevents activation of naive autoreactive T lymphocytes upon interaction with antigen-presenting cells (APCs) [<xref rid="B131-vaccines-12-01389" ref-type="bibr">131</xref>]. Exhaustion is typical of Teff cells that receive antigenic stimulation for a long time, for example, during persistent infections or autoimmune inflammation [<xref rid="B132-vaccines-12-01389" ref-type="bibr">132</xref>]. Exhausted cells react weakly to cognate antigens and produce cytokines poorly compared to normal Teff cells. These cells express inhibitory molecules (such as PD1, LAG3, TIGIT, CD38, CD39, TIM3, etc.) and also have special epigenetic, transcriptional, and metabolic features that do not allow them to enter a quiescent-like cell state, characteristic of memory T cells (Tmem) [<xref rid="B86-vaccines-12-01389" ref-type="bibr">86</xref>,<xref rid="B132-vaccines-12-01389" ref-type="bibr">132</xref>]. Like other cells, lymphocytes are also subject to aging. Repeated antigenic stimulation of TCR can lead to replicative exhaustion, shortening of telomeres, decreased reactivity, and other signs of senescence. Although lymphocyte senescence is poorly understood, there is evidence of both low reactivity and proliferative potential of these cells [<xref rid="B133-vaccines-12-01389" ref-type="bibr">133</xref>,<xref rid="B134-vaccines-12-01389" ref-type="bibr">134</xref>,<xref rid="B135-vaccines-12-01389" ref-type="bibr">135</xref>]. One of the most important mechanisms of peripheral tolerance is the deletion of autoreactive cells [<xref rid="B136-vaccines-12-01389" ref-type="bibr">136</xref>,<xref rid="B137-vaccines-12-01389" ref-type="bibr">137</xref>,<xref rid="B138-vaccines-12-01389" ref-type="bibr">138</xref>]. Death by apoptosis can occur in different situations. To form an immune response, activation of a threshold number of T cells or otherwise achieving a quorum of T cells is necessary [<xref rid="B139-vaccines-12-01389" ref-type="bibr">139</xref>]. Without the necessary quorum, the immune response does not develop, and previously activated T cells are likely to die by apoptosis [<xref rid="B140-vaccines-12-01389" ref-type="bibr">140</xref>]. Also, deletion of lymphocytes through apoptosis occurs with insufficient stimulation, and only a small part of these cells goes into anergy. Interaction with tolerogenic APCs or Tregs usually ends in the death of the lymphocyte. However, occasionally it leads to the induction of peripheral Tregs [<xref rid="B141-vaccines-12-01389" ref-type="bibr">141</xref>]. This is an essential mechanism of peripheral tolerance, which plays an important role in expanding the spectrum of antigens to which relatively stable tolerance is formed in the periphery.</p><p>Age-related changes in the repertoires of peripherally presented antigens can lead to activation or, conversely, suppression of the immune response due to the mechanisms described above [<xref rid="B139-vaccines-12-01389" ref-type="bibr">139</xref>,<xref rid="B142-vaccines-12-01389" ref-type="bibr">142</xref>]. Apparently, depletion and transition of T lymphocytes to a senescent state are important factors in suppression of the immune response during prolonged persistence of antigens. This is observed in various chronic infections or malignant processes [<xref rid="B139-vaccines-12-01389" ref-type="bibr">139</xref>]. At the same time, the relationship between persistent infections and the development of autoimmune diseases is well known, which implies non-specific activation of adaptive immunity and violation of auto-tolerance [<xref rid="B143-vaccines-12-01389" ref-type="bibr">143</xref>,<xref rid="B144-vaccines-12-01389" ref-type="bibr">144</xref>]. This relationship is largely explained by genetic factors, dysfunction of Treg cells, and antigen mimicry. However, there is another important mechanism associated with an increase in the probability of achieving a quorum by potentially autoreactive T cells. Thus, during acute or short-term infections, high-amplitude activation of a small number of T-lymphocyte clones specific to the most immunogenic antigens occurs [<xref rid="B139-vaccines-12-01389" ref-type="bibr">139</xref>,<xref rid="B145-vaccines-12-01389" ref-type="bibr">145</xref>]. In long-term persistent infections, the diversity of antigens that activate different clones of T cells is significantly higher. This is due to the duration of the process, tissue damage, and an increased availability of some autoantigens [<xref rid="B139-vaccines-12-01389" ref-type="bibr">139</xref>,<xref rid="B146-vaccines-12-01389" ref-type="bibr">146</xref>]. All this leads to an expansion of the repertoire of T lymphocytes involved in the immune response and increases the likelihood of the involvement of cross-reactive T cells capable of recognizing self-antigens. Moreover, the activation of such cells and their transition from naive cells to Teff and Tmem cells is accompanied by a decrease in the activation threshold due to increased expression of co-stimulation receptors, as well as oligomerization and formation of TCR nanoclusters [<xref rid="B147-vaccines-12-01389" ref-type="bibr">147</xref>,<xref rid="B148-vaccines-12-01389" ref-type="bibr">148</xref>]. A decrease in the activation threshold as well as a significant increase in the probability of achieving quorum by potentially autoreactive cells under inflammatory conditions are critical risk factors for the breakdown of auto-tolerance in persistent infections and oncological processes.</p><p>Senescent cells are constantly formed throughout life. With age, they accumulate in tissues. The constant expansion of the SA spectrum leads to an increase in the clonal diversity of anti-senescent T lymphocytes. Together with the production of inflammatory SASP factors, this increases the probability of activation of the threshold number of potentially autoreactive T lymphocytes [<xref rid="B149-vaccines-12-01389" ref-type="bibr">149</xref>]. This, apparently, is one of the risk factors for the development of autoimmune reactions associated with aging [<xref rid="B150-vaccines-12-01389" ref-type="bibr">150</xref>]. At the same time, senescent cells have developed certain mechanisms for evading immune surveillance. They increase the expression of HLA-E (H2-Qa-1), which protects them from NK and CD8<sup>+</sup> lymphocytes, and also express the molecules CD24, CD47, and GD2, which transmit the &#x0201c;do not eat me&#x0201d; signal [<xref rid="B85-vaccines-12-01389" ref-type="bibr">85</xref>,<xref rid="B151-vaccines-12-01389" ref-type="bibr">151</xref>]. Apparently, the age-related decrease in the efficiency of elimination of senescent cells by the immune system is associated with the processes described earlier for persistent antigens. A gradual increase in the antigen load exhausts the reserves of the immune system; constant stimulation leads to the depletion of specific T cells or their transition to a senescent state.</p><p>Age-related changes in the repertoires of antigen-recognizing receptors of T and B lymphocytes are directly related to the dynamics of the diversity of commensal antigens. There is an increasing body of evidence pointing at the influence of the intestinal microbiome on the aging processes associated with the accumulation of senescent cells, an increase in systemic inflammation, and an increased predisposition to various age-related diseases [<xref rid="B152-vaccines-12-01389" ref-type="bibr">152</xref>]. Recent studies demonstrated that constant stimulation of the intestinal microbiome with antigens causes aging of B cells of the germinal centers in the lymph nodes of the small intestine. This leads to the accumulation of B cells with signs of senescence and a shift in the diversity of B cell-produced IgA molecules. In turn, this disrupts the balance of the microbiome and causes additional antigen stimulation, which closes the vicious circle (see <xref rid="vaccines-12-01389-f001" ref-type="fig">Figure 1</xref>) [<xref rid="B153-vaccines-12-01389" ref-type="bibr">153</xref>]. Chronic local inflammation leads to the damage of tissue barriers and promotes bacterial translocation (the penetration of bacteria or their antigens into the systemic bloodstream) [<xref rid="B154-vaccines-12-01389" ref-type="bibr">154</xref>,<xref rid="B155-vaccines-12-01389" ref-type="bibr">155</xref>]. Chronic inflammation and stimulation with multiple commensal antigens lead to imbalance in the repertoires of antigen-recognizing receptors of Teff and Treg cells, accumulation of Tmem cells, and a decrease in the number of naive lymphocytes [<xref rid="B156-vaccines-12-01389" ref-type="bibr">156</xref>,<xref rid="B157-vaccines-12-01389" ref-type="bibr">157</xref>,<xref rid="B158-vaccines-12-01389" ref-type="bibr">158</xref>]. Under these conditions, the activation threshold of a large number of T cells of various specificities decreases and the probability of achieving quorum by autoreactive lymphocytes increases. In addition, it has been shown that disturbances in the intestinal microbiome cause a decrease in the efficiency of hematopoiesis due to the suppression of multipotent progenitor cells [<xref rid="B159-vaccines-12-01389" ref-type="bibr">159</xref>]. Thus, constant antigen stimulation depletes the immune system and is one of the causes of immunoaging and decreased immunoreactivity in old age. This is reflected in an increased risk of autoimmune and oncological processes, as well as an increased susceptibility to infectious diseases and reduced vaccination efficiency in the elderly [<xref rid="B160-vaccines-12-01389" ref-type="bibr">160</xref>]. Therefore, the development of senotherapy methods aimed at reducing the number of senescent cells in the gastrointestinal tract along with restoring microbiome balance may be a promising strategy to mitigate the negative consequences of aging. In this context, the development of senolytic vaccines aimed at eliminating senescent B lymphocytes in the germinal centers of the small intestinal lymph nodes represents an example of a potential tissue-specific vaccination strategy. This is of interest from the point of view of the uniqueness of the pathogenetic mechanisms of aging inherent in each tissue or organ. Age-related changes in the microbiome adversely affect the bone marrow output of B cells, their differentiation, and antibody production [<xref rid="B161-vaccines-12-01389" ref-type="bibr">161</xref>]. The spontaneous development of germinal centers observed with aging, coupled with the accumulation of senescence-associated T and B cells, contributes to immunoaging and increases the risk of autoimmune reactions [<xref rid="B162-vaccines-12-01389" ref-type="bibr">162</xref>]. These changes, in turn, diminish the effectiveness of vaccination and elevate the risks of adverse reactions. This underscores the necessity for further research into the role of the microbiome in shaping the immune response to vaccination, as well as the development of effective strategies for microbiome correction in older individuals, particularly during vaccination periods. Recent studies have demonstrated that bifidobacterium can significantly enhance the vaccine response and represent an important component of the microbiome in youth [<xref rid="B163-vaccines-12-01389" ref-type="bibr">163</xref>]. It is evident that vaccination, when combined with microbiome correction, may enhance the efficacy and safety of the use of senolytic vaccines in older individuals.</p><p>Thus, the development of autoimmune reactions appears to be the greatest threat to the intensification of the immune response against SA, and both the formed tolerance to SA and the reduced immune reactivity typical of old age create additional difficulties in the development of senolytic vaccines [<xref rid="B164-vaccines-12-01389" ref-type="bibr">164</xref>]. Despite the attractiveness of such platforms and the demand for vaccine-based approaches for the prevention and therapy of age-related diseases, the development of such methods still presents a serious challenge for modern immunology and biotechnology [<xref rid="B165-vaccines-12-01389" ref-type="bibr">165</xref>]. However, alternative methods of combating the pathological accumulation of senescent cells, which rely on various senolytics and senomorphics, are currently being widely studied [<xref rid="B166-vaccines-12-01389" ref-type="bibr">166</xref>,<xref rid="B167-vaccines-12-01389" ref-type="bibr">167</xref>]. Perhaps the use of approaches combining specific stimulation of the immune response with the use of other methods of senotherapy will provide a safe and effective method for reducing the senescent load.</p></sec><sec id="sec4-vaccines-12-01389"><title>4. The Current State of the Senotherapeutic Approaches</title><p>In the last decade, encouraging results have been obtained in the study of senolytics, drugs that selectively destroy senescent cells by inducing apoptosis [<xref rid="B168-vaccines-12-01389" ref-type="bibr">168</xref>]. The demonstrated positive effect of dasatinib and quercetin on senescent cells led to widespread research into senolytics [<xref rid="B169-vaccines-12-01389" ref-type="bibr">169</xref>]. These drugs are able to induce apoptosis in senescent cells by suppressing ephrins (EFNB-1/3) and phosphatidylinositol 3-kinase (PI3K), respectively [<xref rid="B169-vaccines-12-01389" ref-type="bibr">169</xref>]. These targets play an important role in the molecular cascades that control senescent cell survival and apoptotic death, and their blockade causes the elimination of senescent cells of various localizations [<xref rid="B169-vaccines-12-01389" ref-type="bibr">169</xref>,<xref rid="B170-vaccines-12-01389" ref-type="bibr">170</xref>]. Although the precise mechanisms of action of senolytics are not yet fully understood, it is hypothesized that transcriptomic differences between healthy and senescent cells confer a degree of selectivity in the effects of these drugs [<xref rid="B67-vaccines-12-01389" ref-type="bibr">67</xref>,<xref rid="B171-vaccines-12-01389" ref-type="bibr">171</xref>]. The need to increase efficiency and specificity while reducing the risk of off-target effects led to the emergence of the second generation of senolytics. The substances in this group are diverse and can act through a wide range of senolytic mechanisms. These include inhibition of intracellular pathways essential for senescent cells, depletion of metabolites critical for these cells, disruption of proteostasis, electrolyte balance, aggravation of mitochondrial dysfunction, promotion of ROS accumulation, and many others. [<xref rid="B170-vaccines-12-01389" ref-type="bibr">170</xref>]. The main molecular targets of the second generation of senolytics include proteins of the Bcl-2 family, p16, p21, p53, Akt, HSP90, PI3K, FOXO4, SA-&#x003b2;-Gal, and others [<xref rid="B170-vaccines-12-01389" ref-type="bibr">170</xref>,<xref rid="B172-vaccines-12-01389" ref-type="bibr">172</xref>]. In addition, the action of some substances from this group, such as cardiac glycosides, is associated with suppression of Na<sup>+</sup>/K<sup>+</sup>-ATPase, which leads to destabilization of the membrane potential and a decrease in intracellular pH [<xref rid="B173-vaccines-12-01389" ref-type="bibr">173</xref>]. It is assumed that senescent cells are already at the limit of their adaptive reserve, and additional stress leads to their selective death.</p><p>Another strategy of senotherapy is aimed at minimizing the impact of senescent cells on the body. Usually, drugs from this group (senomorphics) inhibit the production of pro-inflammatory SASP factors in various ways without killing senescent cells [<xref rid="B167-vaccines-12-01389" ref-type="bibr">167</xref>]. The most well-known representatives of senomorphics are rapamycin, metformin, quercetin, resveratrol, aspirin, and statins [<xref rid="B174-vaccines-12-01389" ref-type="bibr">174</xref>]. The mechanisms of action of this group of substances are very diverse and have not been sufficiently studied. Most often, their action is directed at the molecular targets of the following signaling pathways: mTOR, NF-&#x003ba;B, AMPK, SIRT1, IGF-1, NRF2, p38MAPK, IRAK1, etc. [<xref rid="B153-vaccines-12-01389" ref-type="bibr">153</xref>,<xref rid="B174-vaccines-12-01389" ref-type="bibr">174</xref>]. Interestingly, more and more data are accumulating that senescent cells can perform useful physiological functions [<xref rid="B175-vaccines-12-01389" ref-type="bibr">175</xref>]. For example, it was demonstrated that in some cases, their elimination can negatively affect the structure of tissues, slow down regeneration and wound healing, and, at the early stages of development, even lead to disruption of the development of organs and tissues [<xref rid="B175-vaccines-12-01389" ref-type="bibr">175</xref>,<xref rid="B176-vaccines-12-01389" ref-type="bibr">176</xref>]. Therefore, in some situations, the use of senomorphics may be more preferable. The uniqueness of the aging mechanisms for each cell type is associated with the functional and structural features of various tissues and organs. Several SAAs have been identified. Some are common to various senescent cell types (e.g., NKG2DL and uPAR), while others exhibit tissue specificity (e.g., Cathepsin F in dermal fibroblasts, CD9 in endothelial cells, KLRG-1 and CD153 in T cells, and CD30 in B cells; see <xref rid="vaccines-12-01389-t002" ref-type="table">Table 2</xref>) [<xref rid="B69-vaccines-12-01389" ref-type="bibr">69</xref>,<xref rid="B80-vaccines-12-01389" ref-type="bibr">80</xref>,<xref rid="B82-vaccines-12-01389" ref-type="bibr">82</xref>,<xref rid="B177-vaccines-12-01389" ref-type="bibr">177</xref>,<xref rid="B178-vaccines-12-01389" ref-type="bibr">178</xref>]. This suggests the potential for tissue-specific elimination of senescent cells, which is important in the context of the uneven aging of different tissues [<xref rid="B179-vaccines-12-01389" ref-type="bibr">179</xref>]. However, to minimize off-target effects, further investigation into both common and tissue-specific SSAs is required. This would broaden the therapeutic potential of targeted senotherapeutic approaches, including vaccine-based strategies.</p><p>The diversity of the nature of senescent cells explains the selectivity of the action of modern senotherapeutics in relation to certain cell types or subpopulations of senescent cells. Therefore, combinations of some senotherapeutic agents that demonstrated synergistic action and efficiency are currently being studied [<xref rid="B169-vaccines-12-01389" ref-type="bibr">169</xref>,<xref rid="B170-vaccines-12-01389" ref-type="bibr">170</xref>,<xref rid="B172-vaccines-12-01389" ref-type="bibr">172</xref>]. The most studied senotherapeutics include various combinations of dasatinib, quercetin, fisetin, and navitoclax, which have been tested in clinical trials and shown positive results [<xref rid="B166-vaccines-12-01389" ref-type="bibr">166</xref>,<xref rid="B189-vaccines-12-01389" ref-type="bibr">189</xref>]. It should be emphasized that the causes and mechanisms of cellular aging differ for different physiological or pathological processes. This implies the uniqueness of the signs and markers of aging and senescent cells inherent in a specific cell type, tissue, or organ. Therefore, the development of senotherapeutic strategies should take into account not only the fundamental principles of aging but also the specific pathophysiological characteristics of the organism as well as the target tissue or organ. Therefore, the development of senotherapeutic strategies should take into account the specific pathophysiological characteristics of the organism as well as the target tissue or organ. Also promising are strategies targeting the fundamental causes of senescent cell accumulation. For example, selective activation of apoptosis in senescent cells while sparing healthy cells would allow the removal of harmful and dysfunctional cells with minimal side effects. Thus, a primary goal of senotherapy is the safe mitigation of aging&#x02019;s effects and the prolongation of a healthy lifespan.</p></sec><sec sec-type="discussion" id="sec5-vaccines-12-01389"><title>5. Discussion</title><p>The use of various senotherapy strategies opens up great opportunities for extending the period of active longevity. Positive effects from the use of various senolytics and senomorphics have been demonstrated in recent years [<xref rid="B190-vaccines-12-01389" ref-type="bibr">190</xref>,<xref rid="B191-vaccines-12-01389" ref-type="bibr">191</xref>]. However, their action is still insufficiently specific, is associated with the risk of adverse reactions, and requires higher efficiency [<xref rid="B192-vaccines-12-01389" ref-type="bibr">192</xref>]. Relatively high specificity and efficiency in experiments on mice were demonstrated by removing senescent cells using cytotoxic antibodies or CAR-T therapy [<xref rid="B69-vaccines-12-01389" ref-type="bibr">69</xref>,<xref rid="B180-vaccines-12-01389" ref-type="bibr">180</xref>,<xref rid="B193-vaccines-12-01389" ref-type="bibr">193</xref>,<xref rid="B194-vaccines-12-01389" ref-type="bibr">194</xref>,<xref rid="B195-vaccines-12-01389" ref-type="bibr">195</xref>]. However, in the context of widespread use, these approaches are significantly inferior to senolytic vaccines due to their extremely high cost, difficulty of production, and transportation.</p><p>Vaccine development is, in principle, a complex and lengthy process that includes searching for and selecting a target antigen, choosing a platform and adjuvant, and assessing efficacy and safety. The latter is the most important point before widespread clinical use is approved. The development of senolytic vaccines opens a fundamentally new stage in the development of vaccine technology, which will require overcoming many pitfalls and hidden risks, primarily those related to safety. It is currently assumed that the restoration of the functions of old tissues and organs will be associated with the removal and replacement of senescent cells with new intact cells with normal vital activity. However, how timely and effective this process will be in various aged tissues remains unknown. For example, the depletion of cells positive for the senescence marker p16 in mouse models caused damage to the hemato-tissue barriers and led to fibrosis in various organs, while the removal of senescent endothelial cells did not lead to their replacement with new cells [<xref rid="B196-vaccines-12-01389" ref-type="bibr">196</xref>]. This demonstrates the possible negative effects of the elimination of senescent cells in various tissues, which must be taken into account when developing senolytic methods. Mass removal of senescent cells after vaccination can be associated with the development of a dangerous inflammatory response or the triggering of autoimmune reactions [<xref rid="B197-vaccines-12-01389" ref-type="bibr">197</xref>,<xref rid="B198-vaccines-12-01389" ref-type="bibr">198</xref>,<xref rid="B199-vaccines-12-01389" ref-type="bibr">199</xref>,<xref rid="B200-vaccines-12-01389" ref-type="bibr">200</xref>]. This must be taken into account in the context of the development of prophylactic or therapeutic vaccines. Apparently, preventing the accumulation of a large number of senescent cells in tissues by preventive vaccination carries fewer risks than using a therapeutic approach. In order to minimize the associated risks, senotherapeutic vaccines may be aimed at a narrower range of targets, act on specific target tissues or organs, and take into account their regenerative potential. Hypothetically, senolytic vaccines could be utilized for both therapeutic and preventive purposes. In the therapeutic context, it is proposed that they would eliminate accumulated senescent cells and restore tissue functions. In the preventive context, these vaccines may be administered at a younger age to prevent the age-related accumulation of senescent cells and reduce the likelihood of age-related changes. This is a promising prospect that necessitates further investigation.</p><p>Thus, in addition to identifying strictly specific antigens and obtaining an effective immune response that eliminates senescent cells, it is necessary to assess the potential risks associated with the removal of these cells. It is necessary to consider how the elimination of senescent cells will affect the function of the tissue or organ, as well as whether the regenerative potential is sufficient enough to replenish the lost elements in a timely manner [<xref rid="B201-vaccines-12-01389" ref-type="bibr">201</xref>]. It is impossible to &#x0201c;cancel&#x0201d; the formed immune response to the vaccine, so minimizing the likelihood of developing an excessive inflammatory response and triggering autoimmune processes is a critical aspect of the development of senolytic vaccines. Obviously, the creation of senolytic vaccines for various purposes will allow the use of personalized approaches for the prevention or treatment of certain age-associated diseases, as well as for the implementation of other anti-aging strategies.</p></sec><sec sec-type="conclusions" id="sec6-vaccines-12-01389"><title>6. Conclusions</title><p>In the last 10 years, the rapid development of genetic and omics technologies has opened up great opportunities for detailed research of various aspects of cell aging. High-resolution proteome assessment and single-cell transcriptome studies facilitate the search for new senescence-associated and senescence-specific antigens and allow for a more in-depth analysis of the heterogeneity of senescent cells within a tissue, organ, or between individuals. The novel coronavirus pandemic has accelerated the advancement of various platforms for the development of highly effective and safe vaccines. The new approaches rely on various adjuvants to selectively stimulate humoral or cellular immunity [<xref rid="B202-vaccines-12-01389" ref-type="bibr">202</xref>,<xref rid="B203-vaccines-12-01389" ref-type="bibr">203</xref>,<xref rid="B204-vaccines-12-01389" ref-type="bibr">204</xref>]. In vitro and in silico models are being developed for personalized prediction of adverse effects from vaccination [<xref rid="B205-vaccines-12-01389" ref-type="bibr">205</xref>,<xref rid="B206-vaccines-12-01389" ref-type="bibr">206</xref>,<xref rid="B207-vaccines-12-01389" ref-type="bibr">207</xref>]. In the long term, this will help overcome the main difficulties associated with the search for specific antigens absent in healthy tissues and develop a vaccine-based approach for safe and effective stimulation of the immune response to eliminate senescent cells of a specific type or a more universal method. Therefore, continued research in the field of senotherapy and the development of senolytic vaccines has great potential and opens up prospects for extending the period of active and healthy longevity.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, D.V.S. and E.M.; writing&#x02014;review and editing, D.V.S. and R.A.I.; writing&#x02014;original draft preparation, M.I.V., D.V.S., K.S.M., V.V.S. and R.O.S.; project administration, D.V.S. and R.A.I.; funding acquisition, D.V.S. All authors have read and agreed to the published version of the manuscript.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-vaccines-12-01389"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vaupel</surname><given-names>J.W.</given-names></name>
<name><surname>Villavicencio</surname><given-names>F.</given-names></name>
<name><surname>Bergeron-Boucher</surname><given-names>M.-P.</given-names></name>
</person-group><article-title>Demographic Perspectives on the Rise of Longevity</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2021</year><volume>118</volume><fpage>e2019536118</fpage><pub-id pub-id-type="doi">10.1073/pnas.2019536118</pub-id><pub-id pub-id-type="pmid">33571137</pub-id>
</element-citation></ref><ref id="B2-vaccines-12-01389"><label>2.</label><element-citation publication-type="webpage"><article-title>Global Health Estimates: Life Expectancy and Leading Causes of Death and Disability</article-title><comment>Available online: <ext-link xlink:href="https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates" ext-link-type="uri">https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-11-30">(accessed on 30 November 2024)</date-in-citation></element-citation></ref><ref id="B3-vaccines-12-01389"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Crimmins</surname><given-names>E.M.</given-names></name>
</person-group><article-title>Lifespan and Healthspan: Past, Present, and Promise</article-title><source>Gerontologist</source><year>2015</year><volume>55</volume><fpage>901</fpage><lpage>911</lpage><pub-id pub-id-type="doi">10.1093/geront/gnv130</pub-id><pub-id pub-id-type="pmid">26561272</pub-id>
</element-citation></ref><ref id="B4-vaccines-12-01389"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Scott</surname><given-names>A.J.</given-names></name>
</person-group><article-title>The Longevity Economy</article-title><source>Lancet Healthy Longev.</source><year>2021</year><volume>2</volume><fpage>e828</fpage><lpage>e835</lpage><pub-id pub-id-type="doi">10.1016/S2666-7568(21)00250-6</pub-id><pub-id pub-id-type="pmid">36098039</pub-id>
</element-citation></ref><ref id="B5-vaccines-12-01389"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Harinath</surname><given-names>G.</given-names></name>
<name><surname>Zalzala</surname><given-names>S.</given-names></name>
<name><surname>Nyquist</surname><given-names>A.</given-names></name>
<name><surname>Wouters</surname><given-names>M.</given-names></name>
<name><surname>Isman</surname><given-names>A.</given-names></name>
<name><surname>Moel</surname><given-names>M.</given-names></name>
<name><surname>Verdin</surname><given-names>E.</given-names></name>
<name><surname>Kaeberlein</surname><given-names>M.</given-names></name>
<name><surname>Kennedy</surname><given-names>B.</given-names></name>
<name><surname>Bischof</surname><given-names>E.</given-names></name>
</person-group><article-title>The Role of Quality of Life Data as an Endpoint for Collecting Real-World Evidence within Geroscience Clinical Trials</article-title><source>Ageing Res. Rev.</source><year>2024</year><volume>97</volume><fpage>102293</fpage><pub-id pub-id-type="doi">10.1016/j.arr.2024.102293</pub-id><pub-id pub-id-type="pmid">38574864</pub-id>
</element-citation></ref><ref id="B6-vaccines-12-01389"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wu</surname><given-names>R.</given-names></name>
<name><surname>Sun</surname><given-names>F.</given-names></name>
<name><surname>Zhang</surname><given-names>W.</given-names></name>
<name><surname>Ren</surname><given-names>J.</given-names></name>
<name><surname>Liu</surname><given-names>G.-H.</given-names></name>
</person-group><article-title>Targeting Aging and Age-Related Diseases with Vaccines</article-title><source>Nat. Aging</source><year>2024</year><volume>4</volume><fpage>464</fpage><lpage>482</lpage><pub-id pub-id-type="doi">10.1038/s43587-024-00597-0</pub-id><pub-id pub-id-type="pmid">38622408</pub-id>
</element-citation></ref><ref id="B7-vaccines-12-01389"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ghattas</surname><given-names>M.</given-names></name>
<name><surname>Dwivedi</surname><given-names>G.</given-names></name>
<name><surname>Lavertu</surname><given-names>M.</given-names></name>
<name><surname>Alameh</surname><given-names>M.-G.</given-names></name>
</person-group><article-title>Vaccine Technologies and Platforms for Infectious Diseases: Current Progress, Challenges, and Opportunities</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><elocation-id>1490</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines9121490</pub-id><pub-id pub-id-type="pmid">34960236</pub-id>
</element-citation></ref><ref id="B8-vaccines-12-01389"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Muhs</surname><given-names>A.</given-names></name>
<name><surname>Hickman</surname><given-names>D.T.</given-names></name>
<name><surname>Pihlgren</surname><given-names>M.</given-names></name>
<name><surname>Chuard</surname><given-names>N.</given-names></name>
<name><surname>Giriens</surname><given-names>V.</given-names></name>
<name><surname>Meerschman</surname><given-names>C.</given-names></name>
<name><surname>van der Auwera</surname><given-names>I.</given-names></name>
<name><surname>van Leuven</surname><given-names>F.</given-names></name>
<name><surname>Sugawara</surname><given-names>M.</given-names></name>
<name><surname>Weingertner</surname><given-names>M.-C.</given-names></name>
<etal/>
</person-group><article-title>Liposomal Vaccines with Conformation-Specific Amyloid Peptide Antigens Define Immune Response and Efficacy in APP Transgenic Mice</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2007</year><volume>104</volume><fpage>9810</fpage><lpage>9815</lpage><pub-id pub-id-type="doi">10.1073/pnas.0703137104</pub-id><pub-id pub-id-type="pmid">17517595</pub-id>
</element-citation></ref><ref id="B9-vaccines-12-01389"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hickman</surname><given-names>D.T.</given-names></name>
<name><surname>L&#x000f3;pez-Deber</surname><given-names>M.P.</given-names></name>
<name><surname>Ndao</surname><given-names>D.M.</given-names></name>
<name><surname>Silva</surname><given-names>A.B.</given-names></name>
<name><surname>Nand</surname><given-names>D.</given-names></name>
<name><surname>Pihlgren</surname><given-names>M.</given-names></name>
<name><surname>Giriens</surname><given-names>V.</given-names></name>
<name><surname>Madani</surname><given-names>R.</given-names></name>
<name><surname>St-Pierre</surname><given-names>A.</given-names></name>
<name><surname>Karastaneva</surname><given-names>H.</given-names></name>
<etal/>
</person-group><article-title>Sequence-Independent Control of Peptide Conformation in Liposomal Vaccines for Targeting Protein Misfolding Diseases</article-title><source>J. Biol. Chem.</source><year>2011</year><volume>286</volume><fpage>13966</fpage><lpage>13976</lpage><pub-id pub-id-type="doi">10.1074/jbc.M110.186338</pub-id><pub-id pub-id-type="pmid">21343310</pub-id>
</element-citation></ref><ref id="B10-vaccines-12-01389"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rafii</surname><given-names>M.S.</given-names></name>
<name><surname>Sol</surname><given-names>O.</given-names></name>
<name><surname>Mobley</surname><given-names>W.C.</given-names></name>
<name><surname>Delpretti</surname><given-names>S.</given-names></name>
<name><surname>Skotko</surname><given-names>B.G.</given-names></name>
<name><surname>Burke</surname><given-names>A.D.</given-names></name>
<name><surname>Sabbagh</surname><given-names>M.N.</given-names></name>
<name><surname>Yuan</surname><given-names>S.H.</given-names></name>
<name><surname>Rissman</surname><given-names>R.A.</given-names></name>
<name><surname>Pulsifer</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Safety, Tolerability, and Immunogenicity of the ACI-24 Vaccine in Adults with Down Syndrome: A Phase 1b Randomized Clinical Trial</article-title><source>JAMA Neurol.</source><year>2022</year><volume>79</volume><fpage>565</fpage><lpage>574</lpage><pub-id pub-id-type="doi">10.1001/jamaneurol.2022.0983</pub-id><pub-id pub-id-type="pmid">35532913</pub-id>
</element-citation></ref><ref id="B11-vaccines-12-01389"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>C.Y.</given-names></name>
<name><surname>Wang</surname><given-names>P.-N.</given-names></name>
<name><surname>Chiu</surname><given-names>M.-J.</given-names></name>
<name><surname>Finstad</surname><given-names>C.L.</given-names></name>
<name><surname>Lin</surname><given-names>F.</given-names></name>
<name><surname>Lynn</surname><given-names>S.</given-names></name>
<name><surname>Tai</surname><given-names>Y.-H.</given-names></name>
<name><surname>De Fang</surname><given-names>X.</given-names></name>
<name><surname>Zhao</surname><given-names>K.</given-names></name>
<name><surname>Hung</surname><given-names>C.-H.</given-names></name>
<etal/>
</person-group><article-title>UB-311, a Novel UBITh<sup>&#x000ae;</sup> Amyloid &#x003b2; Peptide Vaccine for Mild Alzheimer&#x02019;s Disease</article-title><source>Alzheimer&#x02019;s Dement.</source><year>2017</year><volume>3</volume><fpage>262</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.1016/j.trci.2017.03.005</pub-id></element-citation></ref><ref id="B12-vaccines-12-01389"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yu</surname><given-names>H.J.</given-names></name>
<name><surname>Dickson</surname><given-names>S.P.</given-names></name>
<name><surname>Wang</surname><given-names>P.-N.</given-names></name>
<name><surname>Chiu</surname><given-names>M.-J.</given-names></name>
<name><surname>Huang</surname><given-names>C.-C.</given-names></name>
<name><surname>Chang</surname><given-names>C.-C.</given-names></name>
<name><surname>Liu</surname><given-names>H.</given-names></name>
<name><surname>Hendrix</surname><given-names>S.B.</given-names></name>
<name><surname>Dodart</surname><given-names>J.-C.</given-names></name>
<name><surname>Verma</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Safety, Tolerability, Immunogenicity, and Efficacy of UB-311 in Participants with Mild Alzheimer&#x02019;s Disease: A Randomised, Double-Blind, Placebo-Controlled, Phase 2a Study</article-title><source>EBioMedicine</source><year>2023</year><volume>94</volume><elocation-id>104665</elocation-id><pub-id pub-id-type="doi">10.1016/j.ebiom.2023.104665</pub-id><pub-id pub-id-type="pmid">37392597</pub-id>
</element-citation></ref><ref id="B13-vaccines-12-01389"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Davtyan</surname><given-names>H.</given-names></name>
<name><surname>Ghochikyan</surname><given-names>A.</given-names></name>
<name><surname>Petrushina</surname><given-names>I.</given-names></name>
<name><surname>Hovakimyan</surname><given-names>A.</given-names></name>
<name><surname>Davtyan</surname><given-names>A.</given-names></name>
<name><surname>Cribbs</surname><given-names>D.H.</given-names></name>
<name><surname>Agadjanyan</surname><given-names>M.G.</given-names></name>
</person-group><article-title>The MultiTEP Platform-Based Alzheimer&#x02019;s Disease Epitope Vaccine Activates a Broad Repertoire of T Helper Cells in Nonhuman Primates</article-title><source>Alzheimer&#x02019;s Dement.</source><year>2014</year><volume>10</volume><fpage>271</fpage><lpage>283</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2013.12.003</pub-id><pub-id pub-id-type="pmid">24560029</pub-id>
</element-citation></ref><ref id="B14-vaccines-12-01389"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lacosta</surname><given-names>A.-M.</given-names></name>
<name><surname>Pascual-Lucas</surname><given-names>M.</given-names></name>
<name><surname>Pesini</surname><given-names>P.</given-names></name>
<name><surname>Casabona</surname><given-names>D.</given-names></name>
<name><surname>P&#x000e9;rez-Grijalba</surname><given-names>V.</given-names></name>
<name><surname>Marcos-Campos</surname><given-names>I.</given-names></name>
<name><surname>Sarasa</surname><given-names>L.</given-names></name>
<name><surname>Canudas</surname><given-names>J.</given-names></name>
<name><surname>Badi</surname><given-names>H.</given-names></name>
<name><surname>Monle&#x000f3;n</surname><given-names>I.</given-names></name>
<etal/>
</person-group><article-title>Safety, Tolerability and Immunogenicity of an Active Anti-A&#x003b2;40 Vaccine (ABvac40) in Patients with Alzheimer&#x02019;s Disease: A Randomised, Double-Blind, Placebo-Controlled, Phase I Trial</article-title><source>Alzheimer&#x02019;s Res. Ther.</source><year>2018</year><volume>10</volume><fpage>12</fpage><pub-id pub-id-type="doi">10.1186/s13195-018-0340-8</pub-id><pub-id pub-id-type="pmid">29378651</pub-id>
</element-citation></ref><ref id="B15-vaccines-12-01389"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Theunis</surname><given-names>C.</given-names></name>
<name><surname>Crespo-Biel</surname><given-names>N.</given-names></name>
<name><surname>Gafner</surname><given-names>V.</given-names></name>
<name><surname>Pihlgren</surname><given-names>M.</given-names></name>
<name><surname>L&#x000f3;pez-Deber</surname><given-names>M.P.</given-names></name>
<name><surname>Reis</surname><given-names>P.</given-names></name>
<name><surname>Hickman</surname><given-names>D.T.</given-names></name>
<name><surname>Adolfsson</surname><given-names>O.</given-names></name>
<name><surname>Chuard</surname><given-names>N.</given-names></name>
<name><surname>Ndao</surname><given-names>D.M.</given-names></name>
<etal/>
</person-group><article-title>Efficacy and Safety of a Liposome-Based Vaccine against Protein Tau, Assessed in Tau.P301L Mice That Model Tauopathy</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><elocation-id>e72301</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0072301</pub-id><pub-id pub-id-type="pmid">23977276</pub-id>
</element-citation></ref><ref id="B16-vaccines-12-01389"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Novak</surname><given-names>P.</given-names></name>
<name><surname>Schmidt</surname><given-names>R.</given-names></name>
<name><surname>Kontsekova</surname><given-names>E.</given-names></name>
<name><surname>Kovacech</surname><given-names>B.</given-names></name>
<name><surname>Smolek</surname><given-names>T.</given-names></name>
<name><surname>Katina</surname><given-names>S.</given-names></name>
<name><surname>Fialova</surname><given-names>L.</given-names></name>
<name><surname>Prcina</surname><given-names>M.</given-names></name>
<name><surname>Parrak</surname><given-names>V.</given-names></name>
<name><surname>Dal-Bianco</surname><given-names>P.</given-names></name>
<etal/>
</person-group><article-title>FUNDAMANT: An Interventional 72-Week Phase 1 Follow-up Study of AADvac1, an Active Immunotherapy against Tau Protein Pathology in Alzheimer&#x02019;s Disease</article-title><source>Alzheimer&#x02019;s Res. Ther.</source><year>2018</year><volume>10</volume><fpage>108</fpage><pub-id pub-id-type="doi">10.1186/s13195-018-0436-1</pub-id><pub-id pub-id-type="pmid">30355322</pub-id>
</element-citation></ref><ref id="B17-vaccines-12-01389"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Novak</surname><given-names>P.</given-names></name>
<name><surname>Kovacech</surname><given-names>B.</given-names></name>
<name><surname>Katina</surname><given-names>S.</given-names></name>
<name><surname>Schmidt</surname><given-names>R.</given-names></name>
<name><surname>Scheltens</surname><given-names>P.</given-names></name>
<name><surname>Kontsekova</surname><given-names>E.</given-names></name>
<name><surname>Ropele</surname><given-names>S.</given-names></name>
<name><surname>Fialova</surname><given-names>L.</given-names></name>
<name><surname>Kramberger</surname><given-names>M.</given-names></name>
<name><surname>Paulenka-Ivanovova</surname><given-names>N.</given-names></name>
<etal/>
</person-group><article-title>ADAMANT: A Placebo-Controlled Randomized Phase 2 Study of AADvac1, an Active Immunotherapy against Pathological Tau in Alzheimer&#x02019;s Disease</article-title><source>Nat. Aging</source><year>2021</year><volume>1</volume><fpage>521</fpage><lpage>534</lpage><pub-id pub-id-type="doi">10.1038/s43587-021-00070-2</pub-id><pub-id pub-id-type="pmid">37117834</pub-id>
</element-citation></ref><ref id="B18-vaccines-12-01389"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cullen</surname><given-names>N.C.</given-names></name>
<name><surname>Novak</surname><given-names>P.</given-names></name>
<name><surname>Tosun</surname><given-names>D.</given-names></name>
<name><surname>Kovacech</surname><given-names>B.</given-names></name>
<name><surname>Hanes</surname><given-names>J.</given-names></name>
<name><surname>Kontsekova</surname><given-names>E.</given-names></name>
<name><surname>Fresser</surname><given-names>M.</given-names></name>
<name><surname>Ropele</surname><given-names>S.</given-names></name>
<name><surname>Feldman</surname><given-names>H.H.</given-names></name>
<name><surname>Schmidt</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>Efficacy Assessment of an Active Tau Immunotherapy in Alzheimer&#x02019;s Disease Patients with Amyloid and Tau Pathology: A Post Hoc Analysis of the &#x0201c;ADAMANT&#x0201d; Randomised, Placebo-Controlled, Double-Blind, Multi-Centre, Phase 2 Clinical Trial</article-title><source>EBioMedicine</source><year>2024</year><volume>99</volume><elocation-id>104923</elocation-id><pub-id pub-id-type="doi">10.1016/j.ebiom.2023.104923</pub-id><pub-id pub-id-type="pmid">38101301</pub-id>
</element-citation></ref><ref id="B19-vaccines-12-01389"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Park</surname><given-names>H.-H.</given-names></name>
<name><surname>Lee</surname><given-names>K.-Y.</given-names></name>
<name><surname>Kim</surname><given-names>S.</given-names></name>
<name><surname>Lee</surname><given-names>J.W.</given-names></name>
<name><surname>Choi</surname><given-names>N.-Y.</given-names></name>
<name><surname>Lee</surname><given-names>E.-H.</given-names></name>
<name><surname>Lee</surname><given-names>Y.J.</given-names></name>
<name><surname>Lee</surname><given-names>S.-H.</given-names></name>
<name><surname>Koh</surname><given-names>S.-H.</given-names></name>
</person-group><article-title>Novel Vaccine Peptide GV1001 Effectively Blocks &#x003b2;-Amyloid Toxicity by Mimicking the Extra-Telomeric Functions of Human Telomerase Reverse Transcriptase</article-title><source>Neurobiol. Aging</source><year>2014</year><volume>35</volume><fpage>1255</fpage><lpage>1274</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2013.12.015</pub-id><pub-id pub-id-type="pmid">24439482</pub-id>
</element-citation></ref><ref id="B20-vaccines-12-01389"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Frenkel</surname><given-names>D.</given-names></name>
<name><surname>Maron</surname><given-names>R.</given-names></name>
<name><surname>Burt</surname><given-names>D.S.</given-names></name>
<name><surname>Weiner</surname><given-names>H.L.</given-names></name>
</person-group><article-title>Nasal Vaccination with a Proteosome-Based Adjuvant and Glatiramer Acetate Clears Beta-Amyloid in a Mouse Model of Alzheimer Disease</article-title><source>J. Clin. Investig.</source><year>2005</year><volume>115</volume><fpage>2423</fpage><lpage>2433</lpage><pub-id pub-id-type="doi">10.1172/JCI23241</pub-id><pub-id pub-id-type="pmid">16100572</pub-id>
</element-citation></ref><ref id="B21-vaccines-12-01389"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pang</surname><given-names>Z.</given-names></name>
<name><surname>Nakagami</surname><given-names>H.</given-names></name>
<name><surname>Osako</surname><given-names>M.K.</given-names></name>
<name><surname>Koriyama</surname><given-names>H.</given-names></name>
<name><surname>Nakagami</surname><given-names>F.</given-names></name>
<name><surname>Tomioka</surname><given-names>H.</given-names></name>
<name><surname>Shimamura</surname><given-names>M.</given-names></name>
<name><surname>Kurinami</surname><given-names>H.</given-names></name>
<name><surname>Takami</surname><given-names>Y.</given-names></name>
<name><surname>Morishita</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>Therapeutic Vaccine against DPP4 Improves Glucose Metabolism in Mice</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2014</year><volume>111</volume><fpage>E1256-1263</fpage><pub-id pub-id-type="doi">10.1073/pnas.1322009111</pub-id><pub-id pub-id-type="pmid">24639549</pub-id>
</element-citation></ref><ref id="B22-vaccines-12-01389"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cavelti-Weder</surname><given-names>C.</given-names></name>
<name><surname>Timper</surname><given-names>K.</given-names></name>
<name><surname>Seelig</surname><given-names>E.</given-names></name>
<name><surname>Keller</surname><given-names>C.</given-names></name>
<name><surname>Osranek</surname><given-names>M.</given-names></name>
<name><surname>L&#x000e4;ssing</surname><given-names>U.</given-names></name>
<name><surname>Spohn</surname><given-names>G.</given-names></name>
<name><surname>Maurer</surname><given-names>P.</given-names></name>
<name><surname>M&#x000fc;ller</surname><given-names>P.</given-names></name>
<name><surname>Jennings</surname><given-names>G.T.</given-names></name>
<etal/>
</person-group><article-title>Development of an Interleukin-1&#x003b2; Vaccine in Patients with Type 2 Diabetes</article-title><source>Mol. Ther.</source><year>2016</year><volume>24</volume><fpage>1003</fpage><lpage>1012</lpage><pub-id pub-id-type="doi">10.1038/mt.2015.227</pub-id><pub-id pub-id-type="pmid">26686385</pub-id>
</element-citation></ref><ref id="B23-vaccines-12-01389"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Yu</surname><given-names>X.-L.</given-names></name>
<name><surname>Zha</surname><given-names>J.</given-names></name>
<name><surname>Mao</surname><given-names>L.-Z.</given-names></name>
<name><surname>Chai</surname><given-names>J.-Q.</given-names></name>
<name><surname>Liu</surname><given-names>R.-T.</given-names></name>
</person-group><article-title>Therapeutic Vaccine against IL-1&#x003b2; Improved Glucose Control in a Mouse Model of Type 2 Diabetes</article-title><source>Life Sci.</source><year>2018</year><volume>192</volume><fpage>68</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1016/j.lfs.2017.11.021</pub-id><pub-id pub-id-type="pmid">29155303</pub-id>
</element-citation></ref><ref id="B24-vaccines-12-01389"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yokota</surname><given-names>H.</given-names></name>
<name><surname>Hayashi</surname><given-names>H.</given-names></name>
<name><surname>Hanaguri</surname><given-names>J.</given-names></name>
<name><surname>Yamagami</surname><given-names>S.</given-names></name>
<name><surname>Kushiyama</surname><given-names>A.</given-names></name>
<name><surname>Nakagami</surname><given-names>H.</given-names></name>
<name><surname>Nagaoka</surname><given-names>T.</given-names></name>
</person-group><article-title>Effect of Prorenin Peptide Vaccine on the Early Phase of Diabetic Retinopathy in a Murine Model of Type 2 Diabetes</article-title><source>PLoS ONE</source><year>2022</year><volume>17</volume><elocation-id>e0262568</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0262568</pub-id><pub-id pub-id-type="pmid">35041699</pub-id>
</element-citation></ref><ref id="B25-vaccines-12-01389"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Downham</surname><given-names>M.R.</given-names></name>
<name><surname>Auton</surname><given-names>T.R.</given-names></name>
<name><surname>Rosul</surname><given-names>A.</given-names></name>
<name><surname>Sharp</surname><given-names>H.L.</given-names></name>
<name><surname>Sj&#x000f6;str&#x000f6;m</surname><given-names>L.</given-names></name>
<name><surname>Rushton</surname><given-names>A.</given-names></name>
<name><surname>Richards</surname><given-names>J.P.</given-names></name>
<name><surname>Mant</surname><given-names>T.G.K.</given-names></name>
<name><surname>Gardiner</surname><given-names>S.M.</given-names></name>
<name><surname>Bennett</surname><given-names>T.</given-names></name>
<etal/>
</person-group><article-title>Evaluation of Two Carrier Protein-Angiotensin I Conjugate Vaccines to Assess Their Future Potential to Control High Blood Pressure (Hypertension) in Man</article-title><source>Br. J. Clin. Pharmacol.</source><year>2003</year><volume>56</volume><fpage>505</fpage><lpage>512</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2125.2003.01926.x</pub-id><pub-id pub-id-type="pmid">14651724</pub-id>
</element-citation></ref><ref id="B26-vaccines-12-01389"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brown</surname><given-names>M.J.</given-names></name>
<name><surname>Coltart</surname><given-names>J.</given-names></name>
<name><surname>Gunewardena</surname><given-names>K.</given-names></name>
<name><surname>Ritter</surname><given-names>J.M.</given-names></name>
<name><surname>Auton</surname><given-names>T.R.</given-names></name>
<name><surname>Glover</surname><given-names>J.F.</given-names></name>
</person-group><article-title>Randomized Double-Blind Placebo-Controlled Study of an Angiotensin Immunotherapeutic Vaccine (PMD3117) in Hypertensive Subjects</article-title><source>Clin. Sci.</source><year>2004</year><volume>107</volume><fpage>167</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.1042/CS20030381</pub-id></element-citation></ref><ref id="B27-vaccines-12-01389"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Amb&#x000fc;hl</surname><given-names>P.M.</given-names></name>
<name><surname>Tissot</surname><given-names>A.C.</given-names></name>
<name><surname>Fulurija</surname><given-names>A.</given-names></name>
<name><surname>Maurer</surname><given-names>P.</given-names></name>
<name><surname>Nussberger</surname><given-names>J.</given-names></name>
<name><surname>Sabat</surname><given-names>R.</given-names></name>
<name><surname>Nief</surname><given-names>V.</given-names></name>
<name><surname>Schellekens</surname><given-names>C.</given-names></name>
<name><surname>Sladko</surname><given-names>K.</given-names></name>
<name><surname>Roubicek</surname><given-names>K.</given-names></name>
<etal/>
</person-group><article-title>A Vaccine for Hypertension Based on Virus-like Particles: Preclinical Efficacy and Phase I Safety and Immunogenicity</article-title><source>J. Hypertens.</source><year>2007</year><volume>25</volume><fpage>63</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1097/HJH.0b013e32800ff5d6</pub-id><pub-id pub-id-type="pmid">17143175</pub-id>
</element-citation></ref><ref id="B28-vaccines-12-01389"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tissot</surname><given-names>A.C.</given-names></name>
<name><surname>Maurer</surname><given-names>P.</given-names></name>
<name><surname>Nussberger</surname><given-names>J.</given-names></name>
<name><surname>Sabat</surname><given-names>R.</given-names></name>
<name><surname>Pfister</surname><given-names>T.</given-names></name>
<name><surname>Ignatenko</surname><given-names>S.</given-names></name>
<name><surname>Volk</surname><given-names>H.-D.</given-names></name>
<name><surname>Stocker</surname><given-names>H.</given-names></name>
<name><surname>M&#x000fc;ller</surname><given-names>P.</given-names></name>
<name><surname>Jennings</surname><given-names>G.T.</given-names></name>
<etal/>
</person-group><article-title>Effect of Immunisation against Angiotensin II with CYT006-AngQb on Ambulatory Blood Pressure: A Double-Blind, Randomised, Placebo-Controlled Phase IIa Study</article-title><source>Lancet</source><year>2008</year><volume>371</volume><fpage>821</fpage><lpage>827</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(08)60381-5</pub-id><pub-id pub-id-type="pmid">18328929</pub-id>
</element-citation></ref><ref id="B29-vaccines-12-01389"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>X.</given-names></name>
<name><surname>Qiu</surname><given-names>Z.</given-names></name>
<name><surname>Yang</surname><given-names>S.</given-names></name>
<name><surname>Ding</surname><given-names>D.</given-names></name>
<name><surname>Chen</surname><given-names>F.</given-names></name>
<name><surname>Zhou</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>M.</given-names></name>
<name><surname>Lin</surname><given-names>J.</given-names></name>
<name><surname>Yu</surname><given-names>X.</given-names></name>
<name><surname>Zhou</surname><given-names>Z.</given-names></name>
<etal/>
</person-group><article-title>Effectiveness and Safety of a Therapeutic Vaccine Against Angiotensin II Receptor Type 1 in Hypertensive Animals</article-title><source>Hypertension</source><year>2013</year><volume>61</volume><fpage>408</fpage><lpage>416</lpage><pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.112.201020</pub-id><pub-id pub-id-type="pmid">23184378</pub-id>
</element-citation></ref><ref id="B30-vaccines-12-01389"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pan</surname><given-names>Y.</given-names></name>
<name><surname>Zhou</surname><given-names>Z.</given-names></name>
<name><surname>Zhang</surname><given-names>H.</given-names></name>
<name><surname>Zhou</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>C.</given-names></name>
<name><surname>Chen</surname><given-names>X.</given-names></name>
<name><surname>Yang</surname><given-names>S.</given-names></name>
<name><surname>Liao</surname><given-names>Y.</given-names></name>
<name><surname>Qiu</surname><given-names>Z.</given-names></name>
</person-group><article-title>The ATRQ&#x003b2;-001 Vaccine Improves Cardiac Function and Prevents Postinfarction Cardiac Remodeling in Mice</article-title><source>Hypertens. Res.</source><year>2019</year><volume>42</volume><fpage>329</fpage><lpage>340</lpage><pub-id pub-id-type="doi">10.1038/s41440-018-0185-3</pub-id><pub-id pub-id-type="pmid">30587854</pub-id>
</element-citation></ref><ref id="B31-vaccines-12-01389"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>C.</given-names></name>
<name><surname>Yan</surname><given-names>X.</given-names></name>
<name><surname>Wu</surname><given-names>D.</given-names></name>
<name><surname>Zhang</surname><given-names>K.</given-names></name>
<name><surname>Liang</surname><given-names>X.</given-names></name>
<name><surname>Pan</surname><given-names>Y.</given-names></name>
<name><surname>Zhou</surname><given-names>Y.</given-names></name>
<name><surname>Chen</surname><given-names>F.</given-names></name>
<name><surname>Chen</surname><given-names>X.</given-names></name>
<name><surname>Yang</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Vaccine Targeted Alpha 1D-Adrenergic Receptor for Hypertension</article-title><source>Hypertension</source><year>2019</year><volume>74</volume><fpage>1551</fpage><lpage>1562</lpage><pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.119.13700</pub-id><pub-id pub-id-type="pmid">31607175</pub-id>
</element-citation></ref><ref id="B32-vaccines-12-01389"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kurashiki</surname><given-names>T.</given-names></name>
<name><surname>Miyake</surname><given-names>T.</given-names></name>
<name><surname>Nakagami</surname><given-names>H.</given-names></name>
<name><surname>Nishimura</surname><given-names>M.</given-names></name>
<name><surname>Morishita</surname><given-names>R.</given-names></name>
</person-group><article-title>Prevention of Progression of Aortic Aneurysm by Peptide Vaccine Against Ang II (Angiotensin II) in a Rat Model</article-title><source>Hypertension</source><year>2020</year><volume>76</volume><fpage>1879</fpage><lpage>1888</lpage><pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.119.14442</pub-id><pub-id pub-id-type="pmid">33040618</pub-id>
</element-citation></ref><ref id="B33-vaccines-12-01389"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>H.</given-names></name>
<name><surname>Liao</surname><given-names>M.</given-names></name>
<name><surname>Cao</surname><given-names>M.</given-names></name>
<name><surname>Qiu</surname><given-names>Z.</given-names></name>
<name><surname>Yan</surname><given-names>X.</given-names></name>
<name><surname>Zhou</surname><given-names>Y.</given-names></name>
<name><surname>Wu</surname><given-names>H.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Zheng</surname><given-names>J.</given-names></name>
<name><surname>Ding</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>ATRQ&#x003b2;-001 Vaccine Prevents Experimental Abdominal Aortic Aneurysms</article-title><source>JAHA</source><year>2019</year><volume>8</volume><fpage>e012341</fpage><pub-id pub-id-type="doi">10.1161/JAHA.119.012341</pub-id><pub-id pub-id-type="pmid">31512549</pub-id>
</element-citation></ref><ref id="B34-vaccines-12-01389"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kimura</surname><given-names>T.</given-names></name>
<name><surname>Kobiyama</surname><given-names>K.</given-names></name>
<name><surname>Winkels</surname><given-names>H.</given-names></name>
<name><surname>Tse</surname><given-names>K.</given-names></name>
<name><surname>Miller</surname><given-names>J.</given-names></name>
<name><surname>Vassallo</surname><given-names>M.</given-names></name>
<name><surname>Wolf</surname><given-names>D.</given-names></name>
<name><surname>Ryden</surname><given-names>C.</given-names></name>
<name><surname>Orecchioni</surname><given-names>M.</given-names></name>
<name><surname>Dileepan</surname><given-names>T.</given-names></name>
<etal/>
</person-group><article-title>Regulatory CD4+ T Cells Recognize Major Histocompatibility Complex Class II Molecule-Restricted Peptide Epitopes of Apolipoprotein B</article-title><source>Circulation</source><year>2018</year><volume>138</volume><fpage>1130</fpage><lpage>1143</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.117.031420</pub-id><pub-id pub-id-type="pmid">29588316</pub-id>
</element-citation></ref><ref id="B35-vaccines-12-01389"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Momtazi-Borojeni</surname><given-names>A.A.</given-names></name>
<name><surname>Jaafari</surname><given-names>M.R.</given-names></name>
<name><surname>Badiee</surname><given-names>A.</given-names></name>
<name><surname>Sahebkar</surname><given-names>A.</given-names></name>
</person-group><article-title>Long-Term Generation of antiPCSK9 Antibody Using a Nanoliposome-Based Vaccine Delivery System</article-title><source>Atherosclerosis</source><year>2019</year><volume>283</volume><fpage>69</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2019.02.001</pub-id><pub-id pub-id-type="pmid">30797988</pub-id>
</element-citation></ref><ref id="B36-vaccines-12-01389"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ma</surname><given-names>Z.</given-names></name>
<name><surname>Mao</surname><given-names>C.</given-names></name>
<name><surname>Chen</surname><given-names>X.</given-names></name>
<name><surname>Yang</surname><given-names>S.</given-names></name>
<name><surname>Qiu</surname><given-names>Z.</given-names></name>
<name><surname>Yu</surname><given-names>B.</given-names></name>
<name><surname>Jia</surname><given-names>Y.</given-names></name>
<name><surname>Wu</surname><given-names>C.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<etal/>
</person-group><article-title>Peptide Vaccine Against ADAMTS-7 Ameliorates Atherosclerosis and Postinjury Neointima Hyperplasia</article-title><source>Circulation</source><year>2023</year><volume>147</volume><fpage>728</fpage><lpage>742</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.122.061516</pub-id><pub-id pub-id-type="pmid">36562301</pub-id>
</element-citation></ref><ref id="B37-vaccines-12-01389"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bourinbaiar</surname><given-names>A.S.</given-names></name>
<name><surname>Jirathitikal</surname><given-names>V.</given-names></name>
</person-group><article-title>Effect of Oral Immunization with Pooled Antigens Derived from Adipose Tissue on Atherosclerosis and Obesity Indices</article-title><source>Vaccine</source><year>2010</year><volume>28</volume><fpage>2763</fpage><lpage>2768</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2010.01.032</pub-id><pub-id pub-id-type="pmid">20117273</pub-id>
</element-citation></ref><ref id="B38-vaccines-12-01389"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bourinbaiar</surname><given-names>A.S.</given-names></name>
<name><surname>Jirathitikal</surname><given-names>V.</given-names></name>
</person-group><article-title>Safety and Efficacy Trial of Adipose-Tissue Derived Oral Preparation V-6 Immunitor (V-6): Results of Open-Label, Two-Month, Follow-up Study</article-title><source>Lipids Health Dis.</source><year>2010</year><volume>9</volume><fpage>14</fpage><pub-id pub-id-type="doi">10.1186/1476-511X-9-14</pub-id><pub-id pub-id-type="pmid">20122177</pub-id>
</element-citation></ref><ref id="B39-vaccines-12-01389"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>von Loga</surname><given-names>I.S.</given-names></name>
<name><surname>El-Turabi</surname><given-names>A.</given-names></name>
<name><surname>Jostins</surname><given-names>L.</given-names></name>
<name><surname>Miotla-Zarebska</surname><given-names>J.</given-names></name>
<name><surname>Mackay-Alderson</surname><given-names>J.</given-names></name>
<name><surname>Zeltins</surname><given-names>A.</given-names></name>
<name><surname>Parisi</surname><given-names>I.</given-names></name>
<name><surname>Bachmann</surname><given-names>M.F.</given-names></name>
<name><surname>Vincent</surname><given-names>T.L.</given-names></name>
</person-group><article-title>Active Immunisation Targeting Nerve Growth Factor Attenuates Chronic Pain Behaviour in Murine Osteoarthritis</article-title><source>Ann. Rheum. Dis.</source><year>2019</year><volume>78</volume><fpage>672</fpage><lpage>675</lpage><pub-id pub-id-type="doi">10.1136/annrheumdis-2018-214489</pub-id><pub-id pub-id-type="pmid">30862648</pub-id>
</element-citation></ref><ref id="B40-vaccines-12-01389"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sobecki</surname><given-names>M.</given-names></name>
<name><surname>Chen</surname><given-names>J.</given-names></name>
<name><surname>Krzywinska</surname><given-names>E.</given-names></name>
<name><surname>Nagarajan</surname><given-names>S.</given-names></name>
<name><surname>Fan</surname><given-names>Z.</given-names></name>
<name><surname>Nelius</surname><given-names>E.</given-names></name>
<name><surname>Monn&#x000e9; Rodriguez</surname><given-names>J.M.</given-names></name>
<name><surname>Seehusen</surname><given-names>F.</given-names></name>
<name><surname>Hussein</surname><given-names>A.</given-names></name>
<name><surname>Moschini</surname><given-names>G.</given-names></name>
<etal/>
</person-group><article-title>Vaccination-Based Immunotherapy to Target Profibrotic Cells in Liver and Lung</article-title><source>Cell Stem Cell</source><year>2022</year><volume>29</volume><fpage>1459</fpage><lpage>1474.e9</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2022.08.012</pub-id><pub-id pub-id-type="pmid">36113462</pub-id>
</element-citation></ref><ref id="B41-vaccines-12-01389"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wu</surname><given-names>D.</given-names></name>
<name><surname>Zhou</surname><given-names>Y.</given-names></name>
<name><surname>Pan</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>C.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Chen</surname><given-names>F.</given-names></name>
<name><surname>Chen</surname><given-names>X.</given-names></name>
<name><surname>Yang</surname><given-names>S.</given-names></name>
<name><surname>Zhou</surname><given-names>Z.</given-names></name>
<name><surname>Liao</surname><given-names>Y.</given-names></name>
<etal/>
</person-group><article-title>Vaccine Against PCSK9 Improved Renal Fibrosis by Regulating Fatty Acid &#x003b2;-Oxidation</article-title><source>J. Am. Heart Assoc.</source><year>2020</year><volume>9</volume><fpage>e014358</fpage><pub-id pub-id-type="doi">10.1161/JAHA.119.014358</pub-id><pub-id pub-id-type="pmid">31870234</pub-id>
</element-citation></ref><ref id="B42-vaccines-12-01389"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Meissner</surname><given-names>W.G.</given-names></name>
<name><surname>Traon</surname><given-names>A.P.-L.</given-names></name>
<name><surname>Foubert-Samier</surname><given-names>A.</given-names></name>
<name><surname>Galabova</surname><given-names>G.</given-names></name>
<name><surname>Galitzky</surname><given-names>M.</given-names></name>
<name><surname>Kutzelnigg</surname><given-names>A.</given-names></name>
<name><surname>Laurens</surname><given-names>B.</given-names></name>
<name><surname>L&#x000fc;hrs</surname><given-names>P.</given-names></name>
<name><surname>Medori</surname><given-names>R.</given-names></name>
<name><surname>P&#x000e9;ran</surname><given-names>P.</given-names></name>
<etal/>
</person-group><article-title>A Phase 1 Randomized Trial of Specific Active &#x003b1;-Synuclein Immunotherapies PD01A and PD03A in Multiple System Atrophy</article-title><source>Mov. Disord.</source><year>2020</year><volume>35</volume><fpage>1957</fpage><lpage>1965</lpage><pub-id pub-id-type="doi">10.1002/mds.28218</pub-id><pub-id pub-id-type="pmid">32882100</pub-id>
</element-citation></ref><ref id="B43-vaccines-12-01389"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nimmo</surname><given-names>J.T.</given-names></name>
<name><surname>Smith</surname><given-names>H.</given-names></name>
<name><surname>Wang</surname><given-names>C.Y.</given-names></name>
<name><surname>Teeling</surname><given-names>J.L.</given-names></name>
<name><surname>Nicoll</surname><given-names>J.A.R.</given-names></name>
<name><surname>Verma</surname><given-names>A.</given-names></name>
<name><surname>Dodart</surname><given-names>J.-C.</given-names></name>
<name><surname>Liu</surname><given-names>Z.</given-names></name>
<name><surname>Lin</surname><given-names>F.</given-names></name>
<name><surname>Carare</surname><given-names>R.O.</given-names></name>
</person-group><article-title>Immunisation with UB-312 in the Thy1SNCA Mouse Prevents Motor Performance Deficits and Oligomeric &#x003b1;-Synuclein Accumulation in the Brain and Gut</article-title><source>Acta Neuropathol.</source><year>2022</year><volume>143</volume><fpage>55</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1007/s00401-021-02381-5</pub-id><pub-id pub-id-type="pmid">34741635</pub-id>
</element-citation></ref><ref id="B44-vaccines-12-01389"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Eijsvogel</surname><given-names>P.</given-names></name>
<name><surname>Misra</surname><given-names>P.</given-names></name>
<name><surname>Concha-Marambio</surname><given-names>L.</given-names></name>
<name><surname>Boyd</surname><given-names>J.D.</given-names></name>
<name><surname>Ding</surname><given-names>S.</given-names></name>
<name><surname>Fedor</surname><given-names>L.</given-names></name>
<name><surname>Hsieh</surname><given-names>Y.-T.</given-names></name>
<name><surname>Sun</surname><given-names>Y.S.</given-names></name>
<name><surname>Vroom</surname><given-names>M.M.</given-names></name>
<name><surname>Farris</surname><given-names>C.M.</given-names></name>
<etal/>
</person-group><article-title>Target Engagement and Immunogenicity of an Active Immunotherapeutic Targeting Pathological &#x003b1;-Synuclein: A Phase 1 Placebo-Controlled Trial</article-title><source>Nat. Med.</source><year>2024</year><volume>30</volume><fpage>2631</fpage><lpage>2640</lpage><pub-id pub-id-type="doi">10.1038/s41591-024-03101-8</pub-id><pub-id pub-id-type="pmid">38902546</pub-id>
</element-citation></ref><ref id="B45-vaccines-12-01389"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Haffer</surname><given-names>K.N.</given-names></name>
</person-group><article-title>Effects of Novel Vaccines on Weight Loss in Diet-Induced-Obese (DIO) Mice</article-title><source>J. Anim. Sci. Biotechnol.</source><year>2012</year><volume>3</volume><elocation-id>21</elocation-id><pub-id pub-id-type="doi">10.1186/2049-1891-3-21</pub-id><pub-id pub-id-type="pmid">22958753</pub-id>
</element-citation></ref><ref id="B46-vaccines-12-01389"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fulurija</surname><given-names>A.</given-names></name>
<name><surname>Lutz</surname><given-names>T.A.</given-names></name>
<name><surname>Sladko</surname><given-names>K.</given-names></name>
<name><surname>Osto</surname><given-names>M.</given-names></name>
<name><surname>Wielinga</surname><given-names>P.Y.</given-names></name>
<name><surname>Bachmann</surname><given-names>M.F.</given-names></name>
<name><surname>Saudan</surname><given-names>P.</given-names></name>
</person-group><article-title>Vaccination against GIP for the Treatment of Obesity</article-title><source>PLoS ONE</source><year>2008</year><volume>3</volume><elocation-id>e3163</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0003163</pub-id><pub-id pub-id-type="pmid">18779862</pub-id>
</element-citation></ref><ref id="B47-vaccines-12-01389"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vizcarra</surname><given-names>J.A.</given-names></name>
<name><surname>Kirby</surname><given-names>J.D.</given-names></name>
<name><surname>Kim</surname><given-names>S.K.</given-names></name>
<name><surname>Galyean</surname><given-names>M.L.</given-names></name>
</person-group><article-title>Active Immunization against Ghrelin Decreases Weight Gain and Alters Plasma Concentrations of Growth Hormone in Growing Pigs</article-title><source>Domest. Anim. Endocrinol.</source><year>2007</year><volume>33</volume><fpage>176</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.1016/j.domaniend.2006.05.005</pub-id><pub-id pub-id-type="pmid">16793235</pub-id>
</element-citation></ref><ref id="B48-vaccines-12-01389"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zorrilla</surname><given-names>E.P.</given-names></name>
<name><surname>Iwasaki</surname><given-names>S.</given-names></name>
<name><surname>Moss</surname><given-names>J.A.</given-names></name>
<name><surname>Chang</surname><given-names>J.</given-names></name>
<name><surname>Otsuji</surname><given-names>J.</given-names></name>
<name><surname>Inoue</surname><given-names>K.</given-names></name>
<name><surname>Meijler</surname><given-names>M.M.</given-names></name>
<name><surname>Janda</surname><given-names>K.D.</given-names></name>
</person-group><article-title>Vaccination against Weight Gain</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2006</year><volume>103</volume><fpage>13226</fpage><lpage>13231</lpage><pub-id pub-id-type="doi">10.1073/pnas.0605376103</pub-id><pub-id pub-id-type="pmid">16891413</pub-id>
</element-citation></ref><ref id="B49-vaccines-12-01389"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Andrade</surname><given-names>S.</given-names></name>
<name><surname>Pinho</surname><given-names>F.</given-names></name>
<name><surname>Ribeiro</surname><given-names>A.M.</given-names></name>
<name><surname>Carreira</surname><given-names>M.</given-names></name>
<name><surname>Casanueva</surname><given-names>F.F.</given-names></name>
<name><surname>Roy</surname><given-names>P.</given-names></name>
<name><surname>Monteiro</surname><given-names>M.P.</given-names></name>
</person-group><article-title>Immunization against Active Ghrelin Using Virus-like Particles for Obesity Treatment</article-title><source>Curr. Pharm. Des.</source><year>2013</year><volume>19</volume><fpage>6551</fpage><lpage>6558</lpage><pub-id pub-id-type="doi">10.2174/13816128113199990506</pub-id><pub-id pub-id-type="pmid">23859551</pub-id>
</element-citation></ref><ref id="B50-vaccines-12-01389"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Karin</surname><given-names>O.</given-names></name>
<name><surname>Agrawal</surname><given-names>A.</given-names></name>
<name><surname>Porat</surname><given-names>Z.</given-names></name>
<name><surname>Krizhanovsky</surname><given-names>V.</given-names></name>
<name><surname>Alon</surname><given-names>U.</given-names></name>
</person-group><article-title>Senescent Cell Turnover Slows with Age Providing an Explanation for the Gompertz Law</article-title><source>Nat. Commun.</source><year>2019</year><volume>10</volume><fpage>5495</fpage><pub-id pub-id-type="doi">10.1038/s41467-019-13192-4</pub-id><pub-id pub-id-type="pmid">31792199</pub-id>
</element-citation></ref><ref id="B51-vaccines-12-01389"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McHugh</surname><given-names>D.</given-names></name>
<name><surname>Gil</surname><given-names>J.</given-names></name>
</person-group><article-title>Senescence and Aging: Causes, Consequences, and Therapeutic Avenues</article-title><source>J. Cell Biol.</source><year>2018</year><volume>217</volume><fpage>65</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1083/jcb.201708092</pub-id><pub-id pub-id-type="pmid">29114066</pub-id>
</element-citation></ref><ref id="B52-vaccines-12-01389"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tripathi</surname><given-names>U.</given-names></name>
<name><surname>Misra</surname><given-names>A.</given-names></name>
<name><surname>Tchkonia</surname><given-names>T.</given-names></name>
<name><surname>Kirkland</surname><given-names>J.L.</given-names></name>
</person-group><article-title>Impact of Senescent Cell Subtypes on Tissue Dysfunction and Repair: Importance and Research Questions</article-title><source>Mech. Ageing Dev.</source><year>2021</year><volume>198</volume><fpage>111548</fpage><pub-id pub-id-type="doi">10.1016/j.mad.2021.111548</pub-id><pub-id pub-id-type="pmid">34352325</pub-id>
</element-citation></ref><ref id="B53-vaccines-12-01389"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Matveeva</surname><given-names>K.</given-names></name>
<name><surname>Vasilieva</surname><given-names>M.</given-names></name>
<name><surname>Minskaia</surname><given-names>E.</given-names></name>
<name><surname>Rybtsov</surname><given-names>S.</given-names></name>
<name><surname>Shevyrev</surname><given-names>D.</given-names></name>
</person-group><article-title>T-Cell Immunity against Senescence: Potential Role and Perspectives</article-title><source>Front. Immunol.</source><year>2024</year><volume>15</volume><elocation-id>1360109</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2024.1360109</pub-id><pub-id pub-id-type="pmid">38504990</pub-id>
</element-citation></ref><ref id="B54-vaccines-12-01389"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shin</surname><given-names>D.-M.</given-names></name>
<name><surname>Kucia</surname><given-names>M.</given-names></name>
<name><surname>Ratajczak</surname><given-names>M.Z.</given-names></name>
</person-group><article-title>Nuclear and Chromatin Reorganization during Cell Senescence and Aging&#x02014;A Mini-Review</article-title><source>Gerontology</source><year>2010</year><volume>57</volume><fpage>76</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1159/000281882</pub-id><pub-id pub-id-type="pmid">20134149</pub-id>
</element-citation></ref><ref id="B55-vaccines-12-01389"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>S&#x00142;awi&#x00144;ska</surname><given-names>N.</given-names></name>
<name><surname>Krupa</surname><given-names>R.</given-names></name>
</person-group><article-title>Molecular Aspects of Senescence and Organismal Ageing-DNA Damage Response, Telomeres, Inflammation and Chromatin</article-title><source>Int. J. Mol. Sci.</source><year>2021</year><volume>22</volume><elocation-id>590</elocation-id><pub-id pub-id-type="doi">10.3390/ijms22020590</pub-id><pub-id pub-id-type="pmid">33435578</pub-id>
</element-citation></ref><ref id="B56-vaccines-12-01389"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wallis</surname><given-names>R.</given-names></name>
<name><surname>Milligan</surname><given-names>D.</given-names></name>
<name><surname>Hughes</surname><given-names>B.</given-names></name>
<name><surname>Mizen</surname><given-names>H.</given-names></name>
<name><surname>L&#x000f3;pez-Dom&#x000ed;nguez</surname><given-names>J.A.</given-names></name>
<name><surname>Eduputa</surname><given-names>U.</given-names></name>
<name><surname>Tyler</surname><given-names>E.J.</given-names></name>
<name><surname>Serrano</surname><given-names>M.</given-names></name>
<name><surname>Bishop</surname><given-names>C.L.</given-names></name>
</person-group><article-title>Senescence-Associated Morphological Profiles (SAMPs): An Image-Based Phenotypic Profiling Method for Evaluating the Inter and Intra Model Heterogeneity of Senescence</article-title><source>Aging</source><year>2022</year><volume>14</volume><fpage>4220</fpage><lpage>4246</lpage><pub-id pub-id-type="doi">10.18632/aging.204072</pub-id><pub-id pub-id-type="pmid">35580013</pub-id>
</element-citation></ref><ref id="B57-vaccines-12-01389"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Heckenbach</surname><given-names>I.</given-names></name>
<name><surname>Mkrtchyan</surname><given-names>G.V.</given-names></name>
<name><surname>Ezra</surname><given-names>M.B.</given-names></name>
<name><surname>Bakula</surname><given-names>D.</given-names></name>
<name><surname>Madsen</surname><given-names>J.S.</given-names></name>
<name><surname>Nielsen</surname><given-names>M.H.</given-names></name>
<name><surname>Or&#x000f3;</surname><given-names>D.</given-names></name>
<name><surname>Osborne</surname><given-names>B.</given-names></name>
<name><surname>Covarrubias</surname><given-names>A.J.</given-names></name>
<name><surname>Idda</surname><given-names>M.L.</given-names></name>
<etal/>
</person-group><article-title>Nuclear Morphology Is a Deep Learning Biomarker of Cellular Senescence</article-title><source>Nat. Aging</source><year>2022</year><volume>2</volume><fpage>742</fpage><lpage>755</lpage><pub-id pub-id-type="doi">10.1038/s43587-022-00263-3</pub-id><pub-id pub-id-type="pmid">37118134</pub-id>
</element-citation></ref><ref id="B58-vaccines-12-01389"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Park</surname><given-names>J.T.</given-names></name>
<name><surname>Lee</surname><given-names>Y.-S.</given-names></name>
<name><surname>Cho</surname><given-names>K.A.</given-names></name>
<name><surname>Park</surname><given-names>S.C.</given-names></name>
</person-group><article-title>Adjustment of the Lysosomal-Mitochondrial Axis for Control of Cellular Senescence</article-title><source>Ageing Res. Rev.</source><year>2018</year><volume>47</volume><fpage>176</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1016/j.arr.2018.08.003</pub-id><pub-id pub-id-type="pmid">30142381</pub-id>
</element-citation></ref><ref id="B59-vaccines-12-01389"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ashraf</surname><given-names>H.M.</given-names></name>
<name><surname>Fernandez</surname><given-names>B.</given-names></name>
<name><surname>Spencer</surname><given-names>S.L.</given-names></name>
</person-group><article-title>The intensities of canonical senescence biomarkers integrate the duration of cell-cycle withdrawal</article-title><source>Nat. Commun.</source><year>2023</year><volume>14</volume><fpage>4527</fpage><pub-id pub-id-type="doi">10.1038/s41467-023-40132-0</pub-id><pub-id pub-id-type="pmid">37500655</pub-id>
</element-citation></ref><ref id="B60-vaccines-12-01389"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hernandez-Segura</surname><given-names>A.</given-names></name>
<name><surname>Nehme</surname><given-names>J.</given-names></name>
<name><surname>Demaria</surname><given-names>M.</given-names></name>
</person-group><article-title>Hallmarks of Cellular Senescence</article-title><source>Trends Cell Biol.</source><year>2018</year><volume>28</volume><fpage>436</fpage><lpage>453</lpage><pub-id pub-id-type="doi">10.1016/j.tcb.2018.02.001</pub-id><pub-id pub-id-type="pmid">29477613</pub-id>
</element-citation></ref><ref id="B61-vaccines-12-01389"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dodig</surname><given-names>S.</given-names></name>
<name><surname>&#x0010c;epelak</surname><given-names>I.</given-names></name>
<name><surname>Pavi&#x00107;</surname><given-names>I.</given-names></name>
</person-group><article-title>Hallmarks of Senescence and Aging</article-title><source>Biochem. Med.</source><year>2019</year><volume>29</volume><elocation-id>030501</elocation-id><pub-id pub-id-type="doi">10.11613/BM.2019.030501</pub-id></element-citation></ref><ref id="B62-vaccines-12-01389"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kumari</surname><given-names>R.</given-names></name>
<name><surname>Jat</surname><given-names>P.</given-names></name>
</person-group><article-title>Mechanisms of Cellular Senescence: Cell Cycle Arrest and Senescence Associated Secretory Phenotype</article-title><source>Front. Cell Dev. Biol.</source><year>2021</year><volume>9</volume><elocation-id>645593</elocation-id><pub-id pub-id-type="doi">10.3389/fcell.2021.645593</pub-id><pub-id pub-id-type="pmid">33855023</pub-id>
</element-citation></ref><ref id="B63-vaccines-12-01389"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Copp&#x000e9;</surname><given-names>J.-P.</given-names></name>
<name><surname>Desprez</surname><given-names>P.-Y.</given-names></name>
<name><surname>Krtolica</surname><given-names>A.</given-names></name>
<name><surname>Campisi</surname><given-names>J.</given-names></name>
</person-group><article-title>The Senescence-Associated Secretory Phenotype: The Dark Side of Tumor Suppression</article-title><source>Annu. Rev. Pathol.</source><year>2010</year><volume>5</volume><fpage>99</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1146/annurev-pathol-121808-102144</pub-id><pub-id pub-id-type="pmid">20078217</pub-id>
</element-citation></ref><ref id="B64-vaccines-12-01389"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Marin</surname><given-names>I.</given-names></name>
<name><surname>Boix</surname><given-names>O.</given-names></name>
<name><surname>Garcia-Garijo</surname><given-names>A.</given-names></name>
<name><surname>Sirois</surname><given-names>I.</given-names></name>
<name><surname>Caballe</surname><given-names>A.</given-names></name>
<name><surname>Zarzuela</surname><given-names>E.</given-names></name>
<name><surname>Ruano</surname><given-names>I.</given-names></name>
<name><surname>Attolini</surname><given-names>C.S.-O.</given-names></name>
<name><surname>Prats</surname><given-names>N.</given-names></name>
<name><surname>L&#x000f3;pez-Dom&#x000ed;nguez</surname><given-names>J.A.</given-names></name>
<etal/>
</person-group><article-title>Cellular Senescence Is Immunogenic and Promotes Antitumor Immunity</article-title><source>Cancer Discov.</source><year>2023</year><volume>13</volume><fpage>410</fpage><lpage>431</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-22-0523</pub-id><pub-id pub-id-type="pmid">36302218</pub-id>
</element-citation></ref><ref id="B65-vaccines-12-01389"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Santos</surname><given-names>A.L.</given-names></name>
<name><surname>Lindner</surname><given-names>A.B.</given-names></name>
</person-group><article-title>Protein Posttranslational Modifications: Roles in Aging and Age-Related Disease</article-title><source>Oxid. Med. Cell Longev.</source><year>2017</year><volume>2017</volume><fpage>5716409</fpage><pub-id pub-id-type="doi">10.1155/2017/5716409</pub-id><pub-id pub-id-type="pmid">28894508</pub-id>
</element-citation></ref><ref id="B66-vaccines-12-01389"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ebert</surname><given-names>T.</given-names></name>
<name><surname>Tran</surname><given-names>N.</given-names></name>
<name><surname>Schurgers</surname><given-names>L.</given-names></name>
<name><surname>Stenvinkel</surname><given-names>P.</given-names></name>
<name><surname>Shiels</surname><given-names>P.G.</given-names></name>
</person-group><article-title>Ageing&#x02014;Oxidative Stress, PTMs and Disease</article-title><source>Mol. Aspects Med.</source><year>2022</year><volume>86</volume><fpage>101099</fpage><pub-id pub-id-type="doi">10.1016/j.mam.2022.101099</pub-id><pub-id pub-id-type="pmid">35689974</pub-id>
</element-citation></ref><ref id="B67-vaccines-12-01389"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wu</surname><given-names>Z.</given-names></name>
<name><surname>Qu</surname><given-names>J.</given-names></name>
<name><surname>Liu</surname><given-names>G.-H.</given-names></name>
</person-group><article-title>Roles of Chromatin and Genome Instability in Cellular Senescence and Their Relevance to Ageing and Related Diseases</article-title><source>Nat. Rev. Mol. Cell Biol.</source><year>2024</year><volume>25</volume><fpage>979</fpage><lpage>1000</lpage><pub-id pub-id-type="doi">10.1038/s41580-024-00775-3</pub-id><pub-id pub-id-type="pmid">39363000</pub-id>
</element-citation></ref><ref id="B68-vaccines-12-01389"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Di Giorgio</surname><given-names>E.</given-names></name>
<name><surname>Ranzino</surname><given-names>L.</given-names></name>
<name><surname>Tolotto</surname><given-names>V.</given-names></name>
<name><surname>Dalla</surname><given-names>E.</given-names></name>
<name><surname>Burelli</surname><given-names>M.</given-names></name>
<name><surname>Gualandi</surname><given-names>N.</given-names></name>
<name><surname>Brancolini</surname><given-names>C.</given-names></name>
</person-group><article-title>Transcription of Endogenous Retroviruses in Senescent Cells Contributes to the Accumulation of Double-Stranded RNAs That Trigger an Anti-Viral Response That Reinforces Senescence</article-title><source>Cell Death Dis.</source><year>2024</year><volume>15</volume><fpage>157</fpage><pub-id pub-id-type="doi">10.1038/s41419-024-06548-2</pub-id><pub-id pub-id-type="pmid">38383514</pub-id>
</element-citation></ref><ref id="B69-vaccines-12-01389"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Amor</surname><given-names>C.</given-names></name>
<name><surname>Fern&#x000e1;ndez-Maestre</surname><given-names>I.</given-names></name>
<name><surname>Chowdhury</surname><given-names>S.</given-names></name>
<name><surname>Ho</surname><given-names>Y.-J.</given-names></name>
<name><surname>Nadella</surname><given-names>S.</given-names></name>
<name><surname>Graham</surname><given-names>C.</given-names></name>
<name><surname>Carrasco</surname><given-names>S.E.</given-names></name>
<name><surname>Nnuji-John</surname><given-names>E.</given-names></name>
<name><surname>Feucht</surname><given-names>J.</given-names></name>
<name><surname>Hinterleitner</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>Prophylactic and Long-Lasting Efficacy of Senolytic CAR T Cells against Age-Related Metabolic Dysfunction</article-title><source>Nat. Aging</source><year>2024</year><volume>4</volume><fpage>336</fpage><lpage>349</lpage><pub-id pub-id-type="doi">10.1038/s43587-023-00560-5</pub-id><pub-id pub-id-type="pmid">38267706</pub-id>
</element-citation></ref><ref id="B70-vaccines-12-01389"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bulbiankova</surname><given-names>D.</given-names></name>
<name><surname>D&#x000ed;az-Puertas</surname><given-names>R.</given-names></name>
<name><surname>&#x000c1;lvarez-Mart&#x000ed;nez</surname><given-names>F.J.</given-names></name>
<name><surname>Herranz-L&#x000f3;pez</surname><given-names>M.</given-names></name>
<name><surname>Barraj&#x000f3;n-Catal&#x000e1;n</surname><given-names>E.</given-names></name>
<name><surname>Micol</surname><given-names>V.</given-names></name>
</person-group><article-title>Hallmarks and Biomarkers of Skin Senescence: An Updated Review of Skin Senotherapeutics</article-title><source>Antioxidants</source><year>2023</year><volume>12</volume><elocation-id>444</elocation-id><pub-id pub-id-type="doi">10.3390/antiox12020444</pub-id><pub-id pub-id-type="pmid">36830002</pub-id>
</element-citation></ref><ref id="B71-vaccines-12-01389"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schmitt</surname><given-names>C.A.</given-names></name>
<name><surname>Wang</surname><given-names>B.</given-names></name>
<name><surname>Demaria</surname><given-names>M.</given-names></name>
</person-group><article-title>Senescence and Cancer&#x02014;Role and Therapeutic Opportunities</article-title><source>Nat. Rev. Clin. Oncol.</source><year>2022</year><volume>19</volume><fpage>619</fpage><lpage>636</lpage><pub-id pub-id-type="doi">10.1038/s41571-022-00668-4</pub-id><pub-id pub-id-type="pmid">36045302</pub-id>
</element-citation></ref><ref id="B72-vaccines-12-01389"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fulop</surname><given-names>T.</given-names></name>
<name><surname>Larbi</surname><given-names>A.</given-names></name>
<name><surname>Pawelec</surname><given-names>G.</given-names></name>
<name><surname>Khalil</surname><given-names>A.</given-names></name>
<name><surname>Cohen</surname><given-names>A.A.</given-names></name>
<name><surname>Hirokawa</surname><given-names>K.</given-names></name>
<name><surname>Witkowski</surname><given-names>J.M.</given-names></name>
<name><surname>Franceschi</surname><given-names>C.</given-names></name>
</person-group><article-title>Immunology of Aging: The Birth of Inflammaging</article-title><source>Clin. Rev. Allergy Immunol.</source><year>2023</year><volume>64</volume><fpage>109</fpage><lpage>122</lpage><pub-id pub-id-type="doi">10.1007/s12016-021-08899-6</pub-id><pub-id pub-id-type="pmid">34536213</pub-id>
</element-citation></ref><ref id="B73-vaccines-12-01389"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cai</surname><given-names>Y.</given-names></name>
<name><surname>Zhou</surname><given-names>H.</given-names></name>
<name><surname>Zhu</surname><given-names>Y.</given-names></name>
<name><surname>Sun</surname><given-names>Q.</given-names></name>
<name><surname>Ji</surname><given-names>Y.</given-names></name>
<name><surname>Xue</surname><given-names>A.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Chen</surname><given-names>W.</given-names></name>
<name><surname>Yu</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>Elimination of Senescent Cells by &#x003b2;-Galactosidase-Targeted Prodrug Attenuates Inflammation and Restores Physical Function in Aged Mice</article-title><source>Cell Res.</source><year>2020</year><volume>30</volume><fpage>574</fpage><lpage>589</lpage><pub-id pub-id-type="doi">10.1038/s41422-020-0314-9</pub-id><pub-id pub-id-type="pmid">32341413</pub-id>
</element-citation></ref><ref id="B74-vaccines-12-01389"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>B.</given-names></name>
<name><surname>Zhu</surname><given-names>R.</given-names></name>
<name><surname>Hu</surname><given-names>H.</given-names></name>
<name><surname>Zhan</surname><given-names>M.</given-names></name>
<name><surname>Wang</surname><given-names>T.</given-names></name>
<name><surname>Huang</surname><given-names>F.</given-names></name>
<name><surname>Wei</surname><given-names>F.</given-names></name>
<name><surname>Chai</surname><given-names>Y.</given-names></name>
<name><surname>Ling</surname><given-names>Z.</given-names></name>
<name><surname>Zou</surname><given-names>X.</given-names></name>
</person-group><article-title>Elimination of Senescent Cells by Senolytics Facilitates Bony Endplate Microvessel Formation and Mitigates Disc Degeneration in Aged Mice</article-title><source>Front. Cell Dev. Biol.</source><year>2022</year><volume>10</volume><elocation-id>853688</elocation-id><pub-id pub-id-type="doi">10.3389/fcell.2022.853688</pub-id><pub-id pub-id-type="pmid">35874831</pub-id>
</element-citation></ref><ref id="B75-vaccines-12-01389"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lorenzo</surname><given-names>E.C.</given-names></name>
<name><surname>Torrance</surname><given-names>B.L.</given-names></name>
<name><surname>Haynes</surname><given-names>L.</given-names></name>
</person-group><article-title>Impact of Senolytic Treatment on Immunity, Aging, and Disease</article-title><source>Front. Aging</source><year>2023</year><volume>4</volume><elocation-id>1161799</elocation-id><pub-id pub-id-type="doi">10.3389/fragi.2023.1161799</pub-id><pub-id pub-id-type="pmid">37886012</pub-id>
</element-citation></ref><ref id="B76-vaccines-12-01389"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Aguado</surname><given-names>J.</given-names></name>
<name><surname>Amarilla</surname><given-names>A.A.</given-names></name>
<name><surname>Taherian Fard</surname><given-names>A.</given-names></name>
<name><surname>Albornoz</surname><given-names>E.A.</given-names></name>
<name><surname>Tyshkovskiy</surname><given-names>A.</given-names></name>
<name><surname>Schwabenland</surname><given-names>M.</given-names></name>
<name><surname>Chaggar</surname><given-names>H.K.</given-names></name>
<name><surname>Modhiran</surname><given-names>N.</given-names></name>
<name><surname>G&#x000f3;mez-Incl&#x000e1;n</surname><given-names>C.</given-names></name>
<name><surname>Javed</surname><given-names>I.</given-names></name>
<etal/>
</person-group><article-title>Senolytic Therapy Alleviates Physiological Human Brain Aging and COVID-19 Neuropathology</article-title><source>Nat. Aging</source><year>2023</year><volume>3</volume><fpage>1561</fpage><lpage>1575</lpage><pub-id pub-id-type="doi">10.1038/s43587-023-00519-6</pub-id><pub-id pub-id-type="pmid">37957361</pub-id>
</element-citation></ref><ref id="B77-vaccines-12-01389"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Martel</surname><given-names>J.</given-names></name>
<name><surname>Ojcius</surname><given-names>D.M.</given-names></name>
<name><surname>Wu</surname><given-names>C.-Y.</given-names></name>
<name><surname>Peng</surname><given-names>H.-H.</given-names></name>
<name><surname>Voisin</surname><given-names>L.</given-names></name>
<name><surname>Perfettini</surname><given-names>J.-L.</given-names></name>
<name><surname>Ko</surname><given-names>Y.-F.</given-names></name>
<name><surname>Young</surname><given-names>J.D.</given-names></name>
</person-group><article-title>Emerging Use of Senolytics and Senomorphics against Aging and Chronic Diseases</article-title><source>Med. Res. Rev.</source><year>2020</year><volume>40</volume><fpage>2114</fpage><lpage>2131</lpage><pub-id pub-id-type="doi">10.1002/med.21702</pub-id><pub-id pub-id-type="pmid">32578904</pub-id>
</element-citation></ref><ref id="B78-vaccines-12-01389"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lu&#x000ed;s</surname><given-names>C.</given-names></name>
<name><surname>Maduro</surname><given-names>A.T.</given-names></name>
<name><surname>Pereira</surname><given-names>P.</given-names></name>
<name><surname>Mendes</surname><given-names>J.J.</given-names></name>
<name><surname>Soares</surname><given-names>R.</given-names></name>
<name><surname>Ramalho</surname><given-names>R.</given-names></name>
</person-group><article-title>Nutritional Senolytics and Senomorphics: Implications to Immune Cells Metabolism and Aging&#x02014;From Theory to Practice</article-title><source>Front. Nutr.</source><year>2022</year><volume>9</volume><elocation-id>958563</elocation-id><pub-id pub-id-type="doi">10.3389/fnut.2022.958563</pub-id><pub-id pub-id-type="pmid">36159455</pub-id>
</element-citation></ref><ref id="B79-vaccines-12-01389"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Suda</surname><given-names>M.</given-names></name>
<name><surname>Shimizu</surname><given-names>I.</given-names></name>
<name><surname>Katsuumi</surname><given-names>G.</given-names></name>
<name><surname>Hsiao</surname><given-names>C.L.</given-names></name>
<name><surname>Yoshida</surname><given-names>Y.</given-names></name>
<name><surname>Matsumoto</surname><given-names>N.</given-names></name>
<name><surname>Yoshida</surname><given-names>Y.</given-names></name>
<name><surname>Katayama</surname><given-names>A.</given-names></name>
<name><surname>Wada</surname><given-names>J.</given-names></name>
<name><surname>Seki</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Glycoprotein Nonmetastatic Melanoma Protein B Regulates Lysosomal Integrity and Lifespan of Senescent Cells</article-title><source>Sci. Rep.</source><year>2022</year><volume>12</volume><elocation-id>6522</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-022-10522-3</pub-id><pub-id pub-id-type="pmid">35444208</pub-id>
</element-citation></ref><ref id="B80-vaccines-12-01389"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yoshida</surname><given-names>S.</given-names></name>
<name><surname>Nakagami</surname><given-names>H.</given-names></name>
<name><surname>Hayashi</surname><given-names>H.</given-names></name>
<name><surname>Ikeda</surname><given-names>Y.</given-names></name>
<name><surname>Sun</surname><given-names>J.</given-names></name>
<name><surname>Tenma</surname><given-names>A.</given-names></name>
<name><surname>Tomioka</surname><given-names>H.</given-names></name>
<name><surname>Kawano</surname><given-names>T.</given-names></name>
<name><surname>Shimamura</surname><given-names>M.</given-names></name>
<name><surname>Morishita</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>The CD153 Vaccine Is a Senotherapeutic Option for Preventing the Accumulation of Senescent T Cells in Mice</article-title><source>Nat. Commun.</source><year>2020</year><volume>11</volume><fpage>2482</fpage><pub-id pub-id-type="doi">10.1038/s41467-020-16347-w</pub-id><pub-id pub-id-type="pmid">32424156</pub-id>
</element-citation></ref><ref id="B81-vaccines-12-01389"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lear</surname><given-names>T.B.</given-names></name>
<name><surname>Finkel</surname><given-names>T.</given-names></name>
</person-group><article-title>Senolytic Vaccination: A New Mandate for Cardiovascular Health?</article-title><source>J. Cardiovasc. Aging</source><year>2022</year><volume>2</volume><fpage>17</fpage><pub-id pub-id-type="doi">10.20517/jca.2022.03</pub-id><pub-id pub-id-type="pmid">36819765</pub-id>
</element-citation></ref><ref id="B82-vaccines-12-01389"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Deng</surname><given-names>Y.</given-names></name>
<name><surname>Kumar</surname><given-names>A.</given-names></name>
<name><surname>Xie</surname><given-names>K.</given-names></name>
<name><surname>Schaaf</surname><given-names>K.</given-names></name>
<name><surname>Scifo</surname><given-names>E.</given-names></name>
<name><surname>Morsy</surname><given-names>S.</given-names></name>
<name><surname>Li</surname><given-names>T.</given-names></name>
<name><surname>Ehninger</surname><given-names>A.</given-names></name>
<name><surname>Bano</surname><given-names>D.</given-names></name>
<name><surname>Ehninger</surname><given-names>D.</given-names></name>
</person-group><article-title>Targeting Senescent Cells with NKG2D-CAR T Cells</article-title><source>Cell Death Discov.</source><year>2024</year><volume>10</volume><fpage>217</fpage><pub-id pub-id-type="doi">10.1038/s41420-024-01976-7</pub-id><pub-id pub-id-type="pmid">38704364</pub-id>
</element-citation></ref><ref id="B83-vaccines-12-01389"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mendelsohn</surname><given-names>A.R.</given-names></name>
<name><surname>Larrick</surname><given-names>J.W.</given-names></name>
</person-group><article-title>Antiaging Vaccines Targeting Senescent Cells</article-title><source>Rejuvenation Res.</source><year>2022</year><volume>25</volume><fpage>39</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1089/rej.2022.0008</pub-id><pub-id pub-id-type="pmid">35081729</pub-id>
</element-citation></ref><ref id="B84-vaccines-12-01389"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Prata</surname><given-names>L.G.P.L.</given-names></name>
<name><surname>Ovsyannikova</surname><given-names>I.G.</given-names></name>
<name><surname>Tchkonia</surname><given-names>T.</given-names></name>
<name><surname>Kirkland</surname><given-names>J.L.</given-names></name>
</person-group><article-title>Senescent Cell Clearance by the Immune System: Emerging Therapeutic Opportunities</article-title><source>Semin. Immunol.</source><year>2018</year><volume>40</volume><fpage>101275</fpage><pub-id pub-id-type="doi">10.1016/j.smim.2019.04.003</pub-id><pub-id pub-id-type="pmid">31088710</pub-id>
</element-citation></ref><ref id="B85-vaccines-12-01389"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pereira</surname><given-names>B.I.</given-names></name>
<name><surname>Devine</surname><given-names>O.P.</given-names></name>
<name><surname>Vukmanovic-Stejic</surname><given-names>M.</given-names></name>
<name><surname>Chambers</surname><given-names>E.S.</given-names></name>
<name><surname>Subramanian</surname><given-names>P.</given-names></name>
<name><surname>Patel</surname><given-names>N.</given-names></name>
<name><surname>Virasami</surname><given-names>A.</given-names></name>
<name><surname>Sebire</surname><given-names>N.J.</given-names></name>
<name><surname>Kinsler</surname><given-names>V.</given-names></name>
<name><surname>Valdovinos</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Senescent Cells Evade Immune Clearance via HLA-E-Mediated NK and CD8+ T Cell Inhibition</article-title><source>Nat. Commun.</source><year>2019</year><volume>10</volume><fpage>2387</fpage><pub-id pub-id-type="doi">10.1038/s41467-019-10335-5</pub-id><pub-id pub-id-type="pmid">31160572</pub-id>
</element-citation></ref><ref id="B86-vaccines-12-01389"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nemazee</surname><given-names>D.</given-names></name>
</person-group><article-title>Mechanisms of Central Tolerance for B Cells</article-title><source>Nat. Rev. Immunol.</source><year>2017</year><volume>17</volume><fpage>281</fpage><lpage>294</lpage><pub-id pub-id-type="doi">10.1038/nri.2017.19</pub-id><pub-id pub-id-type="pmid">28368006</pub-id>
</element-citation></ref><ref id="B87-vaccines-12-01389"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xing</surname><given-names>Y.</given-names></name>
<name><surname>Hogquist</surname><given-names>K.A.</given-names></name>
</person-group><article-title>T-Cell Tolerance: Central and Peripheral</article-title><source>Cold Spring Harb. Perspect. Biol.</source><year>2012</year><volume>4</volume><elocation-id>a006957</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a006957</pub-id><pub-id pub-id-type="pmid">22661634</pub-id>
</element-citation></ref><ref id="B88-vaccines-12-01389"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Getahun</surname><given-names>A.</given-names></name>
</person-group><article-title>Role of Inhibitory Signaling in Peripheral B Cell Tolerance</article-title><source>Immunol. Rev.</source><year>2022</year><volume>307</volume><fpage>27</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1111/imr.13070</pub-id><pub-id pub-id-type="pmid">35128676</pub-id>
</element-citation></ref><ref id="B89-vaccines-12-01389"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kishimoto</surname><given-names>H.</given-names></name>
<name><surname>Sprent</surname><given-names>J.</given-names></name>
</person-group><article-title>Negative Selection in the Thymus Includes Semimature T Cells</article-title><source>J. Exp. Med.</source><year>1997</year><volume>185</volume><fpage>263</fpage><lpage>271</lpage><pub-id pub-id-type="doi">10.1084/jem.185.2.263</pub-id><pub-id pub-id-type="pmid">9016875</pub-id>
</element-citation></ref><ref id="B90-vaccines-12-01389"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>J.W.</given-names></name>
<name><surname>Schickel</surname><given-names>J.-N.</given-names></name>
<name><surname>Tsakiris</surname><given-names>N.</given-names></name>
<name><surname>Sng</surname><given-names>J.</given-names></name>
<name><surname>Arbogast</surname><given-names>F.</given-names></name>
<name><surname>Bouis</surname><given-names>D.</given-names></name>
<name><surname>Parisi</surname><given-names>D.</given-names></name>
<name><surname>Gera</surname><given-names>R.</given-names></name>
<name><surname>Boeckers</surname><given-names>J.M.</given-names></name>
<name><surname>Delmotte</surname><given-names>F.R.</given-names></name>
<etal/>
</person-group><article-title>Positive and Negative Selection Shape the Human Naive B Cell Repertoire</article-title><source>J. Clin. Investig.</source><year>2022</year><volume>132</volume><fpage>e150985</fpage><pub-id pub-id-type="doi">10.1172/JCI150985</pub-id><pub-id pub-id-type="pmid">34813502</pub-id>
</element-citation></ref><ref id="B91-vaccines-12-01389"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shevyrev</surname><given-names>D.</given-names></name>
<name><surname>Tereshchenko</surname><given-names>V.</given-names></name>
<name><surname>Kozlov</surname><given-names>V.</given-names></name>
<name><surname>Sennikov</surname><given-names>S.</given-names></name>
</person-group><article-title>Phylogeny, Structure, Functions, and Role of AIRE in the Formation of T-Cell Subsets</article-title><source>Cells</source><year>2022</year><volume>11</volume><elocation-id>194</elocation-id><pub-id pub-id-type="doi">10.3390/cells11020194</pub-id><pub-id pub-id-type="pmid">35053310</pub-id>
</element-citation></ref><ref id="B92-vaccines-12-01389"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ding</surname><given-names>P.</given-names></name>
<name><surname>Gao</surname><given-names>C.</given-names></name>
<name><surname>Gao</surname><given-names>Y.</given-names></name>
<name><surname>Liu</surname><given-names>D.</given-names></name>
<name><surname>Li</surname><given-names>H.</given-names></name>
<name><surname>Xu</surname><given-names>J.</given-names></name>
<name><surname>Chen</surname><given-names>X.</given-names></name>
<name><surname>Huang</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>C.</given-names></name>
<name><surname>Zheng</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Osteocytes Regulate Senescence of Bone and Bone Marrow</article-title><source>Elife</source><year>2022</year><volume>11</volume><fpage>e81480</fpage><pub-id pub-id-type="doi">10.7554/eLife.81480</pub-id><pub-id pub-id-type="pmid">36305580</pub-id>
</element-citation></ref><ref id="B93-vaccines-12-01389"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hellmich</surname><given-names>C.</given-names></name>
<name><surname>Moore</surname><given-names>J.A.</given-names></name>
<name><surname>Bowles</surname><given-names>K.M.</given-names></name>
<name><surname>Rushworth</surname><given-names>S.A.</given-names></name>
</person-group><article-title>Bone Marrow Senescence and the Microenvironment of Hematological Malignancies</article-title><source>Front. Oncol.</source><year>2020</year><volume>10</volume><elocation-id>230</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2020.00230</pub-id><pub-id pub-id-type="pmid">32161723</pub-id>
</element-citation></ref><ref id="B94-vaccines-12-01389"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>X.</given-names></name>
</person-group><article-title>From Immune Equilibrium to Immunodynamics</article-title><source>Front. Microbiol.</source><year>2022</year><volume>13</volume><elocation-id>1018817</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2022.1018817</pub-id><pub-id pub-id-type="pmid">36504800</pub-id>
</element-citation></ref><ref id="B95-vaccines-12-01389"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Eberl</surname><given-names>G.</given-names></name>
</person-group><article-title>Immunity by Equilibrium</article-title><source>Nat. Rev. Immunol.</source><year>2016</year><volume>16</volume><fpage>524</fpage><lpage>532</lpage><pub-id pub-id-type="doi">10.1038/nri.2016.75</pub-id><pub-id pub-id-type="pmid">27396446</pub-id>
</element-citation></ref><ref id="B96-vaccines-12-01389"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>B&#x00159;ezina</surname><given-names>J.</given-names></name>
<name><surname>Vobo&#x00159;il</surname><given-names>M.</given-names></name>
<name><surname>Filipp</surname><given-names>D.</given-names></name>
</person-group><article-title>Mechanisms of Direct and Indirect Presentation of Self-Antigens in the Thymus</article-title><source>Front. Immunol.</source><year>2022</year><volume>13</volume><elocation-id>926625</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2022.926625</pub-id><pub-id pub-id-type="pmid">35774801</pub-id>
</element-citation></ref><ref id="B97-vaccines-12-01389"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Barbouti</surname><given-names>A.</given-names></name>
<name><surname>Evangelou</surname><given-names>K.</given-names></name>
<name><surname>Pateras</surname><given-names>I.S.</given-names></name>
<name><surname>Papoudou-Bai</surname><given-names>A.</given-names></name>
<name><surname>Patereli</surname><given-names>A.</given-names></name>
<name><surname>Stefanaki</surname><given-names>K.</given-names></name>
<name><surname>Rontogianni</surname><given-names>D.</given-names></name>
<name><surname>Mu&#x000f1;oz-Esp&#x000ed;n</surname><given-names>D.</given-names></name>
<name><surname>Kanavaros</surname><given-names>P.</given-names></name>
<name><surname>Gorgoulis</surname><given-names>V.G.</given-names></name>
</person-group><article-title>In Situ Evidence of Cellular Senescence in Thymic Epithelial Cells (TECs) during Human Thymic Involution</article-title><source>Mech. Ageing Dev.</source><year>2019</year><volume>177</volume><fpage>88</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1016/j.mad.2018.02.005</pub-id><pub-id pub-id-type="pmid">29490231</pub-id>
</element-citation></ref><ref id="B98-vaccines-12-01389"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Thomas</surname><given-names>R.</given-names></name>
<name><surname>Wang</surname><given-names>W.</given-names></name>
<name><surname>Su</surname><given-names>D.-M.</given-names></name>
</person-group><article-title>Contributions of Age-Related Thymic Involution to Immunosenescence and Inflammaging</article-title><source>Immun. Ageing</source><year>2020</year><volume>17</volume><fpage>2</fpage><pub-id pub-id-type="doi">10.1186/s12979-020-0173-8</pub-id><pub-id pub-id-type="pmid">31988649</pub-id>
</element-citation></ref><ref id="B99-vaccines-12-01389"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Carter</surname><given-names>J.A.</given-names></name>
<name><surname>Str&#x000f6;mich</surname><given-names>L.</given-names></name>
<name><surname>Peacey</surname><given-names>M.</given-names></name>
<name><surname>Chapin</surname><given-names>S.R.</given-names></name>
<name><surname>Velten</surname><given-names>L.</given-names></name>
<name><surname>Steinmetz</surname><given-names>L.M.</given-names></name>
<name><surname>Brors</surname><given-names>B.</given-names></name>
<name><surname>Pinto</surname><given-names>S.</given-names></name>
<name><surname>Meyer</surname><given-names>H.V.</given-names></name>
</person-group><article-title>Transcriptomic Diversity in Human Medullary Thymic Epithelial Cells</article-title><source>Nat. Commun.</source><year>2022</year><volume>13</volume><fpage>4296</fpage><pub-id pub-id-type="doi">10.1038/s41467-022-31750-1</pub-id><pub-id pub-id-type="pmid">35918316</pub-id>
</element-citation></ref><ref id="B100-vaccines-12-01389"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fergusson</surname><given-names>J.R.</given-names></name>
<name><surname>Morgan</surname><given-names>M.D.</given-names></name>
<name><surname>Bruchard</surname><given-names>M.</given-names></name>
<name><surname>Huitema</surname><given-names>L.</given-names></name>
<name><surname>Heesters</surname><given-names>B.A.</given-names></name>
<name><surname>van Unen</surname><given-names>V.</given-names></name>
<name><surname>van Hamburg</surname><given-names>J.P.</given-names></name>
<name><surname>van der Wel</surname><given-names>N.N.</given-names></name>
<name><surname>Picavet</surname><given-names>D.</given-names></name>
<name><surname>Koning</surname><given-names>F.</given-names></name>
<etal/>
</person-group><article-title>Maturing Human CD127+ CCR7+ PDL1+ Dendritic Cells Express AIRE in the Absence of Tissue Restricted Antigens</article-title><source>Front. Immunol.</source><year>2019</year><volume>9</volume><elocation-id>2902</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2018.02902</pub-id><pub-id pub-id-type="pmid">30692988</pub-id>
</element-citation></ref><ref id="B101-vaccines-12-01389"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Baba</surname><given-names>T.</given-names></name>
<name><surname>Nakamoto</surname><given-names>Y.</given-names></name>
<name><surname>Mukaida</surname><given-names>N.</given-names></name>
</person-group><article-title>Crucial Contribution of Thymic Sirp Alpha+ Conventional Dendritic Cells to Central Tolerance against Blood-Borne Antigens in a CCR2-Dependent Manner</article-title><source>J. Immunol.</source><year>2009</year><volume>183</volume><fpage>3053</fpage><lpage>3063</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.0900438</pub-id><pub-id pub-id-type="pmid">19675159</pub-id>
</element-citation></ref><ref id="B102-vaccines-12-01389"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Agrawal</surname><given-names>A.</given-names></name>
<name><surname>Sridharan</surname><given-names>A.</given-names></name>
<name><surname>Prakash</surname><given-names>S.</given-names></name>
<name><surname>Agrawal</surname><given-names>H.</given-names></name>
</person-group><article-title>Dendritic Cells and Aging: Consequences for Autoimmunity</article-title><source>Expert. Rev. Clin. Immunol.</source><year>2012</year><volume>8</volume><fpage>73</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1586/eci.11.77</pub-id><pub-id pub-id-type="pmid">22149342</pub-id>
</element-citation></ref><ref id="B103-vaccines-12-01389"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hasegawa</surname><given-names>H.</given-names></name>
<name><surname>Matsumoto</surname><given-names>T.</given-names></name>
</person-group><article-title>Mechanisms of Tolerance Induction by Dendritic Cells In Vivo</article-title><source>Front. Immunol.</source><year>2018</year><volume>9</volume><elocation-id>350</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2018.00350</pub-id><pub-id pub-id-type="pmid">29535726</pub-id>
</element-citation></ref><ref id="B104-vaccines-12-01389"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Sekai</surname><given-names>M.</given-names></name>
<name><surname>Matsui</surname><given-names>T.</given-names></name>
<name><surname>Fujii</surname><given-names>Y.</given-names></name>
<name><surname>Matsumoto</surname><given-names>M.</given-names></name>
<name><surname>Takeuchi</surname><given-names>O.</given-names></name>
<name><surname>Minato</surname><given-names>N.</given-names></name>
<name><surname>Hamazaki</surname><given-names>Y.</given-names></name>
</person-group><article-title>Hassall&#x02019;s Corpuscles with Cellular-Senescence Features Maintain IFN&#x003b1; Production through Neutrophils and pDC Activation in the Thymus</article-title><source>Int. Immunol.</source><year>2019</year><volume>31</volume><fpage>127</fpage><lpage>139</lpage><pub-id pub-id-type="doi">10.1093/intimm/dxy073</pub-id><pub-id pub-id-type="pmid">30534943</pub-id>
</element-citation></ref><ref id="B105-vaccines-12-01389"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liang</surname><given-names>Z.</given-names></name>
<name><surname>Dong</surname><given-names>X.</given-names></name>
<name><surname>Zhang</surname><given-names>Z.</given-names></name>
<name><surname>Zhang</surname><given-names>Q.</given-names></name>
<name><surname>Zhao</surname><given-names>Y.</given-names></name>
</person-group><article-title>Age-Related Thymic Involution: Mechanisms and Functional Impact</article-title><source>Aging Cell</source><year>2022</year><volume>21</volume><fpage>e13671</fpage><pub-id pub-id-type="doi">10.1111/acel.13671</pub-id><pub-id pub-id-type="pmid">35822239</pub-id>
</element-citation></ref><ref id="B106-vaccines-12-01389"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Chen</surname><given-names>P.</given-names></name>
<name><surname>Huang</surname><given-names>H.</given-names></name>
<name><surname>Feng</surname><given-names>H.</given-names></name>
<name><surname>Ran</surname><given-names>H.</given-names></name>
<name><surname>Liu</surname><given-names>W.</given-names></name>
</person-group><article-title>Quantification of Dendritic Cell Subsets in Human Thymus Tissues of Various Ages</article-title><source>Immun. Ageing</source><year>2021</year><volume>18</volume><fpage>44</fpage><pub-id pub-id-type="doi">10.1186/s12979-021-00255-8</pub-id><pub-id pub-id-type="pmid">34794472</pub-id>
</element-citation></ref><ref id="B107-vaccines-12-01389"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Granadier</surname><given-names>D.</given-names></name>
<name><surname>Iovino</surname><given-names>L.</given-names></name>
<name><surname>Kinsella</surname><given-names>S.</given-names></name>
<name><surname>Dudakov</surname><given-names>J.A.</given-names></name>
</person-group><article-title>Dynamics of Thymus Function and T Cell Receptor Repertoire Breadth in Health and Disease</article-title><source>Semin. Immunopathol.</source><year>2021</year><volume>43</volume><fpage>119</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1007/s00281-021-00840-5</pub-id><pub-id pub-id-type="pmid">33608819</pub-id>
</element-citation></ref><ref id="B108-vaccines-12-01389"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Britanova</surname><given-names>O.V.</given-names></name>
<name><surname>Putintseva</surname><given-names>E.V.</given-names></name>
<name><surname>Shugay</surname><given-names>M.</given-names></name>
<name><surname>Merzlyak</surname><given-names>E.M.</given-names></name>
<name><surname>Turchaninova</surname><given-names>M.A.</given-names></name>
<name><surname>Staroverov</surname><given-names>D.B.</given-names></name>
<name><surname>Bolotin</surname><given-names>D.A.</given-names></name>
<name><surname>Lukyanov</surname><given-names>S.</given-names></name>
<name><surname>Bogdanova</surname><given-names>E.A.</given-names></name>
<name><surname>Mamedov</surname><given-names>I.Z.</given-names></name>
<etal/>
</person-group><article-title>Age-Related Decrease in TCR Repertoire Diversity Measured with Deep and Normalized Sequence Profiling</article-title><source>J. Immunol.</source><year>2014</year><volume>192</volume><fpage>2689</fpage><lpage>2698</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1302064</pub-id><pub-id pub-id-type="pmid">24510963</pub-id>
</element-citation></ref><ref id="B109-vaccines-12-01389"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jennings</surname><given-names>E.Q.</given-names></name>
<name><surname>Fritz</surname><given-names>K.S.</given-names></name>
<name><surname>Galligan</surname><given-names>J.J.</given-names></name>
</person-group><article-title>Biochemical Genesis of Enzymatic and Non-Enzymatic Post-Translational Modifications</article-title><source>Mol. Aspects Med.</source><year>2022</year><volume>86</volume><fpage>101053</fpage><pub-id pub-id-type="doi">10.1016/j.mam.2021.101053</pub-id><pub-id pub-id-type="pmid">34838336</pub-id>
</element-citation></ref><ref id="B110-vaccines-12-01389"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kelly</surname><given-names>J.J.</given-names></name>
<name><surname>Bloodworth</surname><given-names>N.</given-names></name>
<name><surname>Shao</surname><given-names>Q.</given-names></name>
<name><surname>Shabanowitz</surname><given-names>J.</given-names></name>
<name><surname>Hunt</surname><given-names>D.</given-names></name>
<name><surname>Meiler</surname><given-names>J.</given-names></name>
<name><surname>Pires</surname><given-names>M.M.</given-names></name>
</person-group><article-title>A Chemical Approach to Assess the Impact of Post-Translational Modification on MHC Peptide Binding and Effector Cell Engagement</article-title><source>ACS Chem. Biol.</source><year>2024</year><volume>19</volume><fpage>1991</fpage><lpage>2001</lpage><pub-id pub-id-type="doi">10.1021/acschembio.4c00312</pub-id><pub-id pub-id-type="pmid">39150956</pub-id>
</element-citation></ref><ref id="B111-vaccines-12-01389"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Haro</surname><given-names>I.</given-names></name>
<name><surname>Sanmart&#x000ed;</surname><given-names>R.</given-names></name>
<name><surname>G&#x000f3;mara</surname><given-names>M.J.</given-names></name>
</person-group><article-title>Implications of Post-Translational Modifications in Autoimmunity with Emphasis on Citrullination, Homocitrullination and Acetylation for the Pathogenesis, Diagnosis and Prognosis of Rheumatoid Arthritis</article-title><source>Int. J. Mol. Sci.</source><year>2022</year><volume>23</volume><elocation-id>15803</elocation-id><pub-id pub-id-type="doi">10.3390/ijms232415803</pub-id><pub-id pub-id-type="pmid">36555449</pub-id>
</element-citation></ref><ref id="B112-vaccines-12-01389"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Doyle</surname><given-names>H.A.</given-names></name>
<name><surname>Mamula</surname><given-names>M.J.</given-names></name>
</person-group><article-title>Autoantigenesis: The Evolution of Protein Modifications in Autoimmune Disease</article-title><source>Curr. Opin. Immunol.</source><year>2012</year><volume>24</volume><fpage>112</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2011.12.003</pub-id><pub-id pub-id-type="pmid">22209691</pub-id>
</element-citation></ref><ref id="B113-vaccines-12-01389"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Raposo</surname><given-names>B.</given-names></name>
<name><surname>Merky</surname><given-names>P.</given-names></name>
<name><surname>Lundqvist</surname><given-names>C.</given-names></name>
<name><surname>Yamada</surname><given-names>H.</given-names></name>
<name><surname>Urbonaviciute</surname><given-names>V.</given-names></name>
<name><surname>Niaudet</surname><given-names>C.</given-names></name>
<name><surname>Viljanen</surname><given-names>J.</given-names></name>
<name><surname>Kihlberg</surname><given-names>J.</given-names></name>
<name><surname>Kyewski</surname><given-names>B.</given-names></name>
<name><surname>Ekwall</surname><given-names>O.</given-names></name>
<etal/>
</person-group><article-title>T Cells Specific for Post-Translational Modifications Escape Intrathymic Tolerance Induction</article-title><source>Nat. Commun.</source><year>2018</year><volume>9</volume><fpage>353</fpage><pub-id pub-id-type="doi">10.1038/s41467-017-02763-y</pub-id><pub-id pub-id-type="pmid">29367624</pub-id>
</element-citation></ref><ref id="B114-vaccines-12-01389"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hayward</surname><given-names>A.</given-names></name>
<name><surname>Gilbert</surname><given-names>C.</given-names></name>
</person-group><article-title>Transposable Elements</article-title><source>Curr. Biol.</source><year>2022</year><volume>32</volume><fpage>R904</fpage><lpage>R909</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2022.07.044</pub-id><pub-id pub-id-type="pmid">36099891</pub-id>
</element-citation></ref><ref id="B115-vaccines-12-01389"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Larouche</surname><given-names>J.-D.</given-names></name>
<name><surname>Laumont</surname><given-names>C.M.</given-names></name>
<name><surname>Trofimov</surname><given-names>A.</given-names></name>
<name><surname>Vincent</surname><given-names>K.</given-names></name>
<name><surname>Hesnard</surname><given-names>L.</given-names></name>
<name><surname>Brochu</surname><given-names>S.</given-names></name>
<name><surname>C&#x000f4;t&#x000e9;</surname><given-names>C.</given-names></name>
<name><surname>Humeau</surname><given-names>J.F.</given-names></name>
<name><surname>Bonneil</surname><given-names>&#x000c9;.</given-names></name>
<name><surname>Lanoix</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Transposable Elements Regulate Thymus Development and Function</article-title><source>Elife</source><year>2024</year><volume>12</volume><fpage>RP91037</fpage><pub-id pub-id-type="doi">10.7554/eLife.91037</pub-id><pub-id pub-id-type="pmid">38635416</pub-id>
</element-citation></ref><ref id="B116-vaccines-12-01389"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pabis</surname><given-names>K.</given-names></name>
<name><surname>Barardo</surname><given-names>D.</given-names></name>
<name><surname>Sirbu</surname><given-names>O.</given-names></name>
<name><surname>Selvarajoo</surname><given-names>K.</given-names></name>
<name><surname>Gruber</surname><given-names>J.</given-names></name>
<name><surname>Kennedy</surname><given-names>B.K.</given-names></name>
</person-group><article-title>A Concerted Increase in Readthrough and Intron Retention Drives Transposon Expression during Aging and Senescence</article-title><source>Elife</source><year>2024</year><volume>12</volume><fpage>RP87811</fpage><pub-id pub-id-type="doi">10.7554/eLife.87811.3</pub-id><pub-id pub-id-type="pmid">38567944</pub-id>
</element-citation></ref><ref id="B117-vaccines-12-01389"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Colombo</surname><given-names>A.R.</given-names></name>
<name><surname>Elias</surname><given-names>H.K.</given-names></name>
<name><surname>Ramsingh</surname><given-names>G.</given-names></name>
</person-group><article-title>Senescence Induction Universally Activates Transposable Element Expression</article-title><source>Cell Cycle</source><year>2018</year><volume>17</volume><fpage>1846</fpage><lpage>1857</lpage><pub-id pub-id-type="doi">10.1080/15384101.2018.1502576</pub-id><pub-id pub-id-type="pmid">30080431</pub-id>
</element-citation></ref><ref id="B118-vaccines-12-01389"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kelly</surname><given-names>M.</given-names></name>
<name><surname>Lihua</surname><given-names>S.</given-names></name>
<name><surname>Zhe</surname><given-names>Z.</given-names></name>
<name><surname>Li</surname><given-names>S.</given-names></name>
<name><surname>Yoselin</surname><given-names>P.</given-names></name>
<name><surname>Michelle</surname><given-names>P.</given-names></name>
<name><surname>Sullivan Kathleen</surname><given-names>E.</given-names></name>
</person-group><article-title>Transposable Element Dysregulation in Systemic Lupus Erythematosus and Regulation by Histone Conformation and Hsp90</article-title><source>Clin. Immunol.</source><year>2018</year><volume>197</volume><fpage>6</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1016/j.clim.2018.08.011</pub-id><pub-id pub-id-type="pmid">30149120</pub-id>
</element-citation></ref><ref id="B119-vaccines-12-01389"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stetson</surname><given-names>D.B.</given-names></name>
</person-group><article-title>Endogenous Retroelements and Autoimmune Disease</article-title><source>Curr. Opin. Immunol.</source><year>2012</year><volume>24</volume><fpage>692</fpage><lpage>697</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2012.09.007</pub-id><pub-id pub-id-type="pmid">23062469</pub-id>
</element-citation></ref><ref id="B120-vaccines-12-01389"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Volkman</surname><given-names>H.E.</given-names></name>
<name><surname>Stetson</surname><given-names>D.B.</given-names></name>
</person-group><article-title>The Enemy within: Endogenous Retroelements and Autoimmune Disease</article-title><source>Nat. Immunol.</source><year>2014</year><volume>15</volume><fpage>415</fpage><lpage>422</lpage><pub-id pub-id-type="doi">10.1038/ni.2872</pub-id><pub-id pub-id-type="pmid">24747712</pub-id>
</element-citation></ref><ref id="B121-vaccines-12-01389"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>De Cecco</surname><given-names>M.</given-names></name>
<name><surname>Ito</surname><given-names>T.</given-names></name>
<name><surname>Petrashen</surname><given-names>A.P.</given-names></name>
<name><surname>Elias</surname><given-names>A.E.</given-names></name>
<name><surname>Skvir</surname><given-names>N.J.</given-names></name>
<name><surname>Criscione</surname><given-names>S.W.</given-names></name>
<name><surname>Caligiana</surname><given-names>A.</given-names></name>
<name><surname>Brocculi</surname><given-names>G.</given-names></name>
<name><surname>Adney</surname><given-names>E.M.</given-names></name>
<name><surname>Boeke</surname><given-names>J.D.</given-names></name>
<etal/>
</person-group><article-title>L1 Drives IFN in Senescent Cells and Promotes Age-Associated Inflammation</article-title><source>Nature</source><year>2019</year><volume>566</volume><fpage>73</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1038/s41586-018-0784-9</pub-id><pub-id pub-id-type="pmid">30728521</pub-id>
</element-citation></ref><ref id="B122-vaccines-12-01389"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hasegawa</surname><given-names>T.</given-names></name>
<name><surname>Oka</surname><given-names>T.</given-names></name>
<name><surname>Son</surname><given-names>H.G.</given-names></name>
<name><surname>Oliver-Garc&#x000ed;a</surname><given-names>V.S.</given-names></name>
<name><surname>Azin</surname><given-names>M.</given-names></name>
<name><surname>Eisenhaure</surname><given-names>T.M.</given-names></name>
<name><surname>Lieb</surname><given-names>D.J.</given-names></name>
<name><surname>Hacohen</surname><given-names>N.</given-names></name>
<name><surname>Demehri</surname><given-names>S.</given-names></name>
</person-group><article-title>Cytotoxic CD4+ T Cells Eliminate Senescent Cells by Targeting Cytomegalovirus Antigen</article-title><source>Cell</source><year>2023</year><volume>186</volume><fpage>1417</fpage><lpage>1431.e20</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2023.02.033</pub-id><pub-id pub-id-type="pmid">37001502</pub-id>
</element-citation></ref><ref id="B123-vaccines-12-01389"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bordon</surname><given-names>Y.</given-names></name>
</person-group><article-title>T Cells Target Viral Protein to Remove Senescent Fibroblasts</article-title><source>Nat. Rev. Immunol.</source><year>2023</year><volume>23</volume><fpage>271</fpage><pub-id pub-id-type="doi">10.1038/s41577-023-00878-6</pub-id><pub-id pub-id-type="pmid">37041383</pub-id>
</element-citation></ref><ref id="B124-vaccines-12-01389"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Klopack</surname><given-names>E.T.</given-names></name>
</person-group><article-title>Chronic Stress and Latent Virus Reactivation: Effects on Immune Aging, Chronic Disease Morbidity, and Mortality</article-title><source>J. Gerontol. B Psychol. Sci. Soc. Sci.</source><year>2023</year><volume>78</volume><fpage>1707</fpage><lpage>1716</lpage><pub-id pub-id-type="doi">10.1093/geronb/gbad087</pub-id><pub-id pub-id-type="pmid">37294880</pub-id>
</element-citation></ref><ref id="B125-vaccines-12-01389"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stowe</surname><given-names>R.P.</given-names></name>
<name><surname>Kozlova</surname><given-names>E.V.</given-names></name>
<name><surname>Yetman</surname><given-names>D.L.</given-names></name>
<name><surname>Walling</surname><given-names>D.M.</given-names></name>
<name><surname>Goodwin</surname><given-names>J.S.</given-names></name>
<name><surname>Glaser</surname><given-names>R.</given-names></name>
</person-group><article-title>Chronic Herpesvirus Reactivation Occurs in Aging</article-title><source>Exp. Gerontol.</source><year>2007</year><volume>42</volume><fpage>563</fpage><lpage>570</lpage><pub-id pub-id-type="doi">10.1016/j.exger.2007.01.005</pub-id><pub-id pub-id-type="pmid">17337145</pub-id>
</element-citation></ref><ref id="B126-vaccines-12-01389"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kyewski</surname><given-names>B.</given-names></name>
<name><surname>Klein</surname><given-names>L.</given-names></name>
</person-group><article-title>A Central Role for Central Tolerance</article-title><source>Annu. Rev. Immunol.</source><year>2006</year><volume>24</volume><fpage>571</fpage><lpage>606</lpage><pub-id pub-id-type="doi">10.1146/annurev.immunol.23.021704.115601</pub-id><pub-id pub-id-type="pmid">16551260</pub-id>
</element-citation></ref><ref id="B127-vaccines-12-01389"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kishimoto</surname><given-names>H.</given-names></name>
<name><surname>Sprent</surname><given-names>J.</given-names></name>
</person-group><article-title>The Thymus and Central Tolerance</article-title><source>Clin. Immunol.</source><year>2000</year><volume>95</volume><fpage>S3-7</fpage><pub-id pub-id-type="doi">10.1006/clim.1999.4818</pub-id><pub-id pub-id-type="pmid">10729231</pub-id>
</element-citation></ref><ref id="B128-vaccines-12-01389"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>ElTanbouly</surname><given-names>M.A.</given-names></name>
<name><surname>Noelle</surname><given-names>R.J.</given-names></name>
</person-group><article-title>Rethinking Peripheral T Cell Tolerance: Checkpoints across a T Cell&#x02019;s Journey</article-title><source>Nat. Rev. Immunol.</source><year>2021</year><volume>21</volume><fpage>257</fpage><lpage>267</lpage><pub-id pub-id-type="doi">10.1038/s41577-020-00454-2</pub-id><pub-id pub-id-type="pmid">33077935</pub-id>
</element-citation></ref><ref id="B129-vaccines-12-01389"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Paul</surname><given-names>E.</given-names></name>
<name><surname>Nelde</surname><given-names>A.</given-names></name>
<name><surname>Verschoor</surname><given-names>A.</given-names></name>
<name><surname>Carroll</surname><given-names>M.C.</given-names></name>
</person-group><article-title>Follicular Exclusion of Autoreactive B Cells Requires FcgammaRIIb</article-title><source>Int. Immunol.</source><year>2007</year><volume>19</volume><fpage>365</fpage><lpage>373</lpage><pub-id pub-id-type="doi">10.1093/intimm/dxm002</pub-id><pub-id pub-id-type="pmid">17307801</pub-id>
</element-citation></ref><ref id="B130-vaccines-12-01389"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chapman</surname><given-names>N.M.</given-names></name>
<name><surname>Boothby</surname><given-names>M.R.</given-names></name>
<name><surname>Chi</surname><given-names>H.</given-names></name>
</person-group><article-title>Metabolic Coordination of T Cell Quiescence and Activation</article-title><source>Nat. Rev. Immunol.</source><year>2020</year><volume>20</volume><fpage>55</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1038/s41577-019-0203-y</pub-id><pub-id pub-id-type="pmid">31406325</pub-id>
</element-citation></ref><ref id="B131-vaccines-12-01389"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schwartz</surname><given-names>R.H.</given-names></name>
</person-group><article-title>T Cell Anergy</article-title><source>Annu. Rev. Immunol.</source><year>2003</year><volume>21</volume><fpage>305</fpage><lpage>334</lpage><pub-id pub-id-type="doi">10.1146/annurev.immunol.21.120601.141110</pub-id><pub-id pub-id-type="pmid">12471050</pub-id>
</element-citation></ref><ref id="B132-vaccines-12-01389"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Matveeva</surname><given-names>K.S.</given-names></name>
<name><surname>Shevyrev</surname><given-names>D.V.</given-names></name>
<name><surname>Rybtsov</surname><given-names>S.A.</given-names></name>
</person-group><article-title>Senescence-Associated &#x003b2;-Galactosidase Activity in Human Effector and Regulatory T Cells</article-title><source>Immunologiya</source><year>2024</year><volume>45</volume><fpage>290</fpage><lpage>299</lpage><pub-id pub-id-type="doi">10.33029/1816-2134-2024-45-3-290-299</pub-id></element-citation></ref><ref id="B133-vaccines-12-01389"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Matveeva</surname><given-names>K.S.</given-names></name>
<name><surname>Rybtsov</surname><given-names>S.A.</given-names></name>
<name><surname>Shevyrev</surname><given-names>D.V.</given-names></name>
</person-group><article-title>Investigating age-related dynamics and transcriptional signatures of CD8+HLA-DR+ regulatory T lymphocytes: Perspectives in understanding immune system aging</article-title><source>Med. Immunol.</source><year>2024</year><volume>26</volume><fpage>927</fpage><lpage>932</lpage><pub-id pub-id-type="doi">10.15789/1563-0625-IAR-16899</pub-id></element-citation></ref><ref id="B134-vaccines-12-01389"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Huang</surname><given-names>M.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Fang</surname><given-names>L.</given-names></name>
<name><surname>Liu</surname><given-names>C.</given-names></name>
<name><surname>Feng</surname><given-names>F.</given-names></name>
<name><surname>Liu</surname><given-names>L.</given-names></name>
<name><surname>Sun</surname><given-names>C.</given-names></name>
</person-group><article-title>T Cell Senescence: A New Perspective on Immunotherapy in Lung Cancer</article-title><source>Front. Immunol.</source><year>2024</year><volume>15</volume><elocation-id>1338680</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2024.1338680</pub-id><pub-id pub-id-type="pmid">38415245</pub-id>
</element-citation></ref><ref id="B135-vaccines-12-01389"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mart&#x000ed;nez-Zamudio</surname><given-names>R.I.</given-names></name>
<name><surname>Dewald</surname><given-names>H.K.</given-names></name>
<name><surname>Vasilopoulos</surname><given-names>T.</given-names></name>
<name><surname>Gittens-Williams</surname><given-names>L.</given-names></name>
<name><surname>Fitzgerald-Bocarsly</surname><given-names>P.</given-names></name>
<name><surname>Herbig</surname><given-names>U.</given-names></name>
</person-group><article-title>Senescence-associated &#x00392;-galactosidase Reveals the Abundance of Senescent CD8+ T Cells in Aging Humans</article-title><source>Aging Cell</source><year>2021</year><volume>20</volume><fpage>e13344</fpage><pub-id pub-id-type="doi">10.1111/acel.13344</pub-id><pub-id pub-id-type="pmid">33939265</pub-id>
</element-citation></ref><ref id="B136-vaccines-12-01389"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kurts</surname><given-names>C.</given-names></name>
<name><surname>Kosaka</surname><given-names>H.</given-names></name>
<name><surname>Carbone</surname><given-names>F.R.</given-names></name>
<name><surname>Miller</surname><given-names>J.F.</given-names></name>
<name><surname>Heath</surname><given-names>W.R.</given-names></name>
</person-group><article-title>Class I-Restricted Cross-Presentation of Exogenous Self-Antigens Leads to Deletion of Autoreactive CD8(+) T Cells</article-title><source>J. Exp. Med.</source><year>1997</year><volume>186</volume><fpage>239</fpage><lpage>245</lpage><pub-id pub-id-type="doi">10.1084/jem.186.2.239</pub-id><pub-id pub-id-type="pmid">9221753</pub-id>
</element-citation></ref><ref id="B137-vaccines-12-01389"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Davey</surname><given-names>G.M.</given-names></name>
<name><surname>Kurts</surname><given-names>C.</given-names></name>
<name><surname>Miller</surname><given-names>J.F.A.P.</given-names></name>
<name><surname>Bouillet</surname><given-names>P.</given-names></name>
<name><surname>Strasser</surname><given-names>A.</given-names></name>
<name><surname>Brooks</surname><given-names>A.G.</given-names></name>
<name><surname>Carbone</surname><given-names>F.R.</given-names></name>
<name><surname>Heath</surname><given-names>W.R.</given-names></name>
</person-group><article-title>Peripheral Deletion of Autoreactive CD8 T Cells by Cross Presentation of Self-Antigen Occurs by a Bcl-2-Inhibitable Pathway Mediated by Bim</article-title><source>J. Exp. Med.</source><year>2002</year><volume>196</volume><fpage>947</fpage><lpage>955</lpage><pub-id pub-id-type="doi">10.1084/jem.20020827</pub-id><pub-id pub-id-type="pmid">12370256</pub-id>
</element-citation></ref><ref id="B138-vaccines-12-01389"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Adler</surname><given-names>A.J.</given-names></name>
</person-group><article-title>Peripheral Tolerization of Effector and Memory T Cells: Implications for Autoimmunity and Tumor-Immunity</article-title><source>Curr. Immunol. Rev.</source><year>2005</year><volume>1</volume><fpage>21</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.2174/1573395052952879</pub-id><pub-id pub-id-type="pmid">20411047</pub-id>
</element-citation></ref><ref id="B139-vaccines-12-01389"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yin</surname><given-names>R.</given-names></name>
<name><surname>Melton</surname><given-names>S.</given-names></name>
<name><surname>Huseby</surname><given-names>E.S.</given-names></name>
<name><surname>Kardar</surname><given-names>M.</given-names></name>
<name><surname>Chakraborty</surname><given-names>A.K.</given-names></name>
</person-group><article-title>How Persistent Infection Overcomes Peripheral Tolerance Mechanisms to Cause T Cell-Mediated Autoimmune Disease</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2024</year><volume>121</volume><fpage>e2318599121</fpage><pub-id pub-id-type="doi">10.1073/pnas.2318599121</pub-id><pub-id pub-id-type="pmid">38446856</pub-id>
</element-citation></ref><ref id="B140-vaccines-12-01389"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wei</surname><given-names>S.C.</given-names></name>
<name><surname>Sharma</surname><given-names>R.</given-names></name>
<name><surname>Anang</surname><given-names>N.-A.A.S.</given-names></name>
<name><surname>Levine</surname><given-names>J.H.</given-names></name>
<name><surname>Zhao</surname><given-names>Y.</given-names></name>
<name><surname>Mancuso</surname><given-names>J.J.</given-names></name>
<name><surname>Setty</surname><given-names>M.</given-names></name>
<name><surname>Sharma</surname><given-names>P.</given-names></name>
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Pe&#x02019;er</surname><given-names>D.</given-names></name>
<etal/>
</person-group><article-title>Negative Co-Stimulation Constrains T Cell Differentiation by Imposing Boundaries on Possible Cell States</article-title><source>Immunity</source><year>2019</year><volume>50</volume><fpage>1084</fpage><lpage>1098.e10</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2019.03.004</pub-id><pub-id pub-id-type="pmid">30926234</pub-id>
</element-citation></ref><ref id="B141-vaccines-12-01389"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ness</surname><given-names>S.</given-names></name>
<name><surname>Lin</surname><given-names>S.</given-names></name>
<name><surname>Gordon</surname><given-names>J.R.</given-names></name>
</person-group><article-title>Regulatory Dendritic Cells, T Cell Tolerance, and Dendritic Cell Therapy for Immunologic Disease</article-title><source>Front. Immunol.</source><year>2021</year><volume>12</volume><elocation-id>633436</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2021.633436</pub-id><pub-id pub-id-type="pmid">33777019</pub-id>
</element-citation></ref><ref id="B142-vaccines-12-01389"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shevyrev</surname><given-names>D.</given-names></name>
<name><surname>Tereshchenko</surname><given-names>V.</given-names></name>
<name><surname>Blinova</surname><given-names>E.</given-names></name>
<name><surname>Knauer</surname><given-names>N.</given-names></name>
<name><surname>Pashkina</surname><given-names>E.</given-names></name>
<name><surname>Sizikov</surname><given-names>A.</given-names></name>
<name><surname>Kozlov</surname><given-names>V.</given-names></name>
</person-group><article-title>Regulatory T Cells Fail to Suppress Fast Homeostatic Proliferation In Vitro</article-title><source>Life</source><year>2021</year><volume>11</volume><elocation-id>245</elocation-id><pub-id pub-id-type="doi">10.3390/life11030245</pub-id><pub-id pub-id-type="pmid">33809452</pub-id>
</element-citation></ref><ref id="B143-vaccines-12-01389"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Paroli</surname><given-names>M.</given-names></name>
<name><surname>Schiaffella</surname><given-names>E.</given-names></name>
<name><surname>Di Rosa</surname><given-names>F.</given-names></name>
<name><surname>Barnaba</surname><given-names>V.</given-names></name>
</person-group><article-title>Persisting Viruses and Autoimmunity</article-title><source>J. Neuroimmunol.</source><year>2000</year><volume>107</volume><fpage>201</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1016/S0165-5728(00)00228-9</pub-id><pub-id pub-id-type="pmid">10854657</pub-id>
</element-citation></ref><ref id="B144-vaccines-12-01389"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sundaresan</surname><given-names>B.</given-names></name>
<name><surname>Shirafkan</surname><given-names>F.</given-names></name>
<name><surname>Ripperger</surname><given-names>K.</given-names></name>
<name><surname>Rattay</surname><given-names>K.</given-names></name>
</person-group><article-title>The Role of Viral Infections in the Onset of Autoimmune Diseases</article-title><source>Viruses</source><year>2023</year><volume>15</volume><elocation-id>782</elocation-id><pub-id pub-id-type="doi">10.3390/v15030782</pub-id><pub-id pub-id-type="pmid">36992490</pub-id>
</element-citation></ref><ref id="B145-vaccines-12-01389"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bjornevik</surname><given-names>K.</given-names></name>
<name><surname>Cortese</surname><given-names>M.</given-names></name>
<name><surname>Healy</surname><given-names>B.C.</given-names></name>
<name><surname>Kuhle</surname><given-names>J.</given-names></name>
<name><surname>Mina</surname><given-names>M.J.</given-names></name>
<name><surname>Leng</surname><given-names>Y.</given-names></name>
<name><surname>Elledge</surname><given-names>S.J.</given-names></name>
<name><surname>Niebuhr</surname><given-names>D.W.</given-names></name>
<name><surname>Scher</surname><given-names>A.I.</given-names></name>
<name><surname>Munger</surname><given-names>K.L.</given-names></name>
<etal/>
</person-group><article-title>Longitudinal Analysis Reveals High Prevalence of Epstein-Barr Virus Associated with Multiple Sclerosis</article-title><source>Science</source><year>2022</year><volume>375</volume><fpage>296</fpage><lpage>301</lpage><pub-id pub-id-type="doi">10.1126/science.abj8222</pub-id><pub-id pub-id-type="pmid">35025605</pub-id>
</element-citation></ref><ref id="B146-vaccines-12-01389"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lin</surname><given-names>H.-C.</given-names></name>
<name><surname>Wang</surname><given-names>C.-H.</given-names></name>
<name><surname>Tsai</surname><given-names>F.-J.</given-names></name>
<name><surname>Hwang</surname><given-names>K.-P.</given-names></name>
<name><surname>Chen</surname><given-names>W.</given-names></name>
<name><surname>Lin</surname><given-names>C.-C.</given-names></name>
<name><surname>Li</surname><given-names>T.-C.</given-names></name>
</person-group><article-title>Enterovirus Infection Is Associated with an Increased Risk of Childhood Type 1 Diabetes in Taiwan: A Nationwide Population-Based Cohort Study</article-title><source>Diabetologia</source><year>2015</year><volume>58</volume><fpage>79</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1007/s00125-014-3400-z</pub-id><pub-id pub-id-type="pmid">25335440</pub-id>
</element-citation></ref><ref id="B147-vaccines-12-01389"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shevyrev</surname><given-names>D.V.</given-names></name>
<name><surname>Tereshchenko</surname><given-names>V.P.</given-names></name>
<name><surname>Sennikov</surname><given-names>S.V.</given-names></name>
</person-group><article-title>The Enigmatic Nature of the TCR-pMHC Interaction: Implications for CAR-T and TCR-T Engineering</article-title><source>Int. J. Mol. Sci.</source><year>2022</year><volume>23</volume><elocation-id>14728</elocation-id><pub-id pub-id-type="doi">10.3390/ijms232314728</pub-id><pub-id pub-id-type="pmid">36499057</pub-id>
</element-citation></ref><ref id="B148-vaccines-12-01389"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pageon</surname><given-names>S.V.</given-names></name>
<name><surname>Tabarin</surname><given-names>T.</given-names></name>
<name><surname>Yamamoto</surname><given-names>Y.</given-names></name>
<name><surname>Ma</surname><given-names>Y.</given-names></name>
<name><surname>Nicovich</surname><given-names>P.R.</given-names></name>
<name><surname>Bridgeman</surname><given-names>J.S.</given-names></name>
<name><surname>Cohnen</surname><given-names>A.</given-names></name>
<name><surname>Benzing</surname><given-names>C.</given-names></name>
<name><surname>Gao</surname><given-names>Y.</given-names></name>
<name><surname>Crowther</surname><given-names>M.D.</given-names></name>
<etal/>
</person-group><article-title>Functional Role of T-Cell Receptor Nanoclusters in Signal Initiation and Antigen Discrimination</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2016</year><volume>113</volume><fpage>E5454</fpage><lpage>E5463</lpage><pub-id pub-id-type="doi">10.1073/pnas.1607436113</pub-id><pub-id pub-id-type="pmid">27573839</pub-id>
</element-citation></ref><ref id="B149-vaccines-12-01389"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Saito</surname><given-names>Y.</given-names></name>
<name><surname>Yamamoto</surname><given-names>S.</given-names></name>
<name><surname>Chikenji</surname><given-names>T.S.</given-names></name>
</person-group><article-title>Role of Cellular Senescence in Inflammation and Regeneration</article-title><source>Inflamm. Regen.</source><year>2024</year><volume>44</volume><fpage>28</fpage><pub-id pub-id-type="doi">10.1186/s41232-024-00342-5</pub-id><pub-id pub-id-type="pmid">38831382</pub-id>
</element-citation></ref><ref id="B150-vaccines-12-01389"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>Q.</given-names></name>
<name><surname>Zheng</surname><given-names>Y.</given-names></name>
<name><surname>Goronzy</surname><given-names>J.J.</given-names></name>
<name><surname>Weyand</surname><given-names>C.M.</given-names></name>
</person-group><article-title>T Cell Aging as a Risk Factor for Autoimmunity</article-title><source>J. Autoimmun.</source><year>2023</year><volume>137</volume><fpage>102947</fpage><pub-id pub-id-type="doi">10.1016/j.jaut.2022.102947</pub-id><pub-id pub-id-type="pmid">36357240</pub-id>
</element-citation></ref><ref id="B151-vaccines-12-01389"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schloesser</surname><given-names>D.</given-names></name>
<name><surname>Lindenthal</surname><given-names>L.</given-names></name>
<name><surname>Sauer</surname><given-names>J.</given-names></name>
<name><surname>Chung</surname><given-names>K.-J.</given-names></name>
<name><surname>Chavakis</surname><given-names>T.</given-names></name>
<name><surname>Griesser</surname><given-names>E.</given-names></name>
<name><surname>Baskaran</surname><given-names>P.</given-names></name>
<name><surname>Maier-Habelsberger</surname><given-names>U.</given-names></name>
<name><surname>Fundel-Clemens</surname><given-names>K.</given-names></name>
<name><surname>Schlotthauer</surname><given-names>I.</given-names></name>
<etal/>
</person-group><article-title>Senescent Cells Suppress Macrophage-Mediated Corpse Removal via Upregulation of the CD47-QPCT/L Axis</article-title><source>J. Cell Biol.</source><year>2023</year><volume>222</volume><elocation-id>e202207097</elocation-id><pub-id pub-id-type="doi">10.1083/jcb.202207097</pub-id><pub-id pub-id-type="pmid">36459066</pub-id>
</element-citation></ref><ref id="B152-vaccines-12-01389"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bosco</surname><given-names>N.</given-names></name>
<name><surname>Noti</surname><given-names>M.</given-names></name>
</person-group><article-title>The Aging Gut Microbiome and Its Impact on Host Immunity</article-title><source>Genes Immun.</source><year>2021</year><volume>22</volume><fpage>289</fpage><lpage>303</lpage><pub-id pub-id-type="doi">10.1038/s41435-021-00126-8</pub-id><pub-id pub-id-type="pmid">33875817</pub-id>
</element-citation></ref><ref id="B153-vaccines-12-01389"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jang</surname><given-names>D.-H.</given-names></name>
<name><surname>Shin</surname><given-names>J.-W.</given-names></name>
<name><surname>Shim</surname><given-names>E.</given-names></name>
<name><surname>Ohtani</surname><given-names>N.</given-names></name>
<name><surname>Jeon</surname><given-names>O.H.</given-names></name>
</person-group><article-title>The Connection between Aging, Cellular Senescence and Gut Microbiome Alterations: A Comprehensive Review</article-title><source>Aging Cell</source><year>2024</year><volume>23</volume><fpage>e14315</fpage><pub-id pub-id-type="doi">10.1111/acel.14315</pub-id><pub-id pub-id-type="pmid">39148278</pub-id>
</element-citation></ref><ref id="B154-vaccines-12-01389"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Berg</surname><given-names>R.D.</given-names></name>
</person-group><article-title>Bacterial Translocation from the Gastrointestinal Tract</article-title><source>Adv. Exp. Med. Biol.</source><year>1999</year><volume>473</volume><fpage>11</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1007/978-1-4615-4143-1_2</pub-id><pub-id pub-id-type="pmid">10659341</pub-id>
</element-citation></ref><ref id="B155-vaccines-12-01389"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fine</surname><given-names>R.L.</given-names></name>
<name><surname>Manfredo Vieira</surname><given-names>S.</given-names></name>
<name><surname>Gilmore</surname><given-names>M.S.</given-names></name>
<name><surname>Kriegel</surname><given-names>M.A.</given-names></name>
</person-group><article-title>Mechanisms and Consequences of Gut Commensal Translocation in Chronic Diseases</article-title><source>Gut Microbes</source><year>2020</year><volume>11</volume><fpage>217</fpage><lpage>230</lpage><pub-id pub-id-type="doi">10.1080/19490976.2019.1629236</pub-id><pub-id pub-id-type="pmid">31306081</pub-id>
</element-citation></ref><ref id="B156-vaccines-12-01389"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kawamoto</surname><given-names>S.</given-names></name>
<name><surname>Uemura</surname><given-names>K.</given-names></name>
<name><surname>Hori</surname><given-names>N.</given-names></name>
<name><surname>Takayasu</surname><given-names>L.</given-names></name>
<name><surname>Konishi</surname><given-names>Y.</given-names></name>
<name><surname>Katoh</surname><given-names>K.</given-names></name>
<name><surname>Matsumoto</surname><given-names>T.</given-names></name>
<name><surname>Suzuki</surname><given-names>M.</given-names></name>
<name><surname>Sakai</surname><given-names>Y.</given-names></name>
<name><surname>Matsudaira</surname><given-names>T.</given-names></name>
<etal/>
</person-group><article-title>Bacterial Induction of B Cell Senescence Promotes Age-Related Changes in the Gut Microbiota</article-title><source>Nat. Cell Biol.</source><year>2023</year><volume>25</volume><fpage>865</fpage><lpage>876</lpage><pub-id pub-id-type="doi">10.1038/s41556-023-01145-5</pub-id><pub-id pub-id-type="pmid">37169880</pub-id>
</element-citation></ref><ref id="B157-vaccines-12-01389"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Foth</surname><given-names>S.</given-names></name>
<name><surname>V&#x000f6;lkel</surname><given-names>S.</given-names></name>
<name><surname>Bauersachs</surname><given-names>D.</given-names></name>
<name><surname>Zemlin</surname><given-names>M.</given-names></name>
<name><surname>Skevaki</surname><given-names>C.</given-names></name>
</person-group><article-title>T Cell Repertoire During Ontogeny and Characteristics in Inflammatory Disorders in Adults and Childhood</article-title><source>Front. Immunol.</source><year>2020</year><volume>11</volume><elocation-id>611573</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2020.611573</pub-id><pub-id pub-id-type="pmid">33633732</pub-id>
</element-citation></ref><ref id="B158-vaccines-12-01389"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>X.</given-names></name>
<name><surname>Li</surname><given-names>C.</given-names></name>
<name><surname>Zhang</surname><given-names>W.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Qian</surname><given-names>P.</given-names></name>
<name><surname>Huang</surname><given-names>H.</given-names></name>
</person-group><article-title>Inflammation and Aging: Signaling Pathways and Intervention Therapies</article-title><source>Signal Transduct. Target. Ther.</source><year>2023</year><volume>8</volume><fpage>239</fpage><pub-id pub-id-type="doi">10.1038/s41392-023-01502-8</pub-id><pub-id pub-id-type="pmid">37291105</pub-id>
</element-citation></ref><ref id="B159-vaccines-12-01389"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yan</surname><given-names>H.</given-names></name>
<name><surname>Baldridge</surname><given-names>M.T.</given-names></name>
<name><surname>King</surname><given-names>K.Y.</given-names></name>
</person-group><article-title>Hematopoiesis and the Bacterial Microbiome</article-title><source>Blood</source><year>2018</year><volume>132</volume><fpage>559</fpage><lpage>564</lpage><pub-id pub-id-type="doi">10.1182/blood-2018-02-832519</pub-id><pub-id pub-id-type="pmid">29853538</pub-id>
</element-citation></ref><ref id="B160-vaccines-12-01389"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>Z.</given-names></name>
<name><surname>Zhang</surname><given-names>Z.</given-names></name>
<name><surname>Ren</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Fang</surname><given-names>J.</given-names></name>
<name><surname>Yue</surname><given-names>H.</given-names></name>
<name><surname>Ma</surname><given-names>S.</given-names></name>
<name><surname>Guan</surname><given-names>F.</given-names></name>
</person-group><article-title>Aging and Age-Related Diseases: From Mechanisms to Therapeutic Strategies</article-title><source>Biogerontology</source><year>2021</year><volume>22</volume><fpage>165</fpage><lpage>187</lpage><pub-id pub-id-type="doi">10.1007/s10522-021-09910-5</pub-id><pub-id pub-id-type="pmid">33502634</pub-id>
</element-citation></ref><ref id="B161-vaccines-12-01389"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kumar</surname><given-names>M.</given-names></name>
<name><surname>James</surname><given-names>M.M.</given-names></name>
<name><surname>Kumawat</surname><given-names>M.</given-names></name>
<name><surname>Nabi</surname><given-names>B.</given-names></name>
<name><surname>Sharma</surname><given-names>P.</given-names></name>
<name><surname>Pal</surname><given-names>N.</given-names></name>
<name><surname>Shubham</surname><given-names>S.</given-names></name>
<name><surname>Tiwari</surname><given-names>R.R.</given-names></name>
<name><surname>Sarma</surname><given-names>D.K.</given-names></name>
<name><surname>Nagpal</surname><given-names>R.</given-names></name>
</person-group><article-title>Aging and Microbiome in the Modulation of Vaccine Efficacy</article-title><source>Biomedicines</source><year>2022</year><volume>10</volume><elocation-id>1545</elocation-id><pub-id pub-id-type="doi">10.3390/biomedicines10071545</pub-id><pub-id pub-id-type="pmid">35884849</pub-id>
</element-citation></ref><ref id="B162-vaccines-12-01389"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mouat</surname><given-names>I.C.</given-names></name>
<name><surname>Goldberg</surname><given-names>E.</given-names></name>
<name><surname>Horwitz</surname><given-names>M.S.</given-names></name>
</person-group><article-title>Age-Associated B Cells in Autoimmune Diseases</article-title><source>Cell Mol. Life Sci.</source><year>2022</year><volume>79</volume><fpage>402</fpage><pub-id pub-id-type="doi">10.1007/s00018-022-04433-9</pub-id><pub-id pub-id-type="pmid">35798993</pub-id>
</element-citation></ref><ref id="B163-vaccines-12-01389"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jordan</surname><given-names>A.</given-names></name>
<name><surname>Carding</surname><given-names>S.R.</given-names></name>
<name><surname>Hall</surname><given-names>L.J.</given-names></name>
</person-group><article-title>The Early-Life Gut Microbiome and Vaccine Efficacy</article-title><source>Lancet Microbe</source><year>2022</year><volume>3</volume><fpage>e787</fpage><lpage>e794</lpage><pub-id pub-id-type="doi">10.1016/S2666-5247(22)00185-9</pub-id><pub-id pub-id-type="pmid">36088916</pub-id>
</element-citation></ref><ref id="B164-vaccines-12-01389"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Weyand</surname><given-names>C.M.</given-names></name>
<name><surname>Goronzy</surname><given-names>J.J.</given-names></name>
</person-group><article-title>Aging of the Immune System. Mechanisms and Therapeutic Targets</article-title><source>Ann. Am. Thorac. Soc.</source><year>2016</year><volume>13</volume><issue>(Suppl. 5)</issue><fpage>S422</fpage><lpage>S428</lpage><pub-id pub-id-type="doi">10.1513/AnnalsATS.201602-095AW</pub-id><pub-id pub-id-type="pmid">28005419</pub-id>
</element-citation></ref><ref id="B165-vaccines-12-01389"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rodrigues</surname><given-names>C.M.C.</given-names></name>
<name><surname>Plotkin</surname><given-names>S.A.</given-names></name>
</person-group><article-title>Impact of Vaccines; Health, Economic and Social Perspectives</article-title><source>Front. Microbiol.</source><year>2020</year><volume>11</volume><elocation-id>1526</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2020.01526</pub-id><pub-id pub-id-type="pmid">32760367</pub-id>
</element-citation></ref><ref id="B166-vaccines-12-01389"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>L.</given-names></name>
<name><surname>Pitcher</surname><given-names>L.E.</given-names></name>
<name><surname>Prahalad</surname><given-names>V.</given-names></name>
<name><surname>Niedernhofer</surname><given-names>L.J.</given-names></name>
<name><surname>Robbins</surname><given-names>P.D.</given-names></name>
</person-group><article-title>Targeting Cellular Senescence with Senotherapeutics: Senolytics and Senomorphics</article-title><source>FEBS J.</source><year>2023</year><volume>290</volume><fpage>1362</fpage><lpage>1383</lpage><pub-id pub-id-type="doi">10.1111/febs.16350</pub-id><pub-id pub-id-type="pmid">35015337</pub-id>
</element-citation></ref><ref id="B167-vaccines-12-01389"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lagoumtzi</surname><given-names>S.M.</given-names></name>
<name><surname>Chondrogianni</surname><given-names>N.</given-names></name>
</person-group><article-title>Senolytics and Senomorphics: Natural and Synthetic Therapeutics in the Treatment of Aging and Chronic Diseases</article-title><source>Free Radic. Biol. Med.</source><year>2021</year><volume>171</volume><fpage>169</fpage><lpage>190</lpage><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2021.05.003</pub-id><pub-id pub-id-type="pmid">33989756</pub-id>
</element-citation></ref><ref id="B168-vaccines-12-01389"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Deryabin</surname><given-names>P.I.</given-names></name>
<name><surname>Shatrova</surname><given-names>A.N.</given-names></name>
<name><surname>Borodkina</surname><given-names>A.V.</given-names></name>
</person-group><article-title>Apoptosis Resistance of Senescent Cells Is an Intrinsic Barrier for Senolysis Induced by Cardiac Glycosides</article-title><source>Cell Mol. Life Sci.</source><year>2021</year><volume>78</volume><fpage>7757</fpage><lpage>7776</lpage><pub-id pub-id-type="doi">10.1007/s00018-021-03980-x</pub-id><pub-id pub-id-type="pmid">34714358</pub-id>
</element-citation></ref><ref id="B169-vaccines-12-01389"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhu</surname><given-names>Y.</given-names></name>
<name><surname>Tchkonia</surname><given-names>T.</given-names></name>
<name><surname>Pirtskhalava</surname><given-names>T.</given-names></name>
<name><surname>Gower</surname><given-names>A.C.</given-names></name>
<name><surname>Ding</surname><given-names>H.</given-names></name>
<name><surname>Giorgadze</surname><given-names>N.</given-names></name>
<name><surname>Palmer</surname><given-names>A.K.</given-names></name>
<name><surname>Ikeno</surname><given-names>Y.</given-names></name>
<name><surname>Hubbard</surname><given-names>G.B.</given-names></name>
<name><surname>Lenburg</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>The Achilles&#x02019; Heel of Senescent Cells: From Transcriptome to Senolytic Drugs</article-title><source>Aging Cell</source><year>2015</year><volume>14</volume><fpage>644</fpage><lpage>658</lpage><pub-id pub-id-type="doi">10.1111/acel.12344</pub-id><pub-id pub-id-type="pmid">25754370</pub-id>
</element-citation></ref><ref id="B170-vaccines-12-01389"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chaib</surname><given-names>S.</given-names></name>
<name><surname>Tchkonia</surname><given-names>T.</given-names></name>
<name><surname>Kirkland</surname><given-names>J.L.</given-names></name>
</person-group><article-title>Cellular Senescence and Senolytics: The Path to the Clinic</article-title><source>Nat. Med.</source><year>2022</year><volume>28</volume><fpage>1556</fpage><lpage>1568</lpage><pub-id pub-id-type="doi">10.1038/s41591-022-01923-y</pub-id><pub-id pub-id-type="pmid">35953721</pub-id>
</element-citation></ref><ref id="B171-vaccines-12-01389"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chan</surname><given-names>K.T.</given-names></name>
<name><surname>Blake</surname><given-names>S.</given-names></name>
<name><surname>Zhu</surname><given-names>H.</given-names></name>
<name><surname>Kang</surname><given-names>J.</given-names></name>
<name><surname>Trigos</surname><given-names>A.S.</given-names></name>
<name><surname>Madhamshettiwar</surname><given-names>P.B.</given-names></name>
<name><surname>Diesch</surname><given-names>J.</given-names></name>
<name><surname>Paavolainen</surname><given-names>L.</given-names></name>
<name><surname>Horvath</surname><given-names>P.</given-names></name>
<name><surname>Hannan</surname><given-names>R.D.</given-names></name>
<etal/>
</person-group><article-title>A Functional Genetic Screen Defines the AKT-Induced Senescence Signaling Network</article-title><source>Cell Death Differ.</source><year>2020</year><volume>27</volume><fpage>725</fpage><lpage>741</lpage><pub-id pub-id-type="doi">10.1038/s41418-019-0384-8</pub-id><pub-id pub-id-type="pmid">31285545</pub-id>
</element-citation></ref><ref id="B172-vaccines-12-01389"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>L&#x02019;H&#x000f4;te</surname><given-names>V.</given-names></name>
<name><surname>Mann</surname><given-names>C.</given-names></name>
<name><surname>Thuret</surname><given-names>J.-Y.</given-names></name>
</person-group><article-title>From the Divergence of Senescent Cell Fates to Mechanisms and Selectivity of Senolytic Drugs</article-title><source>Open Biol.</source><year>2022</year><volume>12</volume><elocation-id>220171</elocation-id><pub-id pub-id-type="doi">10.1098/rsob.220171</pub-id><pub-id pub-id-type="pmid">36128715</pub-id>
</element-citation></ref><ref id="B173-vaccines-12-01389"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bartlett</surname><given-names>D.E.</given-names></name>
<name><surname>Miller</surname><given-names>R.B.</given-names></name>
<name><surname>Thiesfeldt</surname><given-names>S.</given-names></name>
<name><surname>Lakhani</surname><given-names>H.V.</given-names></name>
<name><surname>Shapiro</surname><given-names>J.I.</given-names></name>
<name><surname>Sodhi</surname><given-names>K.</given-names></name>
</person-group><article-title>The Role of Na/K-ATPase Signaling in Oxidative Stress Related to Aging: Implications in Obesity and Cardiovascular Disease</article-title><source>Int. J. Mol. Sci.</source><year>2018</year><volume>19</volume><elocation-id>2139</elocation-id><pub-id pub-id-type="doi">10.3390/ijms19072139</pub-id><pub-id pub-id-type="pmid">30041449</pub-id>
</element-citation></ref><ref id="B174-vaccines-12-01389"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>von Kobbe</surname><given-names>C.</given-names></name>
</person-group><article-title>Targeting Senescent Cells: Approaches, Opportunities, Challenges</article-title><source>Aging</source><year>2019</year><volume>11</volume><fpage>12844</fpage><lpage>12861</lpage><pub-id pub-id-type="doi">10.18632/aging.102557</pub-id><pub-id pub-id-type="pmid">31789602</pub-id>
</element-citation></ref><ref id="B175-vaccines-12-01389"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Huang</surname><given-names>W.</given-names></name>
<name><surname>Hickson</surname><given-names>L.J.</given-names></name>
<name><surname>Eirin</surname><given-names>A.</given-names></name>
<name><surname>Kirkland</surname><given-names>J.L.</given-names></name>
<name><surname>Lerman</surname><given-names>L.O.</given-names></name>
</person-group><article-title>Cellular Senescence: The Good, the Bad and the Unknown</article-title><source>Nat. Rev. Nephrol.</source><year>2022</year><volume>18</volume><fpage>611</fpage><lpage>627</lpage><pub-id pub-id-type="doi">10.1038/s41581-022-00601-z</pub-id><pub-id pub-id-type="pmid">35922662</pub-id>
</element-citation></ref><ref id="B176-vaccines-12-01389"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Storer</surname><given-names>M.</given-names></name>
<name><surname>Mas</surname><given-names>A.</given-names></name>
<name><surname>Robert-Moreno</surname><given-names>A.</given-names></name>
<name><surname>Pecoraro</surname><given-names>M.</given-names></name>
<name><surname>Ortells</surname><given-names>M.C.</given-names></name>
<name><surname>Di Giacomo</surname><given-names>V.</given-names></name>
<name><surname>Yosef</surname><given-names>R.</given-names></name>
<name><surname>Pilpel</surname><given-names>N.</given-names></name>
<name><surname>Krizhanovsky</surname><given-names>V.</given-names></name>
<name><surname>Sharpe</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Senescence Is a Developmental Mechanism That Contributes to Embryonic Growth and Patterning</article-title><source>Cell</source><year>2013</year><volume>155</volume><fpage>1119</fpage><lpage>1130</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2013.10.041</pub-id><pub-id pub-id-type="pmid">24238961</pub-id>
</element-citation></ref><ref id="B177-vaccines-12-01389"><label>177.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fukushima</surname><given-names>Y.</given-names></name>
<name><surname>Sakamoto</surname><given-names>K.</given-names></name>
<name><surname>Matsuda</surname><given-names>M.</given-names></name>
<name><surname>Yoshikai</surname><given-names>Y.</given-names></name>
<name><surname>Yagita</surname><given-names>H.</given-names></name>
<name><surname>Kitamura</surname><given-names>D.</given-names></name>
<name><surname>Chihara</surname><given-names>M.</given-names></name>
<name><surname>Minato</surname><given-names>N.</given-names></name>
<name><surname>Hattori</surname><given-names>M.</given-names></name>
</person-group><article-title>Cis Interaction of CD153 with TCR/CD3 Is Crucial for the Pathogenic Activation of Senescence-Associated T Cells</article-title><source>Cell Rep.</source><year>2022</year><volume>40</volume><fpage>111373</fpage><pub-id pub-id-type="doi">10.1016/j.celrep.2022.111373</pub-id><pub-id pub-id-type="pmid">36130493</pub-id>
</element-citation></ref><ref id="B178-vaccines-12-01389"><label>178.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Takaya</surname><given-names>K.</given-names></name>
<name><surname>Asou</surname><given-names>T.</given-names></name>
<name><surname>Kishi</surname><given-names>K.</given-names></name>
</person-group><article-title>Cathepsin F Is a Potential Marker for Senescent Human Skin Fibroblasts and Keratinocytes Associated with Skin Aging</article-title><source>GeroScience</source><year>2023</year><volume>45</volume><fpage>427</fpage><lpage>437</lpage><pub-id pub-id-type="doi">10.1007/s11357-022-00648-7</pub-id><pub-id pub-id-type="pmid">36057013</pub-id>
</element-citation></ref><ref id="B179-vaccines-12-01389"><label>179.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yang</surname><given-names>M.</given-names></name>
<name><surname>Harrison</surname><given-names>B.R.</given-names></name>
<name><surname>Promislow</surname><given-names>D.E.L.</given-names></name>
</person-group><article-title>Cellular Age Explains Variation in Age-Related Cell-to-Cell Transcriptome Variability</article-title><source>Genome Res.</source><year>2023</year><volume>33</volume><fpage>1906</fpage><lpage>1916</lpage><pub-id pub-id-type="doi">10.1101/gr.278144.123</pub-id><pub-id pub-id-type="pmid">37973195</pub-id>
</element-citation></ref><ref id="B180-vaccines-12-01389"><label>180.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Takaya</surname><given-names>K.</given-names></name>
<name><surname>Asou</surname><given-names>T.</given-names></name>
<name><surname>Kishi</surname><given-names>K.</given-names></name>
</person-group><article-title>New Senolysis Approach via Antibody-Drug Conjugate Targeting of the Senescent Cell Marker Apolipoprotein D for Skin Rejuvenation</article-title><source>Int. J. Mol. Sci.</source><year>2023</year><volume>24</volume><elocation-id>5857</elocation-id><pub-id pub-id-type="doi">10.3390/ijms24065857</pub-id><pub-id pub-id-type="pmid">36982931</pub-id>
</element-citation></ref><ref id="B181-vaccines-12-01389"><label>181.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Takaya</surname><given-names>K.</given-names></name>
<name><surname>Asou</surname><given-names>T.</given-names></name>
<name><surname>Kishi</surname><given-names>K.</given-names></name>
</person-group><article-title>Identification of Apolipoprotein D as a Dermal Fibroblast Marker of Human Aging for Development of Skin Rejuvenation Therapy</article-title><source>Rejuvenation Res.</source><year>2023</year><volume>26</volume><fpage>42</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1089/rej.2022.0056</pub-id><pub-id pub-id-type="pmid">36571249</pub-id>
</element-citation></ref><ref id="B182-vaccines-12-01389"><label>182.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Amor</surname><given-names>C.</given-names></name>
<name><surname>Feucht</surname><given-names>J.</given-names></name>
<name><surname>Leibold</surname><given-names>J.</given-names></name>
<name><surname>Ho</surname><given-names>Y.-J.</given-names></name>
<name><surname>Zhu</surname><given-names>C.</given-names></name>
<name><surname>Alonso-Curbelo</surname><given-names>D.</given-names></name>
<name><surname>Mansilla-Soto</surname><given-names>J.</given-names></name>
<name><surname>Boyer</surname><given-names>J.A.</given-names></name>
<name><surname>Li</surname><given-names>X.</given-names></name>
<name><surname>Giavridis</surname><given-names>T.</given-names></name>
<etal/>
</person-group><article-title>Senolytic CAR T Cells Reverse Senescence-Associated Pathologies</article-title><source>Nature</source><year>2020</year><volume>583</volume><fpage>127</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2403-9</pub-id><pub-id pub-id-type="pmid">32555459</pub-id>
</element-citation></ref><ref id="B183-vaccines-12-01389"><label>183.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cho</surname><given-names>J.H.</given-names></name>
<name><surname>Kim</surname><given-names>E.-C.</given-names></name>
<name><surname>Son</surname><given-names>Y.</given-names></name>
<name><surname>Lee</surname><given-names>D.-W.</given-names></name>
<name><surname>Park</surname><given-names>Y.S.</given-names></name>
<name><surname>Choi</surname><given-names>J.H.</given-names></name>
<name><surname>Cho</surname><given-names>K.-H.</given-names></name>
<name><surname>Kwon</surname><given-names>K.-S.</given-names></name>
<name><surname>Kim</surname><given-names>J.-R.</given-names></name>
</person-group><article-title>CD9 Induces Cellular Senescence and Aggravates Atherosclerotic Plaque Formation</article-title><source>Cell Death Differ.</source><year>2020</year><volume>27</volume><fpage>2681</fpage><lpage>2696</lpage><pub-id pub-id-type="doi">10.1038/s41418-020-0537-9</pub-id><pub-id pub-id-type="pmid">32346137</pub-id>
</element-citation></ref><ref id="B184-vaccines-12-01389"><label>184.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shang</surname><given-names>D.</given-names></name>
<name><surname>Sun</surname><given-names>D.</given-names></name>
<name><surname>Shi</surname><given-names>C.</given-names></name>
<name><surname>Xu</surname><given-names>J.</given-names></name>
<name><surname>Shen</surname><given-names>M.</given-names></name>
<name><surname>Hu</surname><given-names>X.</given-names></name>
<name><surname>Liu</surname><given-names>H.</given-names></name>
<name><surname>Tu</surname><given-names>Z.</given-names></name>
</person-group><article-title>Activation of Epidermal Growth Factor Receptor Signaling Mediates Cellular Senescence Induced by Certain Pro-inflammatory Cytokines</article-title><source>Aging Cell</source><year>2020</year><volume>19</volume><fpage>e13145</fpage><pub-id pub-id-type="doi">10.1111/acel.13145</pub-id><pub-id pub-id-type="pmid">32323422</pub-id>
</element-citation></ref><ref id="B185-vaccines-12-01389"><label>185.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cao</surname><given-names>Y.</given-names></name>
<name><surname>Du</surname><given-names>X.</given-names></name>
<name><surname>Yu</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Jin</surname><given-names>X.</given-names></name>
<name><surname>Gu</surname><given-names>B.</given-names></name>
<name><surname>Yin</surname><given-names>Q.</given-names></name>
</person-group><article-title>Seno-Antigen-Pulsed Dendritic Cell Vaccine Induce Anti-Aging Immunity to Improve Adipose Tissue Senescence and Metabolic Abnormalities</article-title><source>Biomed. Pharmacother.</source><year>2024</year><volume>179</volume><elocation-id>117433</elocation-id><pub-id pub-id-type="doi">10.1016/j.biopha.2024.117433</pub-id><pub-id pub-id-type="pmid">39260327</pub-id>
</element-citation></ref><ref id="B186-vaccines-12-01389"><label>186.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Suda</surname><given-names>M.</given-names></name>
<name><surname>Shimizu</surname><given-names>I.</given-names></name>
<name><surname>Katsuumi</surname><given-names>G.</given-names></name>
<name><surname>Yoshida</surname><given-names>Y.</given-names></name>
<name><surname>Hayashi</surname><given-names>Y.</given-names></name>
<name><surname>Ikegami</surname><given-names>R.</given-names></name>
<name><surname>Matsumoto</surname><given-names>N.</given-names></name>
<name><surname>Yoshida</surname><given-names>Y.</given-names></name>
<name><surname>Mikawa</surname><given-names>R.</given-names></name>
<name><surname>Katayama</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Senolytic Vaccination Improves Normal and Pathological Age-Related Phenotypes and Increases Lifespan in Progeroid Mice</article-title><source>Nat. Aging</source><year>2021</year><volume>1</volume><fpage>1117</fpage><lpage>1126</lpage><pub-id pub-id-type="doi">10.1038/s43587-021-00151-2</pub-id><pub-id pub-id-type="pmid">37117524</pub-id>
</element-citation></ref><ref id="B187-vaccines-12-01389"><label>187.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Henson</surname><given-names>S.M.</given-names></name>
<name><surname>Akbar</surname><given-names>A.N.</given-names></name>
</person-group><article-title>KLRG1&#x02014;More than a Marker for T Cell Senescence</article-title><source>Age</source><year>2009</year><volume>31</volume><fpage>285</fpage><lpage>291</lpage><pub-id pub-id-type="doi">10.1007/s11357-009-9100-9</pub-id><pub-id pub-id-type="pmid">19479342</pub-id>
</element-citation></ref><ref id="B188-vaccines-12-01389"><label>188.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Chen</surname><given-names>S.</given-names></name>
<name><surname>Tang</surname><given-names>X.</given-names></name>
<name><surname>Peng</surname><given-names>Y.</given-names></name>
<name><surname>Jiang</surname><given-names>T.</given-names></name>
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Liu</surname><given-names>Y.</given-names></name>
<name><surname>Yang</surname><given-names>Z.</given-names></name>
</person-group><article-title>The Role of KLRG1: A Novel Biomarker and New Therapeutic Target</article-title><source>Cell Commun. Signal.</source><year>2024</year><volume>22</volume><fpage>337</fpage><pub-id pub-id-type="doi">10.1186/s12964-024-01714-7</pub-id><pub-id pub-id-type="pmid">38898461</pub-id>
</element-citation></ref><ref id="B189-vaccines-12-01389"><label>189.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Islam</surname><given-names>M.T.</given-names></name>
<name><surname>Tuday</surname><given-names>E.</given-names></name>
<name><surname>Allen</surname><given-names>S.</given-names></name>
<name><surname>Kim</surname><given-names>J.</given-names></name>
<name><surname>Trott</surname><given-names>D.W.</given-names></name>
<name><surname>Holland</surname><given-names>W.L.</given-names></name>
<name><surname>Donato</surname><given-names>A.J.</given-names></name>
<name><surname>Lesniewski</surname><given-names>L.A.</given-names></name>
</person-group><article-title>Senolytic Drugs, Dasatinib and Quercetin, Attenuate Adipose Tissue Inflammation, and Ameliorate Metabolic Function in Old Age</article-title><source>Aging Cell</source><year>2023</year><volume>22</volume><fpage>e13767</fpage><pub-id pub-id-type="doi">10.1111/acel.13767</pub-id><pub-id pub-id-type="pmid">36637079</pub-id>
</element-citation></ref><ref id="B190-vaccines-12-01389"><label>190.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Raffaele</surname><given-names>M.</given-names></name>
<name><surname>Vinciguerra</surname><given-names>M.</given-names></name>
</person-group><article-title>The Costs and Benefits of Senotherapeutics for Human Health</article-title><source>Lancet Healthy Longev.</source><year>2022</year><volume>3</volume><fpage>e67</fpage><lpage>e77</lpage><pub-id pub-id-type="doi">10.1016/S2666-7568(21)00300-7</pub-id><pub-id pub-id-type="pmid">36098323</pub-id>
</element-citation></ref><ref id="B191-vaccines-12-01389"><label>191.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zonari</surname><given-names>A.</given-names></name>
<name><surname>Brace</surname><given-names>L.E.</given-names></name>
<name><surname>Al-Katib</surname><given-names>K.</given-names></name>
<name><surname>Porto</surname><given-names>W.F.</given-names></name>
<name><surname>Foyt</surname><given-names>D.</given-names></name>
<name><surname>Guiang</surname><given-names>M.</given-names></name>
<name><surname>Cruz</surname><given-names>E.A.O.</given-names></name>
<name><surname>Marshall</surname><given-names>B.</given-names></name>
<name><surname>Gentz</surname><given-names>M.</given-names></name>
<name><surname>Guimar&#x000e3;es</surname><given-names>G.R.</given-names></name>
<etal/>
</person-group><article-title>Senotherapeutic Peptide Treatment Reduces Biological Age and Senescence Burden in Human Skin Models</article-title><source>NPJ Aging</source><year>2023</year><volume>9</volume><fpage>10</fpage><pub-id pub-id-type="doi">10.1038/s41514-023-00109-1</pub-id><pub-id pub-id-type="pmid">37217561</pub-id>
</element-citation></ref><ref id="B192-vaccines-12-01389"><label>192.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Goronzy</surname><given-names>J.J.</given-names></name>
<name><surname>Weyand</surname><given-names>C.M.</given-names></name>
</person-group><article-title>Understanding Immunosenescence to Improve Responses to Vaccines</article-title><source>Nat. Immunol.</source><year>2013</year><volume>14</volume><fpage>428</fpage><lpage>436</lpage><pub-id pub-id-type="doi">10.1038/ni.2588</pub-id><pub-id pub-id-type="pmid">23598398</pub-id>
</element-citation></ref><ref id="B193-vaccines-12-01389"><label>193.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Poblocka</surname><given-names>M.</given-names></name>
<name><surname>Bassey</surname><given-names>A.L.</given-names></name>
<name><surname>Smith</surname><given-names>V.M.</given-names></name>
<name><surname>Falcicchio</surname><given-names>M.</given-names></name>
<name><surname>Manso</surname><given-names>A.S.</given-names></name>
<name><surname>Althubiti</surname><given-names>M.</given-names></name>
<name><surname>Sheng</surname><given-names>X.</given-names></name>
<name><surname>Kyle</surname><given-names>A.</given-names></name>
<name><surname>Barber</surname><given-names>R.</given-names></name>
<name><surname>Frigerio</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Targeted Clearance of Senescent Cells Using an Antibody-Drug Conjugate against a Specific Membrane Marker</article-title><source>Sci. Rep.</source><year>2021</year><volume>11</volume><elocation-id>20358</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-021-99852-2</pub-id><pub-id pub-id-type="pmid">34645909</pub-id>
</element-citation></ref><ref id="B194-vaccines-12-01389"><label>194.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Takaya</surname><given-names>K.</given-names></name>
<name><surname>Asou</surname><given-names>T.</given-names></name>
<name><surname>Kishi</surname><given-names>K.</given-names></name>
</person-group><article-title>Development of a Novel Senolysis Approach Targeting the Senescent Fibroblast Marker HTR2A via Antibody-Dependent Cellular Cytotoxicity</article-title><source>Rejuvenation Res.</source><year>2023</year><volume>26</volume><fpage>147</fpage><lpage>158</lpage><pub-id pub-id-type="doi">10.1089/rej.2023.0020</pub-id><pub-id pub-id-type="pmid">37345689</pub-id>
</element-citation></ref><ref id="B195-vaccines-12-01389"><label>195.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rettko</surname><given-names>N.J.</given-names></name>
<name><surname>Campisi</surname><given-names>J.</given-names></name>
<name><surname>Wells</surname><given-names>J.A.</given-names></name>
</person-group><article-title>Engineering Antibodies Targeting P16 MHC-Peptide Complexes</article-title><source>ACS Chem. Biol.</source><year>2022</year><volume>17</volume><fpage>545</fpage><lpage>555</lpage><pub-id pub-id-type="doi">10.1021/acschembio.1c00808</pub-id><pub-id pub-id-type="pmid">35212540</pub-id>
</element-citation></ref><ref id="B196-vaccines-12-01389"><label>196.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Grosse</surname><given-names>L.</given-names></name>
<name><surname>Wagner</surname><given-names>N.</given-names></name>
<name><surname>Emelyanov</surname><given-names>A.</given-names></name>
<name><surname>Molina</surname><given-names>C.</given-names></name>
<name><surname>Lacas-Gervais</surname><given-names>S.</given-names></name>
<name><surname>Wagner</surname><given-names>K.-D.</given-names></name>
<name><surname>Bulavin</surname><given-names>D.V.</given-names></name>
</person-group><article-title>Defined p16High Senescent Cell Types Are Indispensable for Mouse Healthspan</article-title><source>Cell Metab.</source><year>2020</year><volume>32</volume><fpage>87</fpage><lpage>99.e6</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2020.05.002</pub-id><pub-id pub-id-type="pmid">32485135</pub-id>
</element-citation></ref><ref id="B197-vaccines-12-01389"><label>197.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rock</surname><given-names>K.L.</given-names></name>
<name><surname>Kono</surname><given-names>H.</given-names></name>
</person-group><article-title>The Inflammatory Response to Cell Death</article-title><source>Annu. Rev. Pathol.</source><year>2008</year><volume>3</volume><fpage>99</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1146/annurev.pathmechdis.3.121806.151456</pub-id><pub-id pub-id-type="pmid">18039143</pub-id>
</element-citation></ref><ref id="B198-vaccines-12-01389"><label>198.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bock</surname><given-names>F.J.</given-names></name>
<name><surname>Riley</surname><given-names>J.S.</given-names></name>
</person-group><article-title>When Cell Death Goes Wrong: Inflammatory Outcomes of Failed Apoptosis and Mitotic Cell Death</article-title><source>Cell Death Differ.</source><year>2023</year><volume>30</volume><fpage>293</fpage><lpage>303</lpage><pub-id pub-id-type="doi">10.1038/s41418-022-01082-0</pub-id><pub-id pub-id-type="pmid">36376381</pub-id>
</element-citation></ref><ref id="B199-vaccines-12-01389"><label>199.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bo&#x0017e;i&#x0010d;</surname><given-names>B.</given-names></name>
<name><surname>Rozman</surname><given-names>B.</given-names></name>
</person-group><article-title>Apoptosis and Autoimmunity</article-title><source>EJIFCC</source><year>2006</year><volume>17</volume><fpage>69</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">29760634</pub-id>
</element-citation></ref><ref id="B200-vaccines-12-01389"><label>200.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brieske</surname><given-names>C.</given-names></name>
<name><surname>Lamprecht</surname><given-names>P.</given-names></name>
<name><surname>Kerstein-Staehle</surname><given-names>A.</given-names></name>
</person-group><article-title>Immunogenic Cell Death as Driver of Autoimmunity in Granulomatosis with Polyangiitis</article-title><source>Front. Immunol.</source><year>2022</year><volume>13</volume><elocation-id>1007092</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2022.1007092</pub-id><pub-id pub-id-type="pmid">36275673</pub-id>
</element-citation></ref><ref id="B201-vaccines-12-01389"><label>201.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mancinelli</surname><given-names>L.</given-names></name>
<name><surname>Intini</surname><given-names>G.</given-names></name>
</person-group><article-title>Age-Associated Declining of the Regeneration Potential of Skeletal Stem/Progenitor Cells</article-title><source>Front. Physiol.</source><year>2023</year><volume>14</volume><elocation-id>1087254</elocation-id><pub-id pub-id-type="doi">10.3389/fphys.2023.1087254</pub-id><pub-id pub-id-type="pmid">36818437</pub-id>
</element-citation></ref><ref id="B202-vaccines-12-01389"><label>202.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rapaka</surname><given-names>R.R.</given-names></name>
<name><surname>Cross</surname><given-names>A.S.</given-names></name>
<name><surname>McArthur</surname><given-names>M.A.</given-names></name>
</person-group><article-title>Using Adjuvants to Drive T Cell Responses for Next-Generation Infectious Disease Vaccines</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><elocation-id>820</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines9080820</pub-id><pub-id pub-id-type="pmid">34451945</pub-id>
</element-citation></ref><ref id="B203-vaccines-12-01389"><label>203.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Muslimov</surname><given-names>A.</given-names></name>
<name><surname>Tereshchenko</surname><given-names>V.</given-names></name>
<name><surname>Shevyrev</surname><given-names>D.</given-names></name>
<name><surname>Rogova</surname><given-names>A.</given-names></name>
<name><surname>Lepik</surname><given-names>K.</given-names></name>
<name><surname>Reshetnikov</surname><given-names>V.</given-names></name>
<name><surname>Ivanov</surname><given-names>R.</given-names></name>
</person-group><article-title>The Dual Role of the Innate Immune System in the Effectiveness of mRNA Therapeutics</article-title><source>Int. J. Mol. Sci.</source><year>2023</year><volume>24</volume><elocation-id>14820</elocation-id><pub-id pub-id-type="doi">10.3390/ijms241914820</pub-id><pub-id pub-id-type="pmid">37834268</pub-id>
</element-citation></ref><ref id="B204-vaccines-12-01389"><label>204.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhao</surname><given-names>T.</given-names></name>
<name><surname>Cai</surname><given-names>Y.</given-names></name>
<name><surname>Jiang</surname><given-names>Y.</given-names></name>
<name><surname>He</surname><given-names>X.</given-names></name>
<name><surname>Wei</surname><given-names>Y.</given-names></name>
<name><surname>Yu</surname><given-names>Y.</given-names></name>
<name><surname>Tian</surname><given-names>X.</given-names></name>
</person-group><article-title>Vaccine Adjuvants: Mechanisms and Platforms</article-title><source>Sig Transduct. Target. Ther.</source><year>2023</year><volume>8</volume><fpage>283</fpage><pub-id pub-id-type="doi">10.1038/s41392-023-01557-7</pub-id><pub-id pub-id-type="pmid">37468460</pub-id>
</element-citation></ref><ref id="B205-vaccines-12-01389"><label>205.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jamshidi</surname><given-names>E.</given-names></name>
<name><surname>Asgary</surname><given-names>A.</given-names></name>
<name><surname>Kharrazi</surname><given-names>A.Y.</given-names></name>
<name><surname>Tavakoli</surname><given-names>N.</given-names></name>
<name><surname>Zali</surname><given-names>A.</given-names></name>
<name><surname>Mehrazi</surname><given-names>M.</given-names></name>
<name><surname>Jamshidi</surname><given-names>M.</given-names></name>
<name><surname>Farrokhi</surname><given-names>B.</given-names></name>
<name><surname>Maher</surname><given-names>A.</given-names></name>
<name><surname>von Garnier</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>Personalized Predictions of Adverse Side Effects of the COVID-19 Vaccines</article-title><source>Heliyon</source><year>2023</year><volume>9</volume><fpage>e12753</fpage><pub-id pub-id-type="doi">10.1016/j.heliyon.2022.e12753</pub-id><pub-id pub-id-type="pmid">36597482</pub-id>
</element-citation></ref><ref id="B206-vaccines-12-01389"><label>206.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Levi</surname><given-names>Y.</given-names></name>
<name><surname>Brandeau</surname><given-names>M.L.</given-names></name>
<name><surname>Shmueli</surname><given-names>E.</given-names></name>
<name><surname>Yamin</surname><given-names>D.</given-names></name>
</person-group><article-title>Prediction and Detection of Side Effects Severity Following COVID-19 and Influenza Vaccinations: Utilizing Smartwatches and Smartphones</article-title><source>Sci. Rep.</source><year>2024</year><volume>14</volume><elocation-id>6012</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-024-56561-w</pub-id><pub-id pub-id-type="pmid">38472345</pub-id>
</element-citation></ref><ref id="B207-vaccines-12-01389"><label>207.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Patrinos</surname><given-names>G.P.</given-names></name>
<name><surname>Sarhangi</surname><given-names>N.</given-names></name>
<name><surname>Sarrami</surname><given-names>B.</given-names></name>
<name><surname>Khodayari</surname><given-names>N.</given-names></name>
<name><surname>Larijani</surname><given-names>B.</given-names></name>
<name><surname>Hasanzad</surname><given-names>M.</given-names></name>
</person-group><article-title>Using ChatGPT to Predict the Future of Personalized Medicine</article-title><source>Pharmacogenom. J.</source><year>2023</year><volume>23</volume><fpage>178</fpage><lpage>184</lpage><pub-id pub-id-type="doi">10.1038/s41397-023-00316-9</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="vaccines-12-01389-f001"><label>Figure 1</label><caption><p>In youth, aged and senescent cells are efficiently eliminated by the immune system. However, with age, the effectiveness of this process declines. This may be due to both the aging of the immune system itself and the development of tolerance to senescent cell antigens. Chronic inflammation caused by SASP factors, as well as the ever-increasing antigenic load, may play a key role in this by leading to exhaustion, anergy, or trans-differentiation of anti-senescent effector cells to Tregs. Senolytic vaccines aim to restore the immune system&#x02019;s ability to selectively eliminate senescent cells without compromising the organism as a whole. To achieve this, it is necessary to consider age-related changes in the system of autotolerance: the appearance of SA in the bone marrow, thymus, and periphery, as well as the microbiome imbalance, as these changes affect the repertoires of effector and regulatory T and B cells specific for SA.</p></caption><graphic xlink:href="vaccines-12-01389-g001" position="float"/></fig><table-wrap position="float" id="vaccines-12-01389-t001"><object-id pub-id-type="pii">vaccines-12-01389-t001_Table 1</object-id><label>Table 1</label><caption><p>Vaccine approaches for combating age-related diseases.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Disease</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Target</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Vaccine Design</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Stage</th></tr></thead><tbody><tr><td rowspan="8" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Alzheimer&#x02019;s disease</td><td rowspan="4" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Amyloid beta (A&#x003b2;)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Palmitoylated peptide A&#x003b2;1&#x02013;15 (for ACI-24) was reconstituted in liposomes.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase II clinical trials (NCT05462106) [<xref rid="B8-vaccines-12-01389" ref-type="bibr">8</xref>,<xref rid="B9-vaccines-12-01389" ref-type="bibr">9</xref>,<xref rid="B10-vaccines-12-01389" ref-type="bibr">10</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">UB-311 comprises two A&#x003b2;1&#x02013;14&#x02013;targeting peptides (B-cell epitope), each synthetically linked to different helper T-cell peptide epitopes (UBITh<sup>&#x000ae;</sup>), and formulated in an alum-containing Th2-biased delivery system.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase II clinical trials (NCT00965588; NCT02551809; NCT03531710) [<xref rid="B11-vaccines-12-01389" ref-type="bibr">11</xref>,<xref rid="B12-vaccines-12-01389" ref-type="bibr">12</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AV-1959 consists of pVAX1 backbone vector which codes a protein consisting of the Ig &#x003ba;- chain signal sequence, three copies of the A1-11 B cell epitope, one synthetic peptide (PADRE), and a string of non-self-promiscuous Th epitopes from Tetanus Toxin, hepatitis B virus and influenza.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase I clinical trials<break/>(NCT05642429) [<xref rid="B13-vaccines-12-01389" ref-type="bibr">13</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A&#x003b2;33&#x02013;40 peptide coupled to monomeric keyhole limpet hemocyanin suspended in the phosphate buffer with 0.35% aluminum hydroxide.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase II clinical trials<break/>(NCT03113812; NCT03461276) [<xref rid="B14-vaccines-12-01389" ref-type="bibr">14</xref>]</td></tr><tr><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Microtubule-associated protein tau (Tau)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ACI-35 is a liposomal vaccine that carried peptide corresponding to residues 393&#x02013;408 in protein Tau (numbering of the Tau441 isoform) with S396 and S404 phosphorylated.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase II clinical trials<break/>(NCT04445831) [<xref rid="B15-vaccines-12-01389" ref-type="bibr">15</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Axon Peptide 108 (N-terminally cysteinylated tau 294&#x02013;305/4R) coupled to keyhole limpet hemocyanin via a maleimide linker, with aluminum hydroxide adjuvant.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase II clinical trials<break/>(NCT01850238; NCT02031198; NCT02579252) [<xref rid="B16-vaccines-12-01389" ref-type="bibr">16</xref>,<xref rid="B17-vaccines-12-01389" ref-type="bibr">17</xref>,<xref rid="B18-vaccines-12-01389" ref-type="bibr">18</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mimicking the extra-telomeric human telomerase reverse transcriptase (hTERT)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GV1001 is a 16-amino-acid vaccine peptide derived from the human telomerase reverse transcriptase (hTERT) sequence.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase II clinical trials (NCT05189210) [<xref rid="B19-vaccines-12-01389" ref-type="bibr">19</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Proteasomes </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nasal vaccination with IVX-908 (Protollin) which is a non-covalent formulation of outer membrane proteins (proteasomes) of <italic toggle="yes">Neisseria meningitides</italic> and lipopolysaccharide from <italic toggle="yes">Shigella flexneri</italic> plus glatiramer acetate (GA).</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Preclinical studies, mice [<xref rid="B20-vaccines-12-01389" ref-type="bibr">20</xref>]</td></tr><tr><td rowspan="4" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Type 2 diabetes</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dipeptidyl peptidase-4 (DPP4)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Peptides E1 and E2, which spans a site in the N-terminal sequence of DPP4; E3, which spans the 89&#x02013;97 a.a. sequence near the opening of the DPP4 active site were conjugated to keyhole limpet hemocyanin.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Preclinical studies, mice [<xref rid="B21-vaccines-12-01389" ref-type="bibr">21</xref>]</td></tr><tr><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Interleukin-1 beta (IL-1&#x003b2;)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A rhesus (rmIL1bQb) and human (hIL1bQb) version of the IL-1&#x003b2; vaccine were generated with an identical inactivating mutation of the IL-1&#x003b2; polypeptide. The corresponding rhesus monkey (rmIL1bQb) and human (hIL1bQb) IL-1&#x003b2; vaccines were produced by chemically crosslinking the engineered IL-1&#x003b2; proteins to Qb virus-like particles.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase I clinical trials (NCT00924105) [<xref rid="B22-vaccines-12-01389" ref-type="bibr">22</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IL-1&#x003b2; epitope peptide formulated with alum-based adjuvant.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Preclinical studies, mice [<xref rid="B23-vaccines-12-01389" ref-type="bibr">23</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prorenin</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Three different epitopes of the prorenin prosegment (E1, E2, and E3) were selected and conjugated to keyhole limpet hemocyanin.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Preclinical studies, mice [<xref rid="B24-vaccines-12-01389" ref-type="bibr">24</xref>]</td></tr><tr><td rowspan="4" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Hypertension</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Angiotensin I</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PMD-2850 contains tetanus toxoid, and PMD-3117 contains keyhole limpet hemocyanin; both are conjugated to Angiotensin I peptide analog and use aluminum hydroxide gel as adjuvant</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase I clinical trials [<xref rid="B25-vaccines-12-01389" ref-type="bibr">25</xref>,<xref rid="B26-vaccines-12-01389" ref-type="bibr">26</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Angiotensin II</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">An angiotensin II-derived peptide was conjugated to the virus-like particles Qbeta (AngQb).</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase II clinical trials<break/>(NCT00500786; NCT00701649; NCT00710372) [<xref rid="B27-vaccines-12-01389" ref-type="bibr">27</xref>,<xref rid="B28-vaccines-12-01389" ref-type="bibr">28</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Angiotensin 1 receptor (AT1R)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Q&#x003b2; virus-like particle protein was covalently conjugated to ATR-001 peptide with the amino acids sequence corresponding to the sequence of the second extracellular loop of the human AT1R.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Preclinical studies, mice [<xref rid="B29-vaccines-12-01389" ref-type="bibr">29</xref>,<xref rid="B30-vaccines-12-01389" ref-type="bibr">30</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Apha-1D adrenergic receptor (ADRA1D)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Epitopes of &#x003b1;1A-adrenergic receptor (&#x003b1;1A-AR) or &#x003b1;1D-adrenergic receptor (&#x003b1;1D-AR) were conjugated to Q&#x003b2; bacteriophage virus-like particle.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Preclinical studies, mice [<xref rid="B31-vaccines-12-01389" ref-type="bibr">31</xref>]</td></tr><tr><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Abdominal aortic aneurysm</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Angiotensin II</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Angiotensin II peptide was conjugated to keyhole limpet hemocyanin.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Preclinical studies, rats [<xref rid="B32-vaccines-12-01389" ref-type="bibr">32</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Angiotensin type 1 receptor (AT1R)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Q&#x003b2; virus-like particle protein was covalently conjugated to ATR-001 peptide with the amino acids sequence corresponding to the sequence of the second extracellular loop of the human AT1R position 180&#x02013;187.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Preclinical studies, mice [<xref rid="B33-vaccines-12-01389" ref-type="bibr">33</xref>]</td></tr><tr><td rowspan="4" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Atherosclerosis</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Apolipoprotein B (ApoB)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A vaccine composed of ApoB peptide and complete Freund&#x02019;s adjuvant.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Preclinical studies, mice [<xref rid="B34-vaccines-12-01389" ref-type="bibr">34</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Proprotein convertase subtilisin/kexin type 9 (PCSK9)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A short PCSK9 peptide (as a B cell epitope) is linked to a tetanus peptide (as a T cell epitope). The peptide was conjugated to the surface of nanoliposome carriers and formulated with alum vaccine adjuvant.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Preclinical studies, mice [<xref rid="B35-vaccines-12-01389" ref-type="bibr">35</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A disintegrin and metalloproteinase with thrombospondin type 1 motif 7 (ADAMTS7)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Three potential vaccines consist of distinct B cell epitope peptides derived from ADAMTS-7 and conjugated with the carrier protein keyhole limpet hemocyanin as well as aluminum hydroxide as an adjuvant.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Preclinical studies, mice [<xref rid="B36-vaccines-12-01389" ref-type="bibr">36</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lysate-based</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Contain pooled antigens derived from pig adipose tissue.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase III clinical trials<break/>(NCT03042741) [<xref rid="B37-vaccines-12-01389" ref-type="bibr">37</xref>,<xref rid="B38-vaccines-12-01389" ref-type="bibr">38</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Osteoarthritis</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nerve growth factor (NGF)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Virus-like particles were derived from the cucumber mosaic virus (CuMV) and coupled to expressed recombinant NGF to create the vaccine.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Preclinical studies, mice [<xref rid="B39-vaccines-12-01389" ref-type="bibr">39</xref>]</td></tr><tr><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Fibrosis</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Disintegrin and metalloproteinase domain-containing protein 12 (ADAM12) and Glioma-associated oncogene family zinc finger 1 (GLI1)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lentiviral vectors with ADAM12 or GLI1 full-length protein coding sequence and incomplete Freund&#x02019;s adjuvant plus the TLR9 agonist CpG oligodeoxynucleotides.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Preclinical studies, mice [<xref rid="B40-vaccines-12-01389" ref-type="bibr">40</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Proprotein convertase subtilisin/kexin type 9 (PCSK9)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Epitope peptide of PCSK9-003 was derived from human PCSK9 and conjugated to Q&#x003b2; virus-like particles.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Preclinical studies, mice [<xref rid="B41-vaccines-12-01389" ref-type="bibr">41</xref>]</td></tr><tr><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Parkinson&#x02019;s Disease and multiple system atrophy</td><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Alpha-synuclein</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AFFITOPE<sup>&#x000ae;</sup> PD01A and PD03A are peptides mimicking an epitope in the C-terminal region of human alpha-synuclein but with a different amino acid sequence. Every protein is conjugated to the carrier protein keyhole limpet hemocyanin and adsorbed to aluminum hydroxide adjuvant.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase II clinical trials (NCT02618941; NCT02267434; NCT02270489) [<xref rid="B42-vaccines-12-01389" ref-type="bibr">42</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">UB-312 a 10-amino-acid fragment from the alpha-synuclein C-terminus is fused to a small peptide UBITh<sup>&#x000ae;</sup> that activates T-helper cells, and combined with adjuvant composed of polyanionic Cytosine phosphoguanine (CpG), oligodeoxynucleotide (ODN), and aluminum-based adjuvant (Adju-Phos<sup>&#x000ae;</sup>).</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase II clinical trials (NCT04075318; NCT05634876) [<xref rid="B43-vaccines-12-01389" ref-type="bibr">43</xref>,<xref rid="B44-vaccines-12-01389" ref-type="bibr">44</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neovascular maculopathy and age-related macular degeneration</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vascular endothelial growth factor receptor 1 and 2 (VEGFR1 and 2)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">An HLA-A*2402 or A*0201 restricted epitope peptides of VEGFR1 and VEGFR2 emulsified with Montanide ISA 51.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clinical trials 1 phase<break/>(NCT00791570)</td></tr><tr><td rowspan="5" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Obesity</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Somatostatin</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A chimeric-somatostatin with either JH17 or JH18 adjuvants.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Preclinical studies, mice [<xref rid="B45-vaccines-12-01389" ref-type="bibr">45</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Glucose-dependent insulinotropic polypeptide</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Immunoconjugate of glucose-dependent insulinotropic polypeptide covalently attached to the Q&#x003b2; bacteriophage virus-like particles.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Preclinical studies, mice [<xref rid="B46-vaccines-12-01389" ref-type="bibr">46</xref>]</td></tr><tr><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Ghrelin</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A common porcine&#x02013;rat&#x02013;human ghrelin sequence is conjugated to BSA and emulsified in Freund&#x02019;s incomplete adjuvant and diethylaminoethyldextran.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Preclinical studies, pigs [<xref rid="B47-vaccines-12-01389" ref-type="bibr">47</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Synthetic ghrelin residues 1&#x02013;10 for Ghr1, 13&#x02013;28 for Ghr2, and 1&#x02013;28 for Ghr3, coupled to the carrier protein keyhole limpet hemocyanin.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Preclinical studies, rats [<xref rid="B48-vaccines-12-01389" ref-type="bibr">48</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chemical conjugation of ghrelin with NS1 protein tubules from the Bluetongue Virus (BTV) as a carrier.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Preclinical studies, mice [<xref rid="B49-vaccines-12-01389" ref-type="bibr">49</xref>]</td></tr></tbody></table></table-wrap><table-wrap position="float" id="vaccines-12-01389-t002"><object-id pub-id-type="pii">vaccines-12-01389-t002_Table 2</object-id><label>Table 2</label><caption><p>Promising antigens for senolytic vaccine development.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Target</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cell Type</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Organism</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Description</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ApoD (Apolipoprotein D)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Senescent skin fibroblast</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Human</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ApoD expression was upregulated in cellular senescence models and correlated with senescence-associated &#x003b2;-galactosidase activity and decreased proliferation, which was concomitant with the upregulation of SASP genes. ApoD-positive cells were found to be more abundant in the aging human dermis, which makes ApoD a promising target for senolytic vaccines [<xref rid="B180-vaccines-12-01389" ref-type="bibr">180</xref>,<xref rid="B181-vaccines-12-01389" ref-type="bibr">181</xref>].</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CD153 (Tumor Necrosis Factor Ligand Superfamily Member 8)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Senescence-associated T cells in adipose tissue and spontaneous germinal centers</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anti-CD153 peptide vaccine reduced the number of senescent T cells in adipose tissue, increased glucose tolerance, and improved the response to endogenous insulin [<xref rid="B80-vaccines-12-01389" ref-type="bibr">80</xref>,<xref rid="B177-vaccines-12-01389" ref-type="bibr">177</xref>].</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CD30 (Tumor Necrosis Factor Receptor Superfamily Member 8)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Senescence-associated T and B cells in spontaneous germinal centers</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Blockade of the CD153/CD30 interaction via an anti-CD153 antibody suppresses the immune senescence phenotype, lupus, and ameliorates inflammaging [<xref rid="B177-vaccines-12-01389" ref-type="bibr">177</xref>].</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CD87 (Urokinase Plasminogen Activator Surface Receptor)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Wide range of senescent cells</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">uPAR-positive senescent cells can be safely targeted with senolytic CAR-T cells. Such treatment improves exercise capacity in physiological aging, and it ameliorates metabolic dysfunction in aged mice and in mice on a high-fat diet [<xref rid="B182-vaccines-12-01389" ref-type="bibr">182</xref>]. </td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CD9 (Tetraspanin-29)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Senescent endothelial cells</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice, <break/>Human</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CD9 is upregulated in senescent endothelial cells, neointimal hyperplasia, and atherosclerotic plaques. CD9 may be a novel target for the prevention and treatment of vascular aging and atherosclerosis. Therefore, CD9 could potentially be used as a target in senolytic vaccines [<xref rid="B183-vaccines-12-01389" ref-type="bibr">183</xref>].</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CTSF (Cathepsin F)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Senescent skin fibroblasts and keratinocytes</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Human</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cathepsin F is associated with the senescence of human fibroblasts and keratinocytes, making it a promising target for senolytic vaccines [<xref rid="B178-vaccines-12-01389" ref-type="bibr">178</xref>].</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EGF (Epidermal Growth Factor)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Umbilical vein endothelial cells, lung fibroblasts</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Human</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EGF treatment can induce cellular senescence via the activation of the EGF receptor. Inhibition of EGF represents a promising treatment against cellular senescence and could be used as a target for senolytic vaccines [<xref rid="B184-vaccines-12-01389" ref-type="bibr">184</xref>].</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GPNMB (Glycoprotein Nonmetastatic Melanoma Protein B)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Senescent endothelial cells, adipocytes, and leukocytes</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The authors identify GPNMB as a senescence-associated antigen and a promising molecular target for senolytic therapy. Immunization of mice against GPNMB improved metabolic parameters, glucose tolerance, and reduced atherosclerotic plaques [<xref rid="B81-vaccines-12-01389" ref-type="bibr">81</xref>,<xref rid="B185-vaccines-12-01389" ref-type="bibr">185</xref>,<xref rid="B186-vaccines-12-01389" ref-type="bibr">186</xref>].</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">KLRG-1 (killer-cell lectin like receptor G1)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Senescent T cells</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice, <break/>Human</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">KLRG1 is expressed on NK cells and antigen-experienced T cells and has been postulated to be a marker of senescence. The elimination of KLRG1-positive cells results in lasting rejuvenation of the immune system [<xref rid="B187-vaccines-12-01389" ref-type="bibr">187</xref>,<xref rid="B188-vaccines-12-01389" ref-type="bibr">188</xref>].</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NKG2DL (Activating Receptor Natural Killer Group 2, Member D Ligand)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Senescent models of mouse embryonic fibroblasts and astrocytes</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The authors demonstrate elevated expression of NKG2DLs in response to genotoxic and oxidative stress in senescent models. NKG2D CAR-T cells displayed potent and selective cytotoxicity against these senescent cells, suggesting their potential as targeted senolytics [<xref rid="B82-vaccines-12-01389" ref-type="bibr">82</xref>].</td></tr></tbody></table></table-wrap></floats-group></article>